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Summary 
Uncontrolled proliferation is one of the characteristic hallmarks of cancer and underlines the 
aberrant nutrient cycling seen in tumors. Cancer cells, therefore, need to rewire their metabolic 
pathways to meet the biosynthetic and bioenergetics demands of rapid growth.  Metabolic 
reprogramming is thus, crucial for oncogenesis. The ‘Warburg effect’ is the most commonly 
reported metabolic characteristic in tumors, where cancer cells consume high amounts of 
glucose which then get shunted mostly into lactate production. Glutamine addiction is 
commonly observed in several cancers making it the second most important carbon source 
which fuels the citric acid (TCA) cycle to provide both energy and biosynthetic precursors. 
Breast cancer is a heterogeneous disease and despite successes in targeted therapy of certain 
subtypes, treatment still remains a clinical challenge. Investigating metabolic changes in breast 
cancer, therefore, provides an opportunity to overcome these therapeutic challenges.  The aim 
of this project was to understand the mechanisms by which tumors efficiently utilize their 
carbon and nitrogen sources and to identify potential targets for future therapeutic 
interventions. To this end, I identified alanine aminotransferase 2(also known as glutamate 
pyruvate transaminase 2 or GPT2) as a highly deregulated enzyme in breast cancer patients 
who have a poor prognosis. GPT2 catalyzes the reversible reaction that generates alanine from 
glutamate and pyruvate which, in turn, are produced by glutaminolysis and glycolysis, 
respectively. I found RNAi and chemical inhibition of GPT2 to suppress proliferation of several 
breast cancer cell lines.  MDA MB 468 cells, which produce the highest levels of GPT2 and 
alanine, show a decrease in the supply of TCA cycle intermediates as well as a reduction in 
glutamine uptake when alanine production is blocked. Furthermore, GPT2 inhibition rewires 
glucose carbon cycling in the cell lines resulting in increased glucose carbon flow into the TCA 
cycle. I found the expression of GPT2 in these cancer cells to be regulated by the transcription 
factors, c-Myc and ATF4. In conclusion, my results demonstrate the role of GPT2 in connecting 
glucose and glutamine anaplerosis, thereby driving carbon atoms into key biosynthetic 
pathways of cancer cells. This study underlines the importance of investigating the balance of 
nutrient cycling in cancer to identify potential targets for therapeutic intervention. 
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Zusammenfassung 
Als Ursache von unkontrollierter Proliferation, die zu den Hauptmerkmalen von Krebs gehört, 
liegt häufig ein abnormaler Nährstoffzyklus der Tumorzellen zugrunde. Daher müssen 
Krebszellen ihre Stoffwechselsignalwege umprogrammieren um biosynthetische und 
bioenergetische Prozesse, die für ein schnelles Tumorwachstum benötigt werden, 
entsprechend anzupassen. Der „Warburg Effekt“ beschreibt metabolische Eigenschaften von 
Tumorzellen, welche ein hohes Maß an Glukose verbrauchen, das hauptsächlich in Laktat 
umgewandelt wird. Glutaminabhängigkeit wird bei vielen Krebsarten beobachtet und bildet die 
zweitwichtigste Kohlenstoffquelle, welche in den Citratzyklus einfließt um Energie und 
biosynthetische Vorläufermoleküle bereit zu stellen. Brustkrebs ist eine heterogene Krankheit 
und die Therapie verbleibt, unabhängig von therapeutischen Erfolgen in einzelnen Subtypen, 
herausfordernd. Ein Ansatz diese therapeutischen Maßnahmen gegen Brustkrebs zu verbessern 
liegt in der Erforschung metabolischer Veränderungen. Ein Ziel dieses Projektes war es die 
Mechanismen zu verstehen, mit welchen Tumore effizient Kohlenstoff- sowie Stickstoffquellen 
nutzen, um so potentielle Ziele für zukünftige therapeutische Interventionen zu entdecken. In 
Bezug auf diese Fragestellung identifizierte ich die Alanin Aminotransferase 2 (auch bekannt als 
Glutamat Pyruvat Transaminase 2 oder GPT2) als stark dereguliertes Enzym in 
Brustkrebspatienten mit schlechter Überlebenswahrscheinlichkeit. GPT2 katalysiert die 
reversible Reaktion, die Alanin aus Glutamat und Pyruvat produziert, welche entsprechend über 
Glutaminolyse und Glycolyse gewonnen werden. Mit RNAi und chemischer Inhibition von GPT2 
konnte ich die Zellproliferation von diversen Brustkrebszelllinien unterdrücken. MDA MB 468 
Zellen, die am meisten GPT2 und Alanin produzieren, zeigen, dass wenn die Alanin Produktion 
geblockt wird, eine Reduktion der Citratzyklus Zwischenprodukte sowie eine verminderte 
Glutaminaufnahme, stattfindet. Weiterhin führt GPT2 Inhibition zu einer Neustrukturierung des 
Glukose-Kohlenstoff-Zyklus in den Zelllinien und resultiert so in einem erhöhten Glukoseflux in 
den Citratzyklus. Die Expression von GPT2 in den verwendeten Brustkrebszellen konnte auf 
Regulation durch die Transkriptionsfaktoren c-Myc und ATF4 zurückgeführt werden.  
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Zusammengefasst zeigen meine Ergebnisse, dass GPT2  Glukose- und Glutaminanaplerose 
verbindet und so zu einer Bereitstellung von Kohlenstoffatomen für spezielle biosynthetische 
Signalwege der Krebszellen führt. Diese Studie betont die Wichtigkeit der Forschung an dem 
Gleichgewicht des Nährstoffzyklus von Brustkrebszellen, um so potentielle Ziele für 
therapeutische Interventionen zu entdecken. 
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1. Introduction 
1.1 Cancer and its hallmarks 
Cancer is a major public health concern worldwide which resulted in 8.8 million deaths in 2015. 
The American Cancer Society has predicted that, in 2017, there will be almost 1.7 million new 
cancer cases diagnosed and over 600,000 cancer related deaths in the United States alone 
(Siegel, Miller, & Jemal, 2017a) Cancer is a complex group of diseases, characterized by 
uncontrolled proliferation, which arises as a result of dynamic genomic changes. The discovery 
of mutations that lead to the dominant gain of function of oncogenes and recessive loss of 
function of tumor suppressor genes and the concomitant effect that these have on cell growth 
form the basis of our knowledge of tumorigenesis. Tumors commonly have a high number of 
mutations, including point mutations, copy number variations and changes in chromosome 
complement(Alexandrov et al., 2013). Relapses and metastases show further mutational 
dynamics(Yates et al., 2017).  
Decades of research in cancer has led to the understanding that the conversion of a normal cell 
to its neoplastic counterpart is a multistep process. Each of these steps reflects genetic 
adaptations that lead to the final malignant form via several pre-malignant states. Parallels can 
be drawn between Darwinian evolution and tumorigenesis where each subsequent change 
results in conferring a growth advantage to the cells, finally leading to the formation of a tumor 
(FOULDS, 1954; Nowell, 1976). 
In 2000, Weinberg and Hanahan proposed the hallmarks of cancer which are essentially 
characteristics gained by cancer cells during the process of tumorigenesis, enabling them to 
proliferate and metastasize efficiently.  These include self-sufficiency in growth signals, 
insensitivity to growth inhibitory signals, evasion of programmed cell death (apoptosis), 
sustained angiogenesis and tissue invasion and metastasis. The hallmarks are enabled by 
genomic instability and mutations acquired by the cancer cells along with tumor promoting 
inflammation (Hanahan & Weinberg, 2000). In 2011, the same authors updated the list of 
hallmarks as a result of progress made in research to include inflammation and genome 
instability The other new hallmark is reprogramming of energy metabolism (Hanahan & 
Introduction 
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Weinberg, 2011). The unrestricted rates of proliferation seen in cancer cells make it necessary 
for them to rewire their metabolic pathways to optimize nutrient utilization and energy 
production to support cell growth. This field has garnered a lot of attention in the past decade 
which has resulted in several clinical trials.  The hope is that by targeting metabolism of cancer 
cells one can target the core of the ability of tumors to rapidly proliferate. 
 
               
Figure 1: Hallmarks of Cancer, adapted from Hanahan and Weinberg, 2011 (Hanahan & Weinberg, 
2011) 
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1.2 Breast Cancer 
Breast cancer is the leading cause of cancer among women and the second most commonly 
occurring carcinoma worldwide. Although it can occur in both genders, the frequency is much 
higher in women and its incidence increases significantly with age. According to the American 
Cancer Society, in 2017, breast cancer is predicted to account for 30% of all new cancer cases 
and 14% of cancer related death among women(Siegel, Miller, & Jemal, 2017b). This translates 
to over 200,000 new cases and 40,000 deaths due to breast cancer.  
Breast cancer is complex and heterogeneous; it is composed of several diseases with distinct 
histopathological and biological features which demand unique treatment strategies. Clinically, 
breast cancer is divided into 4 subtypes, Luminal A which is hormone receptor positive and 
heregulin 2 receptor (HER2, also known as ERBB2) negative, Luminal B which is also hormone 
receptor positive and HER2 positive or negative , HER2 amplified subtype and the triple 
negative subtype (which lack hormone and HER2 receptor)(Dai et al., 2015). These common 
immunohistochemistry markers along with clinical factors such as tumor grade, tumor size and 
nodal involvement are commonly used for tumor management and treatment strategies. 
However, the dawn of the omics era and evolution of high-throughput platforms such as 
microarrays and sequencing have made it possible stratify patients not only according to 
anatomical prognostic factors but also to intrinsic molecular characteristics, leading to better 
therapeutic strategies. 
 
1.2.1 Molecular Subytpes of Cancer 
In their pioneering work, Sorlie et al, identified five molecular subtypes of breast cancer with 
distinct clinical outcome (Sørlie et al., 2001). Subsequently, these five distinct subtypes have 
been identified by other groups using different gene signatures. For example, Hu et al, used a 
306 gene signature to classify breast cancer into these subtypes (Z. Hu et al., 2006). Another 
study found a 50-gene classifier (PAM50, which contains mostly hormone receptor and 
proliferation related genes, and genes exhibiting myoepithelial and basal features) which has 
remarkable prognostic values for breast cancer (Parker et al., 2009). 
Introduction 
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Luminal 
Luminal tumors (also known as ER positive cancers) which express hormone receptors are the 
most common subtype, accounting for nearly 70% of detected breast cancer. Luminal tumors 
can be further subdivided into luminal A and B. Very broadly, luminal A tumors are estrogen 
positive (ER+) (and/or progesterone positive (PR+)), HER2- and low Ki67, while Luminal B HER2+ 
are ER+ (and/or PR+) and HER2+ with low Ki67 and luminal B HER2- are ER+ (and/or PR+) and 
HER2- with high Ki67 (Dai et al., 2015). The luminal A subtype shows a higher expression of ER 
related genes and a lower expression of proliferation related genes. Luminal B subtype 
generally has a higher grade than the A subtype. Compared to the other subtypes of breast 
cancer the luminal subtypes have better prognosis. The luminal tumors are defined by their 
characteristic luminal expression signature. This includes ESR1, GATA3, FOXA1, XBP1 and MYB, 
genes commonly involved in development, which are all highly expressed. Several genes are 
also frequently mutated in luminal cancers, for example GATA1, FOXA1, RUNX1 which encode 
transcription factors involved in development (Cancer Genome Atlas Network, 2012). PIK3CA, 
which is also highly mutated in luminal cancer although it does not lead to pathway activation 
in luminal A cancers. MAP3K1 and MAP2K4 represent another class of genes commonly 
mutated in luminal tumors leading to inactivation of the p-38-JNK1 pathway (Cancer Genome 
Atlas Network, 2012) The tumor suppressor TP53 has a higher frequency of mutations in 
luminal B (29%) than in luminal A (12%). This together with the analysis of another tumor 
suppressor, pRb activity show that tumors of the luminal A subtype retain TP53 and pRb activity 
while these genes are frequently mutated in the more aggressive Luminal B subtype. 
Additionally, luminal B subtypes show hyper activation of MYC and FOXM1, leading to higher 
proliferation rates (Cancer Genome Atlas Network, 2012). 
 
HER2+ 
HER2+ subtype is defined by the overexpression of the HER2 amplicon and is identified by gene 
expression analysis and/or by immunostaining and FISH hybridization(Cancer Genome Atlas 
Network, 2012; Dai et al., 2015). However, not all clinically identified HER2 tumors show 
  Introduction 
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overexpression at the transcriptional level leading to two subclasses of the HER2 subtype. One 
is HER2+ and expresses Her2E mRNA (around 50% of the tumors) and the other is HER2+ but 
essentially luminal(Cancer Genome Atlas Network, 2012). It has been observed that the 
HER2+/HER2E tumors have a dramatically higher expression of several receptor tyrosine 
kinases (RTKs) like FGFR4, EGFR, HER2, while the luminal/HER2+ tumors have a luminal 
expression signature. The HER2+/HER2E or ER negative subgroup also has a higher frequency 
for TP53 mutations whereas the luminal subtype is enriched for GATA3 mutations. Additionally, 
the HER2+/HER2E subtype has high aneuploidy and DNA amplification of other genes such as, 
FGFRs, EGFR and genes involved in cell cycle CDK4 and CCND1. HER2 overexpressing tumors are 
generally Grade 3 and have a poor prognosis(Cancer Genome Atlas Network, 2012). 
 
Triple Negative 
The triple negative subtype is devoid of any ER, PR and Her2 expression. The triple negative 
tumors are highly aggressive having the worst prognosis among the different breast cancer 
subtypes and are generally Grade 3 like the HER2 tumors. This subtype is characterized by 
germline and/or somatic BRCA1 and BRCA2 mutations, or mutations in other genes of the 
homologous end joining mechanism, as well as a high frequency of TP53 mutation and loss of 
RB1. PI3KCA is also frequently mutated in these tumors, and the PI(3)K-AKT pathway is highly 
active probably due to the loss of tumor suppressors PTEN  and INPP4B in addition to 
amplification of PIK3CA. The terms basal and triple-negative are often interchangeably used, 
however, 75% of TNBCs are basal, while the rest are of different subtypes. Lehmann et al., 
originally divided triple negative breast cancer into 6 subtypes, 2 basal-like (BL1 and BL2), 1 
immunomodulatory (IM), 1 mesenchymal (M), 1 mesenchymal stem-like (MSL) and 1 luminal 
androgen receptor (LAR) subtype(Lehmann et al., 2011). The BL1 subtype is enriched for cell 
cycle and cell division genes while BL2 is characterized by genes belonging to growth factor 
signaling and display features that have basal/myoepithelial origin. The IM subtype displays 
high expression of genes involved in the immune cell processes. The M subtype is enriched in 
genes involved in cell motility, ECM receptor interaction and cell differentiation pathways. The 
Introduction 
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MSL subtype is similar to the M subtype but is also enriched in genes involved in growth factor 
signaling and has low expression of claudin 3,4,7. Finally, the LAR subtype is ER- but has a 
luminal gene expression signature. As some of the expression of genes in these specimens were 
discovered to be from tumor infiltrating cells and the tumor stroma, the classification was later 
refined to 4 subtypes, namely  BL1, BL2 M and LAR(Lehmann, Jovanovi, et al., 2016) 
Sorlie et al also defined a fifth subgroup of breast cancer called normal breast-like which have 
high expression of several genes that are expressed in adipose and other non-epithelial 
tissues(Sørlie et al., 2001).  They also display elevated expression of basal epithelial genes and 
low expression of luminal epithelial genes. 
 
1.2.2 Therapy 
Currently the standard treatment regimen for breast cancer is either surgery or radiotherapy. 
Depending on the type of breast cancer, patients may undergo additional treatment. Some 
receive neo-adjuvant therapy to shrink the tumor before surgery, others may receive adjuvant 
therapy post-surgery to treat potential micro-metastases. Therapies include chemotherapy, 
endocrine therapy and targeted therapy.  
Endocrine therapy remains the mainstay and the first line of therapy for hormone receptor 
positive breast cancers(Liedtke & Kolberg, 2016) . Established in 1970, tamoxifen, an ER 
antagonist, remains a viable option with patients responding up to 12-18 months and in some 
cases up to years. However, in recent years tamoxifen has been replaced by aromatase 
inhibitors, AI, (e.g. letrozole and anastrozole) in postmenopausal patients as the first line of 
therapy due to higher response rates(Wood, Smith, & Dowsett, 2003). However, several 
patients have de novo or acquire resistance to first line therapy, leading to relapse. In case of AI 
resistance, estrogen receptor antagonists (tamoxifen and fulvestrant) are used as second line of 
therapy(Chia et al., 2008).  
Dysregulation of the cell cycle is a common phenomenon of breast cancer. CDK4/6 and CCND1 
regulate the transition from G1 to S phase via phosphorylation of pRb and are, therefore, 
  Introduction 
11 
 
important to the highly proliferative cancer cells(Weinberg, 1995). As a result of this, metastatic 
ER+ breast cancers often benefit from additional therapy with cell cycle inhibitors as do cancers 
resistant to endocrine therapy. In view of this, CDK4/6 inhibitors, palbociclib (Ibrance; Pfizer 
Inc), ribociclib (LEE011; Novartis) and abemaciclib (LY2835219; Lilly) are undergoing clinical 
development. Given that cyclin D1 is regulated by PI3K/AKT/mTOR pathway and that over 70% 
of breast cancer show activation of this pathway, inhibiting this pathway provides a potential 
option for therapy(Fu, Osborne, & Schiff, 2013; Pang et al., 2014). As a result of its crosstalk 
with estrogen receptor, this pathway has also been implicated in endocrine resistance, thereby 
providing an opportunity to overcome resistance(Fu et al., 2013). While therapies targeting 
PI3K are still in development, mTOR inhibitor, everolimus, is used in combination with steroidal 
aromatase inhibitor, exemestane, in cases of non-response to non-steroidal aromatase 
inhibitors(Liedtke & Kolberg, 2016). Luminal breast cancers may also be treated with 
antiangiogenic therapy including, bevacizumab, which is an antibody directed against the 
vascular endothelial growth factor (VEGF)(Bear et al., 2012; Liedtke & Kolberg, 2016). Other 
targets for therapy include AKT, using inhibitors of AKT and PARP for patients harboring 
pathogenic mutations in BRCA1/BRCA2 or other genes involved in DNA damage response. 
HER2+ breast cancers are highly aggressive and tend to have a poor prognosis. However, due to 
the presence of the highly druggable target HER2, it has been possible to effectively treat this 
disease. The development of trastuzumab, a humanized monoclonal antibody that targets the 
extracellular domain of the HER2 receptor, has increased the overall survival of HER2+  breast 
cancers(Slamon et al., 2001). In addition, pertuzumab which targets the HER2-HER3 dimer has 
been recently approved for first line therapy and this in combination with 
docetaxel(chemotherapeutic drug) and trastuzumab has been shown to dramatically improved 
overall survival (Baselga et al., 2012).  TDM-1 (Trastuzumab etansine), antibody drug conjugate 
(ADC) of the cytotoxic DM-1 and trastuzumab has proved to be an effective therapy against 
HER2+ cancers(Verma et al., 2012). Besides HER2-targeted antibodies, small HER2-directed 
molecules have also proven to be efficacious treatments. An example of this is Lapatinib 
(targeting both HER1/EGFR and HER2) which is used as a later-line therapy in combination with 
chemotherapy(Geyer et al., 2006) . 
Introduction 
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Due to the lack of a druggable hormone or HER2 receptor, TNBC proves to be the most 
challenging subtype of breast cancer. Additionally, the presence of distinct subgroups within 
this subtype makes it difficult to develop a general therapy for this subtype. Currently, TNBCs 
are heavily dependent on chemotherapy. Due to the common occurrence of BRCA1/2 
mutations, patients suffering from TNBCs benefit from taxane and platinum salts. In addition to 
this, PARP inhibitors, which can prevent DNA damage repair in cells, are commonly used for 
treatment of BRCA1/2 mutated TNBC (Farmer et al., 2005). Increasing evidence suggests that 
tumors with strong lymphocytic infiltration can benefit from immune targeted agents which 
help to expose tumors cells to the immune system. Programmed cell death protein (PD-1) and 
its two ligands, PD-L1 and PD-L2 are currently being investigated as potential therapeutic 
targets. Phase I clinical trial of PD-1 inhibitor pembrolizumab has been a success with TNBC 
patients(Nanda et al., 2016). 
Early detection and targeted therapy have greatly improved survival rates in breast cancer. 
Endocrine therapy and HER2 targeted therapy have been highly successful, however, 
recurrence and development of resistance still remains a problem. Furthermore, TNBCs still lack 
efficient therapy barring chemotherapy. This has led to the need for further molecular 
characterization of breast cancer. Recent studies show that cancers are also metabolic 
diseases(Pavlova & Thompson, 2016). The high rates of cell division demand metabolic 
reprogramming within the tumors. Therefore, targeting metabolism provides a promising 
therapeutic window, especially for tumors that cannot be otherwise treated effectively. 
 
 
 
  Introduction 
13 
 
1.3 Cancer Metabolism 
 
Figure 2:  Metabolic pathways involved in tumorigenesis. Adapted from Berardinis and Chandel 2016(R. 
J. Deberardinis & Chandel, n.d.) 
Metabolic reprogramming in cancer cells plays a crucial role in maintaining high levels of 
proliferation.  Cellular metabolism is defined by three main tasks which are, to maintain energy 
reserves of the cell (via ATP and NADPH regeneration), biosynthesis of macromolecules 
required for cellular homeostasis and to maintain redox state of the cell. In order to fulfill these 
requirements, particularly fast growing cancer cells depend on efficient nutrient cycling. 
Metabolic rewiring is essential in order to maintain optimum levels of four major classes of 
macromolecules comprising carbohydrates, proteins, lipids and nucleic acids.  
The association between cancer and metabolism dates back to nearly 100 years when Otto 
Warburg observed that cancer cells consume high amounts of glucose and instead of funneling 
it into the TCA cycle, it produces lactate via glycolysis(Warburg, 1927). In normal cells this 
occurs when the cells are under hypoxia but as this was observed in cancer cells even in the 
presence of oxygen it is called aerobic glycolysis or more famously the Warburg effect. 
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However, in the following years cancer research focused more on genetic alterations that are 
associated with tumorigenesis. This led to the identification of oncogenes and tumor 
suppressors that control growth factor signaling pathways leading to uncontrolled proliferation 
which remains a hallmark of cancer(Hanahan & Weinberg, 2000). However, in 1956, Otto 
Warburg claimed that “mutation and carcinogenic agents are not alternatives, but empty 
words, unless metabolically specified”(Warburg, 1956), thereby suggesting that despite the fact 
that several different factors can lead to different cancers, ultimately, they all lead to or depend 
on rewiring of metabolic pathways. In recent years, many studies have shown that these 
different signaling pathways indeed reprogram cellular metabolism via regulation of metabolic 
enzymes (Cairns, Harris, & Mak, 2011; Iurlaro, León-Annicchiarico, & Muñoz-Pinedo, 2014). 
Several metabolic enzymes are also amplified or mutated during tumorigenesis(L. Dang et al., 
2009; Martín-Rufián et al., 2014). These findings together with the observations that cancer 
metabolism can influence other hallmarks of cancer has led to the inclusion of cancer 
bioenergetics into the hallmarks of cancer(Hanahan & Weinberg, 2011) and has brought tumor 
metabolism into the forefront of cancer research(Pavlova & Thompson, 2016). The fact that 
cancer cells rely heavily on efficient nutrient utilization provides an opportunity to find 
therapeutic targets especially for those cancers which are otherwise unresponsive to present 
therapies. 
 
1.3.1 Warburg Effect and Glycolysis 
Aerobic glycolysis remains one of the most significant characteristics of tumor metabolism. In 
his seminal work, Warburg observed that ascites cancer cells and tumor slices have a high 
uptake of glucose which, irrespective of the presence of oxygen, is converted into lactate via 
pyruvate(Warburg, 1927). Subsequently, this phenomenon has been observed in several 
cancers including breast cancer(Gatenby & Gillies, 2004). Glucose is transported into the cell via 
glucose transporter proteins (GLUT), of which 14 isoforms have been identified. While the 
different isoforms may have different expression levels in many cancers, GLUT1 seems to be 
predominant in cancer with high rates of glycolysis(Carvalho et al., 2011). In breast cancer, the 
HER2+ and TNBC subtypes, which have the worst prognosis, have high levels of glycolysis and 
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TNBCs show the highest expression of GLUT1 compared to other subtypes of breast 
cancer(Choi, Jung, & Koo, 2013; Pinheiro et al., 2011). In fact, targeting GLUT1 in breast cancer 
cells induces autophagy via AMPK-mTORC1 signaling(Fumarola et al., 2013). Hexokinase 2, the 
first regulatory enzyme in the glycolytic pathway, is activated in several cancers and can be 
targeted to slow down proliferation in cancer cells(Hennipman, van Oirschot, Smits, Rijksen, & 
Staal, 1988). Tumor specific expression of phosphofructokinase 2 (PFK2), which regulates 
intracellular levels of the glycolytic intermediate fructose-1,6-bisphosphate, has made it a 
potential therapeutic target(Atsumi et al., 2002; Telang et al., 2006). Pyruvate kinase (PK) is the 
rate limiting enzyme of glycolysis catalyzing the final reaction converting phosphoenolpyruvate 
to pyruvate generating ATP in the process. The splice variant PKM2 is predominantly expressed 
in tumor cells, but is inhibited by tyrosine kinases which are active in most cancer 
cells(Christofk, Vander Heiden, Harris, et al., 2008; Christofk, Vander Heiden, Wu, Asara, & 
Cantley, 2008). This low activity of PKM2 is essential for growth of tumor cells as it creates a 
buildup of glycolytic intermediates that serve as precursors for biosynthesis of macromolecules 
such as nucleotides and amino acids and generation of NADPH. 
Lactate dehydrogenase (LDH) which catalyzes the interconversion of pyruvate to lactate has 
been implicated in oncogenesis. LDHA is the most common isoform of this enzyme that is 
upregulated in cancers and is being investigated as a target for highly glycolytic cancers(Miao, 
Sheng, Sun, Liu, & Huang, 2013; Xie et al., 2014). In breast cancers upregulation of ERBB2 leads 
to an increased expression of LDHA which promotes glycolysis and proliferation(Y. H. Zhao et 
al., 2009). Lactate produced by cancer cells is secreted into the surrounding of the tumor via 
monocarboxylate transporters (MCT). It has been shown that impaired function of these 
transporters can affect tumorigenesis, thereby suggesting that efficient secretion of lactate is 
important for the tumors(Dimmer, Friedrich, Lang, Deitmer, & Bröer, 2000). Notably, cancer 
cells use lactate to feed neighboring cells that are more oxidative to support its own growth 
and survival(Vegran, Boidot, Michiels, Sonveaux, & Feron, 2011). 
In normal cells, the mitochondria function as the powerhouses of the cell, where oxidative 
phosphorylation and the electron transport chain are utilized to produce ATP in order to meet 
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the bioenergetic needs. Therefore, the propensity of cancer cells to use aerobic glycolysis as the 
major pathway for glucose metabolism over the energetically rich oxidative phosphorylation 
pathway still remains a paradox (Ralph J. DeBerardinis, Lum, Hatzivassiliou, & Thompson, 2008). 
However, plenty of evidence suggests that glycolysis gives the cancer cells a growth advantage. 
It provides intermediates for macromolecule synthesis which contributes to the biomass of the 
cell(Hay, 2016). Glycolysis via the pentose phosphate pathway produces sugars and NADPH that 
support nucleotide synthesis and reductive biosynthesis respectively. It also supports 
hexosamine and glycogen synthesis. Moreover, glycolysis increases serine biosynthesis which is 
essential for tumorigenesis. Serine supports one carbon metabolism via glycine production, 
leading to nucleotide biosynthesis, methylation and production of NADPH. Serine is also a 
source for amino acid, protein and glutathione replenishment of cancer cells(M. Yang & 
Vousden, 2016).  Phosphoglycerate dehydrogenase (PHGDH) which catalyzes the first 
committed step in the biosynthesis of serine and is also the branching point from glycolysis, is 
amplified in 6% of breast cancers and 40% of melanomas(Ralph J DeBerardinis, 2011; Locasale 
et al., 2011; Possemato et al., 2011a). Possemato et al showed that 70% of ER negative breast 
cancers have elevated levels of PHGDH protein which when targeted by RNA interference lead 
to a significant decrease in cell proliferation(Possemato et al., 2011a).The high rates of 
glycolysis in tumors outpace oxidative phosphorylation which may lead to the accumulation of 
pyruvate. This is prevented by diverting excess pyruvate to lactate production. Furthermore, 
although the ATP yield per glucose via glycolysis is low, if the glycolytic rate is sufficiently high 
the percentage of cellular ATP contributed by glycolysis is more than oxidative 
phoshorylation(GUPPY, GREINER, & BRAND, 1993).  
Warburg hypothesized that cancer cells divert glucose from the oxidative phosphorylation and 
produce lactate due to defective mitochondria. However, over the years this theory has been 
disproved and it has been shown that the mitochondria are indeed active in tumors and 
mitochondrial metabolism is important for tumorigenesis(Tan et al., 2015). Pyruvate, produced 
by glycolysis can feed into the TCA cycle via two reactions that are catalyzed by pyruvate 
dehydrogenase (PDH) and pyruvate carboxylase (PC). PDH produces acetyl coA which is then 
condensed with oxaloacetate (OAA) to produce citrate. PC on the other hand directly produces 
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OAA from pyruvate. Recently it was observed that both PDH and PC are essential for KRAS-
driven lung tumors(Davidson et al., 2016) and that PC has a role in breast cancer-derived lung 
metastasis(Christen et al., 2016). Moreover, inhibiting glycolytic ATP production via deletion of 
PKM2 does not affect tumorigenesis, thereby, suggesting that the major role of glycolysis is not 
to supply ATP to the cell (Ralph J. DeBerardinis & Chandel, 2016; Israelsen et al., 2013). Taken 
together these studies show that the TCA cycle is indeed active and is a major source of ATP 
also in cancer cells and that glucose also feeds into this pathway. In rare cases, however, the 
TCA cycle genes are mutated and can function as tumor suppressors. This is seen in cancers 
which have deletions in TCA cycle genes including succinate dehydrogenase (SDH) and fumarate 
hydratase (FH). SDH mutations are found in familial paraganglioma(Astuti et al., 2001; Baysal et 
al., 2000; Müller & Niemann, 2000) while FH mutations can result in uterine fibroids, 
leiomyoma and papillary renal cell cancer(Tomlinson et al., 2002). SDH and FH mutations lead 
to the accumulation of succinate and fumarate respectively, which can promote tumorigenesis 
(Sullivan, Gui, & Heiden, 2016). Both these metabolites have been implicated in epigenetic 
modifications leading to DNA and histone hypermethylation and activation of hypoxic 
signaling(Gimenez-Roqueplo et al., 2002; Hoekstra et al., 2015; Isaacs et al., 2005; Killian et al., 
2013; Letouzé et al., 2013; Pollard et al., 2005). In contrast to this, only 3% of breast cancers 
show loss of SDHA or SDHB expression, while HER2+ breast cancers show high levels of SDHA 
expression(S. Kim, Kim, Jung, & Koo, 2013). A study in a Finnish population has shown that FH 
mutation is not associated with a predisposition to familial breast cancer(Kiuru et al., 2005). 
Furthermore, reports have shown that breast cancers are not associated with promoter 
methylation in SDH and FH genes(K. T. Huang, Dobrovic, Fox, Huang -KatieHuang, & Dobrovic -
AlexanderDobrovic, n.d.). In addition to loss of FH and SDH, mutations in TCA cycle genes can 
result in neomorphic activity in cancers. The most prominent example of this are the isocitrate 
dehyrogenase (IDH1and 2) enzymes which are frequently mutated in glioma, chondrosarcoma, 
cholangiocarcinoma ad acute myeloid leukaemia (AML)(O. Clark, Yen, & Mellinghoff, 2016; 
Figueroa et al., 2010; Yan et al., 2009).  While the wild type forms of these enzymes catalyze the 
reversible conversion of isocitrate to α-ketoglutarate (α-KG), the mutant forms convert α-KG to 
2-hydroxyglutarate (2-HG) via oxidation of NADPH to NADP+(S. Gross et al., 2010). 2-HG can be 
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degraded by D2HGDH, however, its activity is insufficient for the high rate of production seen in 
these cancers (Sullivan et al., 2016). This results in high levels of 2-HG in cancers which leads to 
CpG island and histone hypermethylation(Figueroa et al., 2010). c-Myc-driven breast tumors, 
mostly of basal and mesenchymal origin, show 100 fold higher levels of 2-HG compared to 
other breast cancers leading to elevated levels of DNA methylation and are associated with 
poor prognosis(Terunuma et al., 2014). Therefore, cancer cells maintain an active TCA cycle in 
order to sustain both their biosynthetic and bioenergetic needs. 
 
1.3.2 Glutamine addiction 
An important carbon source for the TCA cycle in cancers is glutamine. Glutamine is the most 
abundant amino acid present in blood and tissues and is the second highest consumed nutrient 
by the cancer cells after glucose. It complements the glycolytic pathway by proving carbon to 
replenish the TCA cycle(R. Deberardinis & Cheng, 2009). Glutamine is thus a crucial anaplerotic 
source for cancer cells. It is not only an important carbon donor but also provides nitrogen for 
de novo biosynthesis of various nitrogenous metabolites required for tumor growth. Glutamine 
addiction in cancer cells was first observed by Harry Eagle in HeLa cells in the 1950s(Eagle, 
1955). In later years this was also observed in Ehrlich ascites carcinomas, hepatomas and 
carcinomas(Márquez, Sánchez-Jiménez, Medina, Quesada, & de Castro, 1989; Sauer, Stayman, 
& Dauchy, 1982). In fact, several studies have shown that depletion of glutamine from the 
tumor microevironment is higher than in normal tissues(Márquez et al., 1989; Yuneva et al., 
2012). Successful detection of glutamine in tumors using 18F-labeled glutamine in preclinical 
and early clinical studies(Lieberman et al., 2011; Venneti et al., 2015), provides a solution for 
cases where glucose tracing is not possible due to high glucose utilization in normal tissues, e.g. 
the brain. Glutamine restriction has been shown to restrict growth of most cancer cells 
including those of breast, thereby displaying what is commonly known as glutamine addiction. 
As is seen with glucose, tumor cells tend to take up glutamine at a much higher rate than their 
normal counterpart. In order to overcome the poor vascularization within tumors tumor cells 
express high levels of transporters thereby behaving like a ‘Glutamine trap’(Souba, 1993). 
  Introduction 
19 
 
Glutamine uptake by cancer cells is mediated by amino acid transporters such as solute-linked 
carrier family A1 member 5 (SLC1A5) (also known as ASCT2) which is over expressed in several 
cancers and has been shown to be critical for tumor survival (Hassanein et al., 2013). High 
expression as well as increased activity of ASCT2 is critical for cell proliferation in triple negative 
breast cancer cells(van Geldermalsen et al., 2015a). Moreover, ASCT2 has been shown as an 
independent prognostic marker  for survival in breast cancer(Bernhardt et al., 2017). There is 
also evidence that glutamine uptake is not only important for supporting the biosynthetic need 
of the cells but is also exported out in exchange for essential amino acids  via  the bidirectional 
amino acid transporter SLC7A5 (also called LAT1)(Nicklin et al., 2009). 
Glutamine is utilized in roughly two ways in the cells. Firstly, its γ-nitrogen is used for nucleotide 
and hexosamine synthesis which supports cancer cell growth(David R Wise & Thompson, 2010). 
Secondly, α-nitrogen and carbon skeleton are used for NEAA synthesis and TCA cycle. 
Glutamine is the main nitrogen donor for the synthesis of NEAA in the cells. In a first step 
glutamine is converted to glutamate via the phosphate dependent glutaminase which removes 
an amide group as ammonia. Glutaminase has been observed to be highly expressed in tumors 
and cancer cell lines and limiting its activity causes growth arrest in tumor cells and xenografts 
(Lobo et al., 2000; Gao et al., 2009). In triple negative breast cancer cells, glutaminase activity 
regulates glutamine and oxygen consumption, glutamate production and levels of TCA cycle 
intermediates(M. I. Gross et al., 2014).  The glutamate generated by glutaminase contains a 
sizeable pool of α (amino) nitrogen which is then distributed to different non-essential amino 
acids via transaminase reactions, namely alanine and aspartate transaminases (in details in the 
next section). Reactions catalyzed by transaminases and glutamate dehydrogenase (via 
liberation of ammonia) convert glutamate from glutamine into α-KG a key metabolic 
intermediate of the TCA cycle. PHGDH, the first enzyme in serine synthesis is also involved in 
supplying glutamine derived α-KG to the TCA cycle(Possemato et al., 2011b). In addition to 
being a TCA cycle metabolite, α-KG also functions as cofactor for various dioxygenases including 
prolyl hydroxylases, histone demethylases, and 5-methylcytosine hydroxylases(Zdzisińska, 
Żurek, & Kandefer-Szerszeń, 2017). Glutamine derived α-KG can be used to drive the TCA cycle 
or can contribute to lipid biosynthesis by a process called reductive carboxylation. Reductive 
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carboxylation or reversal of TCA cycle is a process by which α-KG is converted to citrate via IDH 
and it exits the mitochondria to be used for lipid biosynthesis(Metallo et al., 2011; Mullen et al., 
2011; D. R. Wise et al., 2011). Reductive carboxylation was first observed as a method to 
synthesize lipids in normal brown fat cells, however, later it was shown as a mechanism to 
generate lipids in hypoxic cancer cells(Yoo, Antoniewicz, Stephanopoulos, & Kelleher, 2008). 
Indeed under hypoxia, HIF1α activate pyruvate dehydrogenase kinase 1 (PDK1), an inhibitor of 
PDH, thereby blocking the entry of pyruvate into the TCA cycle and shunting it into lactate, a 
process known as anaerobic glycolysis, leading to a depletion of citrate pools. The same is also 
observed in hypoxic cancer cells, and gives rise to the need for glutamine to feed into the TCA 
cycle and for reductive carboxylation in order to maintain the lipid reserves of the cells(Fendt, 
Bell, Keibler, Olenchock, et al., 2013). Mitochondrial glutamine is also used for production of 
oncometabolite, 2-HG in breast cancer. Malic acid generated via glutaminolysis, is converted to 
lactic acid by malic enzyme thereby generating carbon dioxide, pyruvate and NADPH. NADPH 
generated by production of lactic acid is the used by highly proliferative cells to sustain their 
demand for nucleotide and lipid synthesis and to maintain GSH in its reduced state (R. J. 
DeBerardinis et al., 2007; M. G. Vander Heiden, Cantley, & Thompson, 2009).  Glutaminolysis 
can also be used to maintain glutathione pools, where glutamate is exported via the x-CT 
antiporter in exchange for cystine which is then used to generate glutathione (GSH). In a subset 
of triple negative breast tumors, which are glutamine auxotrophs and require glutamine to 
sustain their GSH pools, inhibition xCT antiporter abrogates tumor growth(Timmerman et al., 
2013). 
 
1.3.3 Transaminase reactions in Cancer 
Alanine (GPT) and aspartate (AAT or GOT) aminotransferases lead to the production of alanine 
and aspartate respectively and are the two most important transaminases in cancer cells(L. 
Yang, Venneti, & Nagrath, 2017).  
Aspartate transaminase derived aspartate is used for protein and nucleotide synthesis as well 
as ATP production via the aspartate malate shuttle. Aspartate is exported from the 
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mitochondria into the cytosol where it is converted to oxaloacetate which is then reduced to 
malate using NADH generated during glycolysis (thereby regenerating NAD+ for glycolysis). 
Malate is then transported into the mitochondria where it donates electrons to complex I of 
the electron transport chain, thereby generating ATP(Sullivan et al., 2015). Inhibition of GOT 
selectively suppresses proliferation of breast cancer cells but not normal mammary epithelial 
cells(Korangath et al., 2015; Thornburg et al., 2008). Aspartate is also used for asparagine 
synthesis in the cells. Asparagine supports proliferation under glutamine deprived or glutamine 
independent conditions. It also serves as an amino acid exchange factor, whereby it is exported 
to increase the uptake of other amino acids including serine. In addition to this, asparagine 
supports protein and nucleotide synthesis via regulation of mTORC1 activity(Krall, Xu, Graeber, 
Braas, & Christofk, 2016). Asparagine directly uses glutamine for its synthesis and is essential 
for cellular proliferation and in fact asparagine synthetase has been proposed as a potential 
biomarker for ovarian cancer(Lorenzi & Weinstein, 2009). 
While the role of GOT has been clearly elucidated in cancers, GPT has emerged as a new target 
in cancers. Alanine is shown to be highly produced in patients including those with breast 
cancer(Budczies et al., 2012; Poschke, Mao, Kiessling, & de Boniface, 2013). Inhibition, of 
alanine aminotransferase like aspartate aminotransferase also impedes cell growth and 
survival(Beuster et al., 2011; Coloff et al., 2016; Hao et al., 2016). Aminooxyacetate which is a 
broad spectrum inhibitor of aminotransferases has been shown in several studies to suppress 
cell growth. In breast cancer cell lines, aminooxyacetate treatment increases the sub G1 
population and leads to S-phase arrest(Korangath et al., 2015). Inhibition of aminotransferase 
results in decrease in amino acids which activates the ER stress pathway leading to 
cytotoxicity(Korangath et al., 2015). This highlights the importance of aminotransferases in 
breast cancer progression. 
 
 
Introduction 
22 
 
1.4 Regulation of Tumor metabolism 
An important aspect of understanding the metabolic rewiring in cancer cells is to investigate 
the mechanism by which the metabolic pathways or individual enzymes are regulated. Cancer is 
driven by gain of function mutations in oncogenes and loss of tumor suppressors that enable 
the cells to proliferate rapidly. However, in recent years, it has become increasingly clear that 
cancer signaling pathways and the tumor microenvironment lead to rewiring of metabolic 
pathways in cancer cells. Moreover, these changes in metabolism are essential for sustaining 
the tumor progression that is propagated by these signaling pathways. 
The oncogene MYC is amplified in several cancers, including breast, prostate, colon and bladder 
cancers and contributes to the cause of nearly 40% cancers(Deming, Nass, Dickson, & Trock, 
2000). c-Myc is a transcription factor that has a central role in cancer progression. It regulates 
the expression of several cell cycle genes as well as those involved in mitochondrial biogenesis 
and stem cell maintenance. The last decade has seen c-Myc emerge into a master regulator of 
cancer cell metabolism(Chi V Dang, Le, & Gao, 2009; Miller, Thomas, Islam, Muench, & Sedoris, 
2012; Wahlström & Henriksson, 2014).  The first link between c-Myc and cancer metabolism 
was established when it was discovered that c-Myc regulates the expression of LDHA(Shim et 
al., 1997). c-Myc also promotes glycolysis via activation of glucose transporter, GLUT1 and other 
glycolytic genes such as hexokinase 2 (HK2), phosphofructokinase (PFKM), and enolase 1 
(ENO1)(J. -w. Kim, Gao, Liu, Semenza, & Dang, 2007; Osthus et al., 2000). Therefore, under 
normoxic conditions c-Myc is believed to be one of the drivers of lactate production. 
Additionally, under hypoxic conditions, c-Myc collaborates with hypoxia inducible factor 1-
alpha (HIF1a) to increase the activity of PDK1 which prevents the formation of acetyl CoA from 
pyruvate thereby promoting more lactate production(J. -w. Kim et al., 2007). However, under 
normoxic conditions c-Myc supports glucose oxidation via regulation of mitochondrial 
biogenesis. c-Myc also promotes RNA splicing to induce PKM2 expression which supports 
different biosynthetic pathways (David 2010). While c-Myc-induced glycolysis and 
glutaminolysis (in details later) promotes lipid biosynthesis, c-Myc can also directly induce fatty 
acid synthesis genes, FASN (fatty acid synthetase) and SCD (stearoyl-CoA desaturase) (Zeller et 
al. 2003; Loven et al. 2012). 
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c-Myc plays a major role in the energy metabolism of cancers via regulation of Glutamine 
metabolism(Chi V Dang et al., 2009). It has been found to increase the expression of Glutamine 
transporters ASCT2 (SLC1A5) and SLC7A5(Shajahan-Haq et al., 2014)(GAO 2009). In addition to 
this, c-Myc promotes expression of glutaminase (GLS1) via inhibition of microRNA-23A and 
microRNA-23B (Gao P, 2009). c-Myc induced GLS1 produces glutamate from glutamine, which 
can then drive the TCA cycle via production of α-KG. It has been shown that c-Myc driven 
glutamine uptake and glutaminolysis lead to glutamine addiction in cancer cells(David R Wise et 
al., 2008). Elevated glutamine metabolism by c-Myc leads to an upregulation of other amino 
acid pathways which are directly or indirectly fed by nitrogen from glutamine. A study in breast 
cancer shows that cancer cells are sensitive to a broad spectrum inhibitor of aminotransferase 
in a Myc dependent fashion. However, c-Myc has not been directly linked to the expression of 
these aminotransferase genes(Korangath et al., 2015).  c-Myc is also involved in the serine and 
one carbon metabolism via regulation of enzymes PHGDH and PSAT (involved in serine 
metabolism, described earlier) and SHMT2 which converts serine to glycine, leading to 
nucleotide synthesis(Nikiforov et al., 2002; Sun et al., 2015). 
One of the main mechanisms by which c-Myc regulates cell cycle is via induction of genes 
involved in cell cycle, E2F and CDK, and by inactivation of the tumor suppressor RB1 thereby 
allowing cells to enter into the S phase(C. V. Dang, 2013). c-Myc and E2F coordinate together to 
activate genes involved in DNA replication and nucleotide metabolism (Rempel et al. 2009, 
Zeller et al. 2006). Interestingly, loss of RB1, which frequently occurs in cancers, promotes 
glutamine metabolism. It has been observed that RB1 knockout cells have elevated expression 
of ASCT2 and GLS and show an increase in carbon flow from glutamine into the TCA 
cycle(Nicolay & Dyson, 2013; M. Reynolds et al., 2013). RB1 is also involved in antioxidation and 
its loss leads to the accumulation of ROS in cancer cells. Similarly, TP53, another well-known 
tumor suppressor, induces the expression of GLS2 which promotes de novo synthesis of GSH 
which also controls the redox potential of the cells (Suzuki, S. et al., 2010). However, the 
primary function of TP53 is to induce cell cycle arrest and apoptosis in case of DNA damage 
which leads to a buildup of ROS. Recent studies have shown that p53 is also involved in glucose 
and energy metabolism(Chen & Russo, 2012). TP53 also activates PTEN which inhibits PI3K-AKT 
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pathway which is known to activate glycolysis and mTOR signaling. mTOR signaling is essential 
in integrating growth signals and nutrient availability which influences cell metabolism and it 
activates HIF1a to stimulate further metabolic changes (details below). 
There are several other oncogenes which have been shown to regulate cancer metabolism. 
Prominent among these are mutant KRAS, which has been found in pancreatic, colon and lung 
cancers and also found in breast cancers. KRAS carrying activating mutations has been shown to 
regulate anabolic glucose metabolism as well as reprogram glutamine metabolism (Son et al., 
2013a; Ying et al., 2012). EGFR which is frequently mutated in breast and lung cancer has been 
shown to regulate glycolysis in triple negative breast cancer cells (Lim et al., 2016) and fatty 
acid synthesis in glioma and has also been implicated in sensitivity to glutamine inhibition in 
lung cancer (Momcilovic et al., 2017).  
Besides the genetic landscape of cancer cells, the tumor microenvironment also regulates 
tumor metabolism. The availability of nutrients, pH of the surrounding and oxygenation of the 
tumor are important factors controlled by the microenvironment that regulate cellular 
metabolism(Cairns et al., 2011). AMP-activated protein kinase (AMPK) functions as a metabolic 
checkpoint, which regulates metabolic pathways under stress including those imposed by the 
microenvironment. Under periods of stress and energy deficit, LKB1, a serine threonine kinase, 
activates AMPK and drives the cells towards a more oxidative metabolic pathway. Therefore, it 
is not surprising to see that LKB1 is mutated in several cancers, including non-small cell lung 
cancer and breast cancer(Avizienyte et al., 1999; Ji et al., 2007), and others show a suppression 
of AMPK signaling(X. Huang et al., 2008; Xiang, Saha, Wen, Ruderman, & Luo, 2004). As an 
mTOR and HIF1α inhibitor, loss of AMPK activity leads to a more glycolytic phenotype in cancer 
cells(Carretero et al., 2007; Luo, Zang, & Guo, 2010). 
As a result of irregular tumor vasculature, parts of the tumor are inconsistently oxygenated and 
receive insufficient nutrients, resulting in hypoxia and stress in these sections of the tumor. Low 
oxygen levels lead to stabilization of HIF1α(Keith, Johnson, & Simon, 2011; Wang, Jiang, Rue, & 
Semenza, 1995). As mentioned earlier, HIF1α can also be activated by mTOR signaling and ROS 
levels in cancer cells. HIF1α elevates glycolysis in the cells and inhibits mitochondrial respiration 
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(Denko N.C. 2008). HIF1α also cooperates with c-Myc to activate PDK1 and induce lactate 
production(Kim et al., 2007). HIF1α also regulates TCA cycle genes to support cancer cell growth 
(Wise et al., 2011). HIF is a heterodimer made up of two subunits HIF1α and HIF1β. The HIF1α 
subunit levels are controlled by oxygen levels and, during hypoxia, HIF1α levels are elevated via 
stabilization of the protein(Keith et al., 2011; Wang et al., 1995). While most of the metabolic 
changes seen under hypoxia are attributed directly to HIF1α, little is known about the 
metabolic role HIF1β (ARNT), which is stabily expressed in the cells. 
Extreme hypoxia (<0.02% O2) leads to endoplasmic reticulum (ER) stress and unfolded protein 
response (UPR) in cells, resulting in further metabolic adaptation that enable the cells to 
survive. For example, activating transcription factor 4 (ATF4) is a stress responsive gene which is 
activated in response to conditions of stress, including hypoxia, ER stress, amino acid 
deprivation, oxidative stress and growth factor heregulin (Cullinan & Diehl, 2006; Harding et al., 
2003; Salgado, Metón, Anemaet, & Baanante, 2014a). ATF4 in turn regulates metabolism to 
protect the cells from stress and ensure sufficient supply of amino acids. In a study conducted 
in liver cells induction of stress lead to an increase in expression of alanine aminotransferase 2 
by ATF4 (Salgado et al., 2014a). 
Tumorigenesis is multistep process orchestrated by changes in cell signaling networks that 
promote rapid cell proliferation. In order to maintain these high levels of proliferation, signaling 
pathways and transcription networks rewire metabolic activities of the cells. However, 
connections between signaling and tumor metabolism are complex and are still not well 
understood. While some potential focal points for these connections have been discovered it is 
difficult to find one master regulator as these associations are temporally and spatially 
regulated. Moreover, integrating data from metabolic and proteomic (or genetic) pathway 
analysis is a challenge and requires further development. Nevertheless, determining the 
regulation of metabolic pathways by signaling molecules will be beneficial in the quest to find 
more effective targets for cancer therapy. 
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Figure 3: Transcription factors and signaling molecules involve in the regulation of cancer 
metabolism. Adapted from Berardinis and Chandel, 2016(R. J. Deberardinis & Chandel, n.d.) 
 
1.5 Tumor Metabolism: Imaging and Therapeutics 
Understanding the metabolic landscape of cancer provides new opportunities for tumor 
imaging, biomarker discovery and treatment strategies.  
The last three decades have seen a surge in imaging of metabolic phenotypes of cancer cells. 
The most commonly used technique is positron imaging tomography (PET). Combined with a 
low-dose CT scan, PET imaging helps generate a three-dimensional image of the tumor. First 
discovered in the 1980s(Som et al., 1980), 18F-labelled fluorodeoxyglucose(FDG) is taken up by  
glucose transporters in the cells but unlike glucose it is phosphorylated to FDG-6 phosphate and 
cannot be metabolized further. Low levels of emission from FDG-6 phosphate are used as a 
measure for glucose consumption by the cells. This method is used to image breast, lung, head 
and neck, lymphoma, and sarcoma(Bar-Shalom et al., 2003).  Although this technique is useful 
to detect the progression of the disease and efficacy of treatment, it is limited by the 
differential ability of cancers to take up FDG(Schirrmeister et al., 2001). This has led to the 
development of other tracers which can track other metabolic pathways in cancer cells, some 
  Introduction 
27 
 
of them include 18F-N-(methyl-(2-fluoroethyl)-1H-[1, 2, 3]triazole-4-yl)glucosamine ([18F] NFTG), 
which is incorporated into glycogen and can be used to measure gluconeogenesis in the 
cells(Cheng et al., 2012). The glutamine analog, g [18F] -(2S,4R)4-fluoroglutamine, is used to 
measure glutamine uptake in cells(Lieberman et al., 2011). Other pathways detected by this 
technique include, fatty acid metabolism using, [11C] acetate-PET(Jadvar, 2011), glutamate 
metabolism via (S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid  (FSPG), which is a glutamate 
analogue(Baek et al., 2012) and amino acid metabolism with 11C methionine (MET-
PET)(Glaudemans et al., 2013). In addition to PET, magnetic resonance spectroscopic imaging 
(MRSI) has been used to monitor choline and NAD+ levels in tumors. Another method known as 
chemical exchange saturation transfer (CEST) has been shown to detect non labeled glucose 
uptake in the cells(Chan et al., 2012). Recent studies have shown the benefits of using dynamic 
nuclear polarization (a form of hyperpolarize MRI) in probing metabolic heterogeneity in cancer 
cells. Conversion of hyperpolarized pyruvate and glucose to lactate have been used in studies 
with tumor patients and models with  promising results(Nelson et al., 2013; Rodrigues et al., 
2013). While these techniques maybe powerful tools for cancer detection, they require further 
translational studies to prove their efficacy and ability to deal with the metabolic heterogeneity 
which is present with the tumor microenvironment. Furthermore, while the advantages of 
developing these techniques are undeniable, there is a need to develop more non-invasive 
methods for detection. 
Metabolic pathways are crucial for the proliferation of cancer cells thereby presenting a new 
vulnerability. The question remains whether, these potential targets can be translated into 
successful treatment strategies. So far, several new drug targets which target either the uptake 
of nutrients or biosynthesis of macromolecules have been identified. However, the success rate 
has not been very satisfactory (Table 1). Targeting glucose uptake or the Warburg effect via 
targeting LDH or PDH has led to limited success. Nevertheless, there are several other targets in 
preclinical or clinical stages of development, which could result in effect cancer therapies. 
Drugs targeting IDH mutations, for example, have been successful in hematological 
cancers(Tateishi et al., 2015).  Glutamine metabolism is another promising target for cancers 
that are dependent on glutamine. Currently, there are clinical trials being conducted with CB-
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839 which a GLS1 inhibitor. Other drugs targeting different amino acid metabolic pathways are 
under preclinical investigation. The hope is that some of these can be translated into effective 
treatment strategies. There are of course several challenges; first of all, most metabolic 
pathways are redundant, and  targeting one pathway may lead to usage of another pathway, 
therefore combinatorial therapies need to be developed.  Also, similar to chemotherapy, which 
targets growing cells, metabolic pathways are used by all metabolically active cells and 
targeting them could lead to severe side effects, especially liver toxicity. Moreover, metabolic 
heterogeneity within the tumor as a result of the presence of different cell types presents a 
formidable challenge to efficacious therapy. However, a deeper understanding of the metabolic 
vulnerabilities of the cells and better metabolic stratification of patients will lead to successful 
therapy regimes. 
 
Target pathway and Protein Drugs Development Stage 
Glycolysis   
Glucose Transporter 1 (GLUT1) WZB117, SILIBININ and RNAi Preclinical studies 
Hexokinases 2-DG, Ionidamine, 3-bromopyruvic 
acid and methyl jasmonate 
Preclinical and clinical studies 
Phospho-fructokinase 2 (isoform 
PFKFB3) 
PFK158 Preclinical studies 
Pyruvate Kinase isoform M2 (PKM2) TLN-232 and RNAi Preclinical and phase II clinical 
studies 
Lactate Dehydrogenase A  (LDHA) GNE-140, FX11, galloflavin and RNAi Preclinical studies 
MCT1 and MCT4 AZD3965 and AZ93 AZD3965 in clinical development 
TCA cycle   
Pyruvate dehydrogenase kinase 1 
(PDK1) 
Dichloroacetate (DCA) and RNAi Approved for treatment of lactic 
acidosis. In phase I clinical trials 
Pyruvate carboxylase RNAi Preclinical studies 
α-ketoglutarate dehydrogenase  CPI-613 Preclinical and clinical studies 
Isocitrate dehydrogenases  AG-120, AG-221, AG-881, and RNAi Preclinical and clinical studies 
Oxidative Phosphorylation   
  Introduction 
29 
 
Mitochondrial membrane potential MKT-077 Clinical studies 
Mitochondrial complex I Metformin, phenformin Phase III Clinical Trials 
Mitochondrial complex III Arsenic trioxide Preclinical and clinical studies 
Glutamine Metabolism   
Glutaminase (GLS1) CB-839, BPTES and RNAi Preclinical and clinical studies 
Amino acid Metabolism   
Asparagine availability L-Asparginase Approved as anticancer agent 
Arginine availability PEG-BCT-100 (ADI-PEG20) 
AEB-1102 
Clinical development: phase II clinical 
trials 
Phosphoglycerate dehydrogenase 
(PHGDH) 
RNAi Preclinical studies 
Approved 
Lipid synthesis   
Fatty acid synthase (FASN)  TVB-2640 Preclinical studies 
ATP citrate lyase (ACL) Hydroxycitrate Preclinical studies 
Acetyl-CoA carboxylase (ACC) 
 
NDI-010976 
 
Preclinical studies and clinical studies 
Choline kinase TCD-717, CK37, MN58b, RSM932A, 
and RNAi 
TCD-717 is in clinical development 
Nucleic Acid Metabolism   
Dihydrofolate reductase 
 
Methotrexate, pemetrexed, and 
pralatrexate  
Approved as anticancer agents 
Thymidylate synthase 5-Fluorouracil Approved as anticancer agents 
Adenine/adenosine deaminase Pentostatin Approved as anticancer agents 
DNA polymerase/ ribonucleotide 
reductase 
Gemcitabine, Cytarabine and 
Fludarabine 
Approved as anticancer agents 
 
Table 1:  Selected metabolic targets under different stages of development. Adapted from Outschoorn et 
al, 2016(Martinez-Outschoorn, Peiris-Pagés, Pestell, Sotgia, & Lisanti, 2016) and Heiden and DeBerardinis 
2017(Matthew G Vander Heiden & DeBerardinis, 2017) 
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2. Aims 
 
Breast cancer is a broad spectrum of diseases affecting the mammary gland. This diversity is 
due the high variability in the genomic and microenvironmental landscape of the tumors. 
Therefore, it is reasonable to assume that metabolism is also variable within breast cancer. 
However, reprogramming of metabolic pathways itself is a common phenomenon of nearly all 
breast cancers. While glycolysis remains the mainstay of this rewiring, most breast cancer cells 
also depend on alternative sources of carbon, including amino acids, especially glutamine, 
which can also be important sources of nitrogen within the cells. Recent advances in this field 
have highlighted the importance of glutamine and other amino acids in tumor progression.  
Therefore, investigation of the cycling of carbon and nitrogen atoms in these pathways may 
provide an insight into the metabolic vulnerabilities of cancer cells which may then be utilized 
to target them. 
 
The aim of this study was to investigate the role of amino acid metabolism in breast cancer 
progression via 
1. Identifying activated amino acid metabolism pathways within different breast cancer 
cell lines using genomic, proteomic and metabolomic approaches. 
2. Using RNAi and chemical inhibitors to perturb the identified pathways and study the 
effect on cell growth. 
3. Elucidating metabolic mechanisms underlying the effect of identified pathways on the 
growth of cancer cells. 
4. Exploring the role of transcription factors in the regulation of identified pathways. 
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3. Materials and Methods 
3.1 Materials 
3.1.1 Instruments 
Aushon 2470 contact printer Aushon BioSystems (Billerica, USA) 
Biohit Proline multichannel pipette Sartorius (Göttingen, Germany) 
Cell counter CASY  Roche Innovatis AG (Bielefeld, Germany)  
Cell culture hood HERA Safe  Thermo Fisher Scientific (Waltham, USA)  
Cell culture incubator  Heraeus (Hanau, Germany)  
Centrifuges  Eppendorf AG (Hamburg, Germany)  
Extracellular flow bioanalyzer (Seahorse 
XF96) 
Agilent Technologies (Santa Clara USA) 
Flow Cytometer FACS Calibur  Becton Dickinson (New Jersey, USA)  
Gel documentation system  Herolab GmbH (Wiesloch, Germany)  
Infinite M200 microplate reader  Tecan Group (Männedorf, Switzerland)  
Molecular Devices Microscope IXM XLS  Molecular Devices (Sunnyvale, USA)  
Nanodrop ND-1000 spectrophotometer  Thermo Fisher Scientific (Waltham, USA)  
Odyssey Infrared Imaging System  Li-Cor Biosciences GmbH (Bad Homburg, 
Germany)  
Pipetboy acu pipette INTEGRA Biosciences (Fernwald, 
Germany) 
Pipetman® pipette Gilson (Limburg, Germany) 
Protein Gel Apparatus MiniProtean II  Bio-Rad (Hercules, USA)  
Sentrix Human HT-12 v4 BeadArrays  Illumina (San Diego, USA)  
Spectrophotometer Nano Drop nd-1000  Thermo Fisher Scientific (Waltham, USA)  
SW41 Ti Rotor and Tubes  Beckman Coulter (Brea, USA)  
Thermocycler  Applied Biosystems (Foster City, USA)  
Titramax 100 rocking platform Heidolph (Schwabach, Germany) 
Trans-Blot SD Semi-Dry Electrophoretic 
Transfer  
Bio-Rad (Hercules, USA)  
Tube Rotator VWR (Darmstadt, Germany) 
Materials and Methods 
34 
 
Ultracentrifuge, Beckman L8-70M  Beckman Coulter (Brea, USA)  
Vacuboy aspiration device INTEGRA Biosciences (Fernwald, 
Germany) 
Vortex mixer  neoLab (Heidelberg, Germany)  
xCelligence Real-time cell analyzer (RTCA)  Roche Diagnostics (Mannheim, Germany)  
HPLC  
GC MS  
Mass spectrometry  
 
3.1.2 Chemicals 
Acrylamide/bisacrylamide 37.5:1  Carl Roth (Karlsruhe, Germany)  
Ammoniumperoxodisulfate (APS)  Sigma-Aldrich (Saint-Louis, USA)  
Β-chloro-L-alanine Sigma-Aldrich (Saint-Louis, USA) 
CASYton Roche Innovatis AG (Bielefeld, Germany) 
cOmplete Mini Protease Inhibitor 
Cocktail 
Roche Diagnostics (Mannheim, Germany) 
Dimethylsulfoxide (DMSO)  Sigma-Aldrich (Saint-Louis, USA)  
EDTA  Sigma-Aldrich (Saint-Louis, USA)  
Ethanol  Sigma-Aldrich (Saint-Louis, USA)  
Fast Green FCF Carl Roth (Karlsruhe, Germany)  
Hoechst 33258 Sigma (Krefeld, Germany) 
Isopropanol  Greiner Bio-One International GmbH 
(Kremsmünster, Austria)  
Metformin Sigma-Aldrich (Saint-Louis, USA) 
Methanol  Greiner Bio-One International GmbH 
(Kremsmünster, Austria)  
M-PER mammalian protein extraction 
reagent 
Thermo Fischer Scientific (Rockford, USA) 
NaCl  VWR International (Darmstadt, Germany)  
NaOH  Sigma-Aldrich (Saint-Louis, USA)  
non-DEPC treated nuclease-free water  Ambion, Thermo Fisher Scientific 
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(Waltham, USA)  
PhosSTOP Phosphatase Inhibitor Cocktail Roche Diagnostics (Mannheim, Germany) 
Protein Marker Precision Plus Protein 
Dual Color 
BioRad 
Proteinase K  Sigma-Aldrich (Saint-Louis, USA)  
RNAiMax Reagent Invitrogen 
Rockland Blocking Buffer Rockland Immunochemicals Inc. 
(Limerick, USA) 
Rotenone Sigma-Aldrich (Saint-Louis, USA) 
Roti®-Load 1, 4x sample loading buffer Carl Roth (Karlsruhe, Germany) 
SDS  Carl Roth (Karlsruhe, Germany)  
siRNAs  Dharmacon, Thermo Fisher Scientific 
(Waltham, USA)  
Sodium Citrate Tribasic Dihydrate  AppliChem (Darmstadt, Germany)  
NaF  
Na2VO4  
TaqMan® Fast Universal PCR Master Mix 
(2x)  
Applied Biosystems (Foster City, USA)  
TEMED  Carl Roth (Karlsruhe, Germany)  
Tricine  Carl Roth (Karlsruhe, Germany)  
Tris HCl  Sigma-Aldrich (Saint-Louis, USA)  
Tris-base  Sigma-Aldrich (Saint-Louis, USA)  
Triton X-100  Sigma-Aldrich (Saint-Louis, USA)  
Tunicamycin Tocris Bioscience 
Tween 20  Sigma-Aldrich (Saint-Louis, USA)  
 
3.1.3 Assay Kits 
ABSOLUTE qPCR Mix  Thermo Fisher Scientific (Waltham, USA)  
BCA Protein Assay Kit PierceTM  Thermo Fisher Scientific (Waltham, USA)  
cDNA Synthesis Kit  Thermo Fisher Scientific (Waltham, USA)  
RNeasy Mini kit  Qiagen (Hilden, Germany)  
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qPCR MasterMix (RT-QP2X-03+NR)  Eurogentec (Lüttich, Belgium)  
RevertAid™ H Minus First Strand cDNA 
synthesis kit  
Fermentas, Thermo Fisher Scientific 
(Waltham, USA)  
RNeasy Mini Kit  Qiagen (Hilden, Germany)  
TaqMan® MicroRNA Assays  Applied Biosystems (Foster City, USA)  
Universal Probe Library (UPL)  Roche Diagnostics (Mannheim, Germany)  
Seahorse kits Agilent Technologies (MA, USA) 
 
3.1.4 Cell culture  
All breast cancer cell lines were purchased from ATCC (LGC Standards GmbH, Wesel, Germany). 
 
0.25% Trypsin EDTA Solution  Gibco BRL (New York, USA)  
DMEM  Gibco BRL (New York, USA)  
DMEM F12  Gibco BRL (New York, USA)  
DMSO  PAN Biotech GmbH (Aidenbach, Germany)  
DPBS  Gibco BRL (New York, USA)  
Fetal Bovine Serum  Gibco BRL (New York, USA)  
L-glutamine, 200mM  Gibco BRL (New York, USA)  
OptiMEM  Gibco BRL (New York, USA)  
RPMI 1640 (A10491-01)  Gibco BRL (New York, USA)  
Sodium pyruvate, 100mM  Gibco BRL (New York, USA)  
 
3.1.5 Glass and Plastic ware 
1.5 mL micro centrifuge tube  Eppendorf AG (Hamburg, Germany)  
10cm Ø Petri dish  Techno Plastic Products (TPP) AG 
(Trasadingen, Switzerland)  
15mL conical tube  Becton Dickinson (New Jersey, USA)  
2 mL micro centrifuge tube  Eppendorf AG (Hamburg, Germany)  
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50mL conical tube  Becton Dickinson (New Jersey, USA)  
6-well plate, flat bottom, transparent  Nunc, Thermo Fisher Scientific (Waltham, 
USA)  
96-well plate, flat bottom, transparent  Becton Dickinson (New Jersey, USA)  
96-well plate, flat bottom, μCLEAR®, 
black  
Greiner Bio-One International GmbH 
(Kremsmünster, Austria)  
96-well plate, flat bottom, white  PerkinElmer (Waltham, USA)  
Adhesive Optically Clear Plate Seal  Thermo Fisher Scientific (Waltham, USA)  
AMICON® Ultra-4 filtration units  Merck Millipore (Darmstadt, Germany)  
Cell Culture Flasks, T-25, T-75, T-175  Greiner Bio-One International GmbH 
(Kremsmünster, Austria)  
Cell Scraper  Corning (Corning, USA)  
Cry vials 1.8mL  Nunc, Thermo Fisher Scientific (Waltham, 
USA)  
Filter tips, 10μL, 20μL, 100μL, 200μL, 
1000μL  
Neptune Scientific (San Diego, USA)  
HumanHT-12 v4 BeadChips  Illumina (San Diego, USA)  
Oncyte® Avid Nitrocellulose Film-Slide Grace Bio-Labs (Bend, USA) 
PCR strips  Steinbrenner Laborsysteme GmbH 
(Wiesenbach, Germany)  
PVDF membrane Immobilon-P  Merck Millipore (Darmstadt, Germany)  
RTCA E-plates  Roche Diagnostics (Mannheim, Germany)  
Seahorse Microplates and cartidges Agilent Biotechnologies (MA, USA) 
Sentrix Human HT-12 v4 BeadArrays  Illumina (San Diego, USA)  
Serological pipettes 2.5mL, 5mL, 10mL, 
25mL, 50ml  
Becton Dickinson (New Jersey, USA)  
Trans-well system (5.0μm pore size)  Corning (Corning, USA)  
Whatman 3 MM filter paper  GE Healthcare (Little Chalfont, United 
Kingdom)  
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3.1.6 Software 
GraphPad Prism 5  GraphPad Software, Inc. (La Jolla, USA)  
Image Studio LI-COR Biosciences (Lincoln USA) 
Inkscape Software Freedom Conservancy, Inc. (NY 
USA) 
Molecular Devices Analysis Software  Molecular Devices (Sunnyvale, USA)  
Odyssey 2.1  LI-COR (Lincoln, USA)  
Roche UPL Design Center Roche Diagnostics (Mannheim, Germany)  
SDS 2.2  Applied Biosystems (Foster City, USA)  
Seahorse analyzer Agilent Technologies (MA, USA) 
xCelligence Real Time Cell Analyzer 
(RTCA) software 1.2  
Roche Diagnostics (Mannheim, Germany)  
 
3.1.7 Database 
METABRIC mRNA data https://www.synapse.org/#!Synapse:syn1688369/wiki/27311  
TCGA mRNA data TCGA_BRCA_exp_HiSeqV2-2015-02-24 
 
 
3.1.8 Buffers and solutions  
 
Lysis buffer for mammalian cells  
MPER Buffer 10ml, 1tbl PhosSTOP Phosphatase Inhibitor, 1tbl Complete Mini Protease Inhibitor 
Cocktail, 10µl Na2VO4, 100µl NaF 
4% SDS-PAGE stacking gel  
1.33mL Acrylamide, 2.55mL 1M Tris pH 6.8, 100μl 10%SDS, 200μl 10%APS, 10μl TEMED, 6mL 
ddH2O  
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12.5 % SDS-PAGE separating gel  
8.3 ml Acrylamide:Bis, 5 ml 4x separation gel buffer, 0.2 ml 10% SDS, 6.4 ml ddH2O, 100 μl 10% 
APS, 20 μl TEMED 
 
SDS-PAGE running buffer  
30.3 g Tris Base (0.25 M), 144.1 g Glycine (1.92 M), 0.1% SDS (w/v), add 1L dH2O  
 
Western Blotting buffers  
Cathode buffer: 40mM aminohexanoic acid, 20% ethanol (v/v)  
Anode buffer I: 300mM Tris Base, 20% ethanol, and 500ml dH20  
Anode buffer II: 25mM Tris Base, 20% ethanol, and 500ml dH20  
Washing buffer: 0.1% Tween®20 in TBS (TBST)  
Blocking buffer: 50% Rockland blocking buffer, 5Mm NaF, 1Mm Na3VO4 
Secondary antibody buffer: Washing buffer + 0.02% SDS (w/v) 
 
10X TBS 
1.37M NaCl, 200mM Tris, pH 7.6 
 
1x TBS  
50mM Tris-HCl pH 7.4, 150mM NaCl 
 
1X TBST 
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0.1% Tween 20 in 1x TBS 
 
4x RPPA printing buffer 
10% Glycerol, 4% SDS, 10mM DTT, 125mM Tris, pH 6.8 
 
FCF staining solution 
0.005% Fast Green FCF, 10% acetic acid, 30% ethanol 
 
FCF destaining solution 
10% acetic acid, 30% ethanol 
 
3.1.9 Antibodies 
 
Primary antibody 
Protein name Host Product ID 
(Company) 
     beta-Actin 
 
mouse Actin (clone C4) (MP 
Biomedicals USA) 
beta-Actin rabbit Actin 21-33 (Sigma 
Aldrich USA) 
pAMPKa rabbit sc-33524 (Santa Cruz 
Biotechnology USA) 
ARG2 rabbit GTX118048 (Genetex 
USA) 
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ASS1 rabbit HPA020896 (Sigma 
Aldrich USA) 
Bcl2-L-4 (Bax) mouse  2772 (Cell Signaling 
Technology USA) 
GLS1 Rabbit ab156876 (Abcam plc 
UK) 
GPT2 Mouse sc-398383 (Santa Cruz 
Biotechnology USA) 
c-Myc Rabbit sc-764 (Santa Cruz 
Biotechnology USA) 
Cleaved PARP Rabbit 9541 (Cell Signaling 
Technology USA) 
PC Rabbit HPA058765 (Atlas 
Antibodies) 
PDH Rabbit 3205 (Cell Signaling 
Technology USA) 
pRPS6 Rabbit 4858 (Cell Signaling 
Technology USA) 
 
3.1.10 siRNAs 
siRNA Annotation Catalogue Number Target Sequence 
siGENOME Non-
Targeting siRNA 
Pool #2 
NTC D-001206-14-05 UAAGGCUAUGAAGAGAUAC 
AUGUAUUGGCCUGUAUUAG 
AUGAACGUGAAUUGCUCAA 
UGGUUUACAUGUCGACUAA 
ON-TARGETplus 
non-targeting Pool 
siControl D-001810-10 UGGUUUACAUGUCGACUAA 
UGGUUUACAUGUUGUGUGA 
UGGUUUACAUGUUUUCUGA 
UGGUUUACAUGUUUUCCUA 
siGenome Set of 4 
Upgrade siRNA 
GPT2 
siGPT2 D-004173-01 UCAAAUGGCUCCAGACAUG 
D-004173-03 GUGAAAGACUUCCACAUCA 
D-004173-04 UCAAGAAGGUGCUGUACGA 
D-004173-18 GUGAAAAGGUUAAAUCGUA 
siGenome Set of 4 siPC D-008950-01 GAAAGCAGAUGAAGCCUAU 
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Upgrade siRNA PC D-008950-03 GAGCUGAUGUGGUGGAUGU 
D-008950-18 GGAUAAUGCUUCCGCCUUC 
D-008950-19 UCUCUGAGCGAGCGGACUU 
 
siRNA pools composed of four different siRNA sequences targeting MYC (Cat. No. M-003282-04) 
and ATF4 (Cat No. M-005125-02) were picked from the human siRNA library of siGENOME 
(Dharmacon). 
 
3.1.11 Primers 
Gene Primer Left Primer Right Probe # 
ATF4 ggtcagtccctccaacaaca ctatacccaacagggcatcc 88 
GPT gggaaggcacctaccacttc ttggcatggaacctgctc 66 
GPT2 ggatcttcattcctgccaaa acatgtctggagccatttga 75 
MYC caccagcagcgactctga gatccagactctgaccttttgc 34 
PUM1 tcacatggatcctcttcaagc cctggagcagcagagatgtat 86 
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Methods 
3.1.12 Cell Culture and Growth Conditions 
All breast cancer cell lines were obtained from ATCC. Cell lines were regularly authenticated by 
multiplex cell line authentication (Multiplexion GmbH, Friedrichshafen, Germany) and tested 
for mycoplasma contamination. The cell lines were cultured in RPMI 1640 media with 10% FBS 
and incubated at 37oC with 5% CO2 in a humidified atmosphere.  Cells were passaged 
approximately every 3 days under aseptic conditions in a laminar air-flow hood. Briefly, medium 
was aspirated from the flask and the cells were washed with PBS following which 0.25% trypsin-
EDTA was added and the cells were returned to 37oC. Once the cells detached, growth medium 
was added to neutralize the trypsin. The cells were counted using the CASY counter. For 
counting, 50µl of cell suspension was diluted in 10ml CASYton and counted automatically. 
Depending on their growth and cell size, 1-2 x 10^6 cells were seeded into a 75 cm2  flask with a 
final volume of 15ml. Cells were used upto passage number 20 for experiments after which new 
cells were thawed. 
To generate frozen cell stocks, the trypsinized cells were counted as described above and 
centrifuged at 1200 rpm for 5min. The resulting pellets were resuspended in freezing media 
(70% growth media, 20%FBS, 10%DMSO) to a concentration of 1 x 10^6 cells per ml media and 
aliquoted into 1.5ml cryovials, The cell suspension was slowly cooled down in an isopropanol 
bath at -80oC for a minimum of 24h before transferring to a liquid nitrogen container for long 
term storage. 
Frozen vials of cells were recovered by thawing quickly in a 37oC water bath. The cell 
suspension was then pipette into a 75cm2 culture flasks with pre-warmed growth medium. Cells 
were allowed to attach overnight before aspirating the medium and replacing it with fresh 
growth medium. 
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3.1.13 siRNAs and Transfections 
Cells were seeded to a confluency of 80%. After overnight incubation, transfections were 
performed with RNAiMax® according to manufacturer’s instructions. Unless otherwise stated, 
siRNAs were used at a final concentration of 10nM. The transfection protocols were 
independent of the plate type, only the volumes of reagents were different.  
Plate Format Vol. of OptMEM 
added (µl) 
Vol. of 
RNAiMax 
added (µl) 
Final 
concentration 
of siRNA(nM) 
Total volume 
of transfection 
mix (µl) 
96 well plate 19.2 0.3 10 20 
6 well plate 231 3 10 240 
10 cm dish 955 15 10 1000 
 
Table 2: Volumes of reagents used for transfections 
A pre-mix of RNAiMax and Opti-MEM was prepared, and in parallel siRNAs were diluted in Opti-
MEM. The siRNA and RNAiMax pre-mix were mixed and incubated for 5min. During this 
incubation, media was aspirated from the cells and replaced with fresh growth media. Post 
incubation, the transfection mix was added to the cells. Cells were then incubated in 37oC, 5% 
CO2   humidified atmosphere for different time points depending on the assay being performed. 
Knockdown efficiency was determined by qPCR and western blot techniques (described below).  
 
3.1.14 Inhibitor Treatment  
Cells were seeded to a confluency of 60%. After overnight incubation cells were treated with 
inhibitors diluted in growth media, water (DMSO for Rotenone) was used as control. Cells were 
incubated in 37oC, 5% CO2 humidified atmosphere for different time points depending on the 
assay being performed. 
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3.1.15 Analysis of RNA expression 
 
3.1.15.1 mRNA isolation 
mRNA was isolated using the “RNeasy Mini” Kit from Qiagen according to manufacturer’s 
recommendations. Extracted RNA was eluted in 50µl of nuclease free water. 
 
3.1.15.2 Quantitative RT PCR 
Primers and probes were designed for Taqman® qRT-PCR using the Roche UPL Design Center 
(Refer to section 3.1.11 for Primer sequences and Probe numbers). For quantification, first 1ug 
of total RNA was reverse transcribed to  cDNA using the RevertAid™ H minus First strand Kit. 
For the Taqman assay the cDNA was first diluted to 2ng/µl. For each gene to be quantified a 
Mastermix was prepared consisting of 5.5µl 2x ABgene mastermix, 0.11µl forward primer, 
0.11µl reverse primer and 0.11µl Taqman probe per well. 6µl of the Mastermix was pipetted 
with 5ul of cDNA into 384 well plates in triplicates.  
A plate layout document was prepared using the SDS software and the PCR conditions were set 
as follows, 2min at 50oC, 15min at 95oC followed by 45 cycles of 15s at 95oC and 60s at 60o C. 
Raw data was analysed using the SDS software with the ΔΔCt method(Yuan, Reed, Chen, & 
Stewart, 2006). The Ct values were normalized to housekeeping gene PUM1. 
 
3.1.15.3 Microarray 
Genome-wide gene expression profiling is performed using HumanHT-12 v4 BeadChips 
(Illumina, San Diego, CA, USA). Raw probe intensities are back-ground corrected using negative 
control probes and a normal+exponential (normexp) convolution model. An offset value (16) is 
added to the data in order to prevent negative expressions in the background correction step. 
Data are then normalized via quantile normalization using the negative and positive probes(Shi, 
Oshlack, & Smyth, 2010) (Shi et al., 2010). Control probes are removed and intensities are log2 
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transformed after normalization. DKFZ microarray core facility performed sample preparation, 
RNA quality control and hybridization. Khalid Abnaof performed data normalization. 
 
3.1.16 Protein Analysis 
 
3.1.16.1 Western Blotting 
 
3.2.5.1.1 Protein Isolation 
After indicated times of incubation post transfection or inhibition, cell lysates were extracted. 
Cells were placed on ice, media was aspirated and cells were washed with ice cold PBS. Cells 
were lysed with M-PER lysis buffer (10ml MPER Buffer, 1x Complete Mini Protease Inhibitor 
Cocktail and 1x Phospho-Stop phosphatase Inhibitor) and detached and homogenized by 
scraping. The lysis reaction was collected in 1.5ml centrifuge tubes and incubated at 4oC for 
30min on a vertical rotor. The lysate was centrifuged at 13,000rpm for 10min and the 
supernatant was transferred to a fresh 1.5ml centrifuge tube. Lysates were stored at -80oC.  
 
3.2.5.1.2 Protein Quantification 
Protein concentrations of the lysates were determined using the BCA™ protein assay kit. 
Protein concentrations were hence, determined by following the kit protocol. Briefly, BSA 
standards of different concentrations (2000µg/ml, 1500µg/ml, 1000µg/ml, 750µg/ml, 
500µg/ml, 250µg/ml, 125µg/ml, 25µg/ml and 0µg/ml) were prepared according to the 
manufacturer’s recommendations. All standards were diluted in PBS. 25µl of each standard was 
pipetted into a 96-well microplate in duplicates. 5µl of each sample was pipetted into the plate 
in duplicates as well. Hence, the dilution factor of samples compared to standards in 1:5.  
BCA™ working reagent is prepared freshly for each assay by mixing Reagent A with Reagent be 
in a 50:1 ratio. The 200µl of the working reagent is then added to each well of the microplate. 
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The plate was protected from light and incubated at 37oC for 30min. Thereafter, the 
absorbance at 562nm was measured on the TECAN infinite200 plate reader. 
A standard curve was prepared after blank correcting the absorbance readings of the BSA 
standards and protein concentration of the samples were calculated from this curve. The 
obtained concentrations were then multiplied by 5 to account for the dilution factor.  
Cell lysates for gel electrophoresis were then prepared for gel electrophoresis by mixing with 
protein loading buffer (4X RotiLoad) in a 1:4 dilution and heated to 95oC for 5min for 
denaturation. 
 
3.2.5.1.3 SDS PAGE 
Gel electrophoresis is a method by which protein can be separated according to their size. In 
SDS PAGE (Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis) heat denatured 
proteins are coated with negatively charged SDS which therefore, migrate towards the cathode 
(irrespective of their intrinsic charge). The polyacrylamide gel serves as a sieve to retard the 
larger proteins while the smaller ones move faster and thus separates the different protein in 
the lysate spatially.  
The gels for electrophoresis were prepared prior to the experiment. Depending on the size of 
the protein to be detected different % acrylamide running gels were cast. The running and 
stacking gels were prepared as indicated earlier. The running gel was prepared first and poured 
into the gel casting chamber upto 2.5cm of the chamber and covered with isopropanol. Once 
the gel polymerized the isopropanol was discard and 4% stacking gel was casted into the 
chamber and a comb was inserted to create wells where protein lysates could be loaded. After 
polymerization the gels were wrapped in wet paper towels and stored at 4oC till they were 
used. 
On the day of the experiment, the gels were loaded onto the running box clamp of the 
MiniProtean gel assembly (BioRad) and the clamp was placed into the gel box. The clamp and 
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the box were filled with 1X running buffer. The comb was then removed and the wells were 
loaded with 5µl molecular weight marker (Precision Plus Protein™ Dual Color Standard) and 
20µg protein lysate. Electrophoresis was performed at 110V for 75min. 
 
3.2.5.1.4 SemiDry Transfer 
Blotting solutions were prepared according to the Section 3.1.8. Whatman filter papers and 
PVDF membranes (Millipore) were cut to a size of 6.5 x 9cm. The membranes were activated in 
ethanol and then soaked in Anode II blotting solution. For the transfer a sandwich was prepared 
with 4 filter papers soaked in Anode I solution, followed by 2 filter papers soaked in Anode II. 
The membrane was then placed and the gel was layered on top of the membrane carefully to 
avoid formation of bubbles. Finally, 6 filter papers soaked in Cathode solution were placed on 
top. The blotter was then assembled and run at 25V for 1h. After the transfer the membranes 
were blocked with blocking buffer (prepared as described in 3.1.8) for 1h at room temperature. 
 
3.2.5.1.5 Antibody Incubation and Detection 
After blocking, the membranes were incubated with primary antibodies (diluted in blocking 
buffer to concentrations indicated in table) overnight at 4oC. After primary antibody incubation 
the membranes were washed 3X for 10min each with TBST (1X TBS with 0.1% Tween-20). The 
membranes were then incubated with secondary IRDye®680 or IRDye®800 conjugated 
antibodies (diluted in TBST to concentrations indicated in table) for 1h at room RT on a shaker. 
The membranes were washed again with TBST (3X for 10min each) and scanned and analyzed 
with the Odyssey® Infrared Imaging System. Local background corrections and β-actin 
normalization was performed for quantification. 
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3.1.16.2 RPPA 
 Another technique used for analysis of protein expression was Reverse Phase Protein Array 
(RPPA)(Paweletz et al., 2001).  
In case of cell line samples, the lysates were harvested and protein concentration was 
determined as described above. In case of tumor specimens, the frozen samples were 
homogenized using a bead mill and tissue protein extraction reagent (50mM Tris, pH 8.5, 
138mM NaCl, 2.7mM KCl, 1% Triton X-100). Protein concentration was determined in the same 
way as for the cell line samples, i.e., with the BCA kit. 
Tumor and cell line lysates were adjusted to a total protein concentration of 2 µg/µl. Samples 
were mixed with 4 x RPPA printing buffer (10% glycerol, 4% SDS, 10 mM DTT, 125 mM Tris–HCl, 
pH 6.8) and denatured at 95°C for 5min. The lysates were then pipetted into 348-well plates 
and centrifuged for 2min at 200 x g. As internal controls a dilution series of tumor samples/cell 
line pools were created. All samples were printed as technical triplicates on Oncyte® Avid 
Nitrocellulose Film-Slides using a Aushon 2470 contact printer equipped with 185 µm solid pins 
(1.6nl sample per spot, average spot diameter 250µm). The humidity during the printing run 
was kept constant at 80%. Slides were stored after the print run at -20°C with desiccant. After 
spotting the slides were blocked for 2h at room temperature with blocking buffer (TBS (50%, v / 
v with 5mM NaF and 1mM Na3VO4). 
Post blocking, the arrays were incubated with target-specific primary antibodies at 4°C 
overnight. Representative subarrays were incubated without primary antibody and served as 
“blank” control. After incubation the slides were washed 4 x 5min with TBST and subsequently 
incubated   with Alexa Fluor® 680 F(ab')2 fragments of goat anti-mouse IgG or anti-rabbit IgG in 
1:12000 dilution for 1h at RT in dark. Slides were again washed 4 x 5min with TBST followed by 
two final washing steps with ultra-pure water for 5min. The slides were then air dried and 
imaged. Every ninth slide of each run was stained using Fast Green FCF protein dye for total 
protein quantification and was used for normalization. The slides were scanned with an 
excitation wavelength of 685nm and a resolution of 21 µm with the Odyssey® Infrared Imaging 
System and the resulting TIFF images (16 bit) were used for further analysis. 
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Signal intensities of individual spots were quantified using GenePixPro 7.0 software. The 
acquired TIFF image of each slide and gene pix array list file (generated by the printer to map 
the sample location on the slide) was matched into a gene pix result file. At this step, a visual 
inspection of each spot was performed and slides without uniform background signal were 
excluded from further analysis. RPPA raw data preprocessing and quality control were 
performed using the RPPanalyzer R-package (Mannsperger, Gade, Henjes, Beissbarth, & Korf, 
2010). The gene pix result files as well as sample and antibody information text files were 
required for further raw data analysis. The raw signal intensities of the control samples were 
plotted against the respective total protein concentration. Only data of antibodies showing a 
linear correlation between target signal intensity and protein concentration were used for 
further analysis. Next, target signals were normalized to the total protein amount per spot via 
Fast Green FCF control. After median calculation of technical replicates, normalized target 
signal intensities were plotted against the signal intensities obtained by incubation of primary 
antibody controls (blank signal).  
Untreated cell line data generation and raw data processing was done by Stephan Bernhardt, 
PhD student, Division of Molecular Genome Analysis. 
Experiments with siRNA and inhibitor treatments were done by me as described above (Section 
3.2.2 and 3.2.3), including protein harvest and protein concentration determination. Sample 
preparation for RPPA was done with the help of Stephan Bernhardt. Antibody incubation and 
imaging of slides were done by Stephan Bernhardt and me. Machine running and raw data 
processing was done by Stephan Bernhardt. 
RPPA of tumor specimens was done by Stephan Bernhardt and the normalized protein data was 
further analyzed by collaboration partners at the Institute of Physics at the Freiburg Institute for 
Advanced Studies (Freiburg, Germany). Details of dataset generation and analysis can be found 
in the thesis of Stephan Bernhardt and the subsequent publication(Bernhardt et al., 2017). 
Briefly, for statistical analysis, different groups were compared using the Kruskal-Wallis Rank 
Sum Test(Kruskal & Wallis, 1952) and p values were adjusted using Benjamini-Hochberg 
procedure(Benjamini & Hochberg, 1995).  
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3.1.16.3 Mass Spectrometry  
 
3.2.5.3.1 Sample preparation 
Cells were washed once with PBS, scratched, collected and transferred into a 1.5 ml Eppi. 
Sample was centrifuged at max. speed at 4°C, supernatant was removed, pellet snap-frozen and 
stored at -20 °C until further processing. Cells were lysed by adding 300 µl of 8M Urea buffer (8 
M Urea, 100 mM TrisHCl, pH 8.5) followed by sonification and centrifugation for 5 min at max. 
speed at 4 °C . Protein content was determined using the BCA Protein Assay Kit (Pierce, Thermo 
Scientific). Prior to digestion the denaturation and alkylation of proteins were performed by 
treating samples with 2 mM DTT (30 min at 25°C), followed by 11 mM iodoacetamide (20 min 
at room temperature in the dark).100 µg of protein were digested according using Lys-C (Wako, 
1:40, w/w, overnight under gentle shaking, 30°C) and immobilized trypsin beads (Applied 
Biosystem, 1:80, w/w, 4 hrs under rotation, 30°C). Lys-C digestions product were diluted four 
times with 50 mM ammonium bicarbonate before continuing the tryptic digestion that was 
stopped through acidification with 5 µL of triflouracetic acid. Fifteen µg of each resulting 
peptide mixture were then desalted on Stage Tip (Rappsilber et.al., 2007), the eluates dried and 
reconstituted to 15 µL in 0.5% acetic acid. 
 
3.2.5.3.2 LC-MS analysis 
5 microliters of each sample were injected in duplicate on a LC-MS/MS system (NanoLC 400 
[Eksigent] coupled to Q Exactive Plus [Thermo]), using a 240 minutes gradient ranging from 5% 
to 40% of solvent B (80% acetonitrile, 0.1 % formic acid; solvent A= 5 % acetonitrile, 0.1 % 
formic acid). For the chromatographic separation 100 cm long MonoCap C18 HighResolution 
2000 (GL Sciences) was used. 
The nanospray source was operated with spay voltage of 2.4 kV and ion transfer tube 
temperature of 260 °C. Data were acquired in data dependent mode, with a top10 method (one 
survey MS scan with resolution 70,000 at m/z 200, followed by up to 10 MS/MS scans on the 
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most intense ions, intensity threshold 5,000). Once selected for fragmentation, ions were 
excluded from further selection for 45 seconds, in order to increase new sequencing events. 
 
3.2.5.3.3 Data analysis 
Raw data were analyzed using the MaxQuant proteomics pipeline (v1.5.3.30) and the built in 
the Andromeda search engine (Cox, Neuhauser et al. 2011) with the human Uniprot database. 
Carbamidomethylation of cysteines was chosen as fixed modification, oxidation of methionine 
and acetylation of N-terminus were chosen as variable modifications. The search engine 
peptide assignments were filtered at 1% FDR and the feature match between runs was enabled; 
other parameters were left as default. Raw data analysis was performed by Nadine Royla. 
Data dependent acquisition (DDA) in label-free quantification (LFQ) of peptides abundances in 
mass-spectrometry (MS) has stochastic precursor selection and low sampling efficiency (Cotte-
Rodriguez, Miao, Zhang, & Chen, 2013; Matthiesen & Bunkenborg, 2013). This intrinsic feature 
of mass-spectrometry technology poses the problem that protein expression is sometimes not 
fully quantifiable, i.e. signals are not determined for those peptides whose abundance have not 
reached the detection limits. This was particularly the case in our study of high throughput 
protein expression in different cell-lines (MDA-MB231, MDA-MB468 and MCF7). Many proteins 
were not expressed across the samples in the data. This implies that conventional t-test based 
approaches cannot be applied directly to test of differentially expressed proteins between 
different cell-lines. A common way to treat these undetermined features is by excluding them 
from the analysis (Noble & MacCoss, 2012). However, the expressions of these features might 
not be missing in all conditions or all replicates of a condition. 
  
In order to account for this issue we developed the double detection procedure, which 
comprises a detection step detection test as first step and in the second step a subsequent 
moderated t-test based approach is used either via the “limma” method. 
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First Step: The detection test is a one-sided t-test to investigate whether expression values of a 
particular feature in a given sample group are statistically significant higher than a defined 
threshold, meaning there is a significant detected protein expression. The threshold was set to 
the average of the minimum observable expression value per sample in a given experimental 
condition (here cell-line). Formally, this means testing for the null hypothesis: 
 H0 : Arg_Avr(Ct)c,m  >  Arg_Avr(min(Ct)c), where m denote features and the conditions c are 
factor combinations of cell-line type and replicates factors. The detection test aims to filter out 
features that are undetectable in a given sample group. Thus, it ensures the applicability of t-
test based significance tests in the subsequent step. 
Second Step: The Moderated test Features, which passed the detection test are checked for 
their differential expression using the “limma” method utilizing empirical Bayes (G. Smyth, 
2005; G. K. Smyth, 2004). However, many features did not pass the detection test. The number 
of which varies between ~700 and ~800 depending on the cell-lines under comparison. These 
features can be very informative, particularly when they pass the detection test in one 
condition in a comparison and measured in more than one peptide in each replicate of that 
condition. However, they cannot be tested in the second step properly.  In order to get useful 
information from these few features we computed a quasi- log fold change by imposing the 
missing values to be the equal to Arg_Avr(min(Ct)c) -1. Data analysis was done by Dr. Khalid 
Abnaof. 
 
3.1.17 Functional assays 
3.1.17.1 Cell Counting Assay 
Cell growth under different treatment (siRNA, inhibitor and media) conditions were analyzed 
with a microscopy based nuclei counting method. Cells were seeded in clear-bottomed 96 well 
black plates and after overnight incubation they were transfected with siRNA or treated with 
inhibitors. At different time points DNA was stained with intercalating dye Hoechst-33258 
(1:1000 dilution in growth media) for 45min. Subsequently, the plates were imaged with a 
molecular devices microscope IXM XLS.  All nuclei were defined by Hoechst signals within a 
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certain size and intensity and were detected and counted by the Molecular Devices Software. 
The number obtained was considered as cell number. 
 
3.1.17.2 RTCA-based Proliferation Assay 
Cell proliferation rates were also determined with the xCelligence Real Time Cell Analyzer 
(RTCA). The RTCA system uses plates which are similar to the 96 well cell culture plates, but are 
in A 16 well format. The plates are provided with golden electrodes at the bottom which can 
sense changes in impedance caused by cell attachment. Increase in electrical impedance can be 
due to increase in the number of cells attaching to the surface or increase in the attachment 
ability of the cells.  
For RTCA-based proliferation assays, RTCA E plates were used. Prior to seeding, background 
impedance was measured with 100µl media. For measurement of growth rates under different 
nutrient conditions, the cells were seeded directly in the indicated media and allowed to grow 
for 5 days. In case of transfection or inhibitor treatment, the day after seeding, the cells were 
treated with the respective conditions and allowed to grow for 72h. Cell Index values were 
recorded every 15 mins. The RTCA machine was kept in a 37oC incubator with 5% CO2 and a 
humidified atmosphere. 
 
3.1.17.3 WST Cell Viability Assay 
One of the methods to assess Cell viability was the WST-1 assay from Roche which measures 
the NADPH content of the cells. For this assay cells were seeded in transparent 96-well plates 
and after overnight incubation cells were treated with different media. 72h after media change, 
10µl of WST-1 reagent was added to each well and absorbance was measured at 450nm using 
the TECAN infinite200. In order to perform background correction, WST-1 was also added to 
wells containing only media without cells and the absorbance values of these wells were 
subtracted from all others. 
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3.1.17.4 Cell Titer Glo Assay 
Cell titer Glo assay from Promega was second assay used for measuring cell viability. This 
method detects the ATP in cells which is an indication of the metabolic activity. The incubation 
with the assay reagent results in lysis of the cells which can then release its ATP. Luciferin in the 
assay is catalyzed by UtraGlo® Luciferase and ATP to generate oxyluciferin which can be 
detected via Luminescence. The resulting signal serves as a quantification of ATP in the wells 
and thereby the metabolic activity of the cells in the well.  
For this assay cells were seeded into opaque white 96-well plates and treated after overnight 
incubation with siRNA or inhibitor. The assay was performed 72h after treatment according to 
the manufacturer’s recommendation. Luminescence was measured using the TECAN 
infinite200. 
 
3.1.17.5 Alanine assay 
Efficiency of the GPT2 inhibitor (BCLA) was determined by measuring the alanine levels in the 
supernatant after inhibitor treatment. Alanine assay kit from Sigma was used for this. In this 
assay alanine is converted to pyruvate which can be detected by fluorescence. The experiment 
was setup as follows; cells were seeded to 80% confluency in 6-well plates. The following day 
growth media was replaced by fresh growth media supplemented with inhibitor (water in 
control wells). After 24h of treatment spent media was collected in 1.5ml centrifuge tube and 
frozen in -80o C. Cells were counted using the CASY counter and cell numbers were used for 
normalization. The spent media was thawed, quickly spun down to remove debris and floating 
cells and diluted 1:10. 5µl of the diluted media was used for the assay. Using the 
manufacturer’s recommendation alanine was detected in the media using fluorescence 
detection which was measured with TECAN infinite200. 
 
3.1.18 Determination of metabolite levels via HPLC 
Aliquots of flash-frozen cell culture supernatants were used for absolute quantification of 
amino acid, cation, organic acid and sugar content each. 
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To analyze the content of amino acids, 10 µl supernatant was mixed with 290 µl cold 0.1M HCl. 
Insoluble material and proteins were precipitated by centrifugation for 10min at 25.000g. 5µl of 
the resulting supernatant were quantified after specific labeling with the fluorescence dye 
AccQ-TagTM (Waters) according to the manufacturers protocol. The resulting derivatives were 
separated by reversed phase chromatography on an Acquity BEH C18 column (150mm x 
2.1mm, 1.7µm, Waters) connected to an Acquity H-class UPLC system and quantified by 
fluorescence detection (Acquity FLR detector, Waters, excitation: 250nm, emission: 395nm) 
using ultrapure standards (Sigma). The column was heated to 42 °C and equilibrated with 5 
column volumes of buffer A (140 mM sodium acetate pH 6.3, 7 mM triethanolamine) at a flow 
rate of 0.45 ml min-1. Baseline separation of amino acid derivates was achieved by increasing 
the concentration of acetonitrile (B) in buffer A as follows: 1 min 8% B, 7 min 9% B, 7.3 min 15% 
B, 12.2 min 18% B, 16.3 min 40% B, 18.5 min 80% B, hold for 3 min, and return to 8% B in 3 min. 
Data acquisition and processing was performed with the Empower3 software suite (Waters). 
For determination of organic acids, cations and sugars, supernatants were diluted with ultra-
pure water before analysis. For sugar determination, samples were diluted 1/1000, for organic 
acids and cations a 1/30 dilution was used. Organic acids were separated using an IonPac AS11-
HC (2mm, ThermoScientific) column connected to an ICS-5000 system (ThermoScientific) and 
quantified by conductivity detection after cation suppression (ASRS-300 2mm, suppressor 
current 95-120 mA). Prior separation, the column was heated to 30°C and equilibrated with 5 
column volumes of solvent A (ultra-pure water) at a flow rate of 0.38ml min-1. Separation of 
anions and organic acids was achieved by increasing the concentration of solvent B (100mM 
NaOH) in buffer A as follows: 8min 4% B, 18min 18% B, 25min 19 % B, 43min 30% B, 53min 62% 
B, 53.1min 80% B for 6min, and return to 4% B in 11min.  
Cations were separated using an IonPac CS16 (2mm, ThermoScientific) column connected to an 
ICS-1000 system (ThermoScientific) and also quantified by conductivity detection after anion 
suppression (CERS-500 2mm, suppressor current 43 mA). Prior separation, the column was 
heated to 43°C and equilibrated with 10 column volumes of 30mM methanesulfonic acid at a 
flow rate of 0.36ml min-1. Cations were eluted using an isocratic run for 27min. Soluble sugars 
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were separated on a CarboPac PA1 column (ThermoScientific) connected to the ICS-5000 
system and quantified by pulsed amperometric detection (HPAEC-PAD). Column temperature 
was kept constant at 25°C and equilibrated with five column volumes of solvent A (ultra-pure 
water) at a flow rate of 1ml min-1. Baseline separation of carbohydrates was achieved by 
increasing the concentration of solvent B (300mM NaOH) in solvent A as follows: From 0 to 25 
min 7.4% B, followed by a gradient to 100% B within 12min, hold for 8min at 100% B, return to 
7.4% B and equilibration of the column for 12min. Data acquisition and quantification was 
performed with Chromeleon 7 (ThermoScientific). 
Sample preparation and raw data analysis was done at the Metabolomics Core Technology 
Platform of the Excellence Cluster CellNetworks by Dr. Gernot Poschet. 
 
3.1.19 Labelling experiments  
In order to investigate the utilization of carbon atoms (derived from one of the main nutrients 
namely Glucose) by different metabolic pathways under different conditions and in different 
cell lines, media supplemented with stable isotope labeled glucose was used. While stationary 
labelling is obtained by longer labeling time, the Kempa Lab at BIMSB, Berlin have developed a 
method called pulsed Stable Isotope Resolved Isotopic Metabolomics (pSIRM) with shorter 
labelling times in order to determine fate of nutrients and metabolic dynamics in a time 
resolved manner(Pietzke & Kempa, 2014). In order to track the fate of carbon atoms of glucose 
in the TCA cycle and adjacent pathways the label was applied for 30mins to the cells. All the 
labelling experiments were performed by me in Stefan Kempa’s lab in collaboration with 
Nadine Royla, PhD student, AG Kempa. 
 
3.2.8.1 Cell culture 
For each cell line (MCF-7, MDAMB231, MDA MB 468) cells were plated with a beforehand 
determined cell number to reach a similar confluency after 48h of incubation. The GPT2 
inhibitor was applied 24h after plating for another 24h. Four hours prior to harvest, 1 ml of 
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media was collected to determine all secreted metabolites and remaining media was renewed. 
Cell culture media was replaced by media containing 13C-glucose (Campro Scientific, Berlin, 
Germany). After incubation of 30min adherent cells were quickly flushed with wash buffer 
(140mM NaCl, 5 mM HEPES, pH 7.4, and supplemented with major carbon sources) to remove 
extracellular metabolites, but not the main carbon sources. Immediately, cells were quenched 
with 5 mL ice-cold 50% methanol (suppl. with cinnamic acid (final concentration: 2 µg/ml)). The 
cells were scratched, collected and transferred into a 15-ml falcon, and stored as well as the 
media samples at -20°C until proceeding with metabolite extraction.  
 
3.2.8.2 Intracellular extraction 
One milliliter chloroform was added to 5 ml of methanolic cell extracts, shaken for 60min at 
4°C, and centrifuged at maximum speed for 15min at 4°C for phase separation (methanol-
chloroform-water extraction). Polar phases were collected. Each polar phase was splitted into 
two aliquots - one for direct infusion MS and one for GS-MS analysis in order to measure 
nucleotides and central carbon metabolites from the same sample - and dried under vacuum. 
The cell extracts were stored at −20°C until preparation of GC-MS analysis or direct infusion MS 
analysis.  
 
3.2.8.3 Extracellular extraction 
One milliliter of methanol-chloroform-water (5:2:1, v/v/v, suppl. with cinnamic acid (final 
concentration: 2 µg/ml)) was added to 50 µL of media samples, shaken for 30 min at 4°C. 500 
µL of H2O were added and samples were centrifuged at maximum speed for 15 min at 4°C for 
phase separation. Two times 500 µL of polar phase were collected and dried under vacuum. 
The extracellular extracts were stored at −20°C until preparation of GC-MS analysis. 
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3.2.8.4 GC-MS analysis  
A quantification dilution series was treated in parallel with extracts. Derivatization was carried 
out as described with modifications (Kempa et. al., 2007). Dried cell extracts were dissolved in 
20 μL of methoxyamine hydrochloride solution (Sigma, 40 mg/mL in pyridine (Roth)) and 
incubated for 60min at 30°C with constant shaking followed by the addition of 80 μL of N-
methyl-N-[trimethylsilyl]trifluoroacetamide (MSTFA; Machery-Nagel, Dueren, Germany) and 
incubation at 37°C for 90min. The extracts were centrifuged for 10min at 10,000 × g, and 
aliquots of 30 μL were transferred into glass vials (Th. Geyer, Berlin, Germany) for gas 
chromatography-mass spectrometry (GC-MS) measurement. 
Metabolite analysis was performed on a gas chromatography coupled to time of flight mass 
spectrometer (Pegasus III- TOF-MS-System, LECO Corp., St. Joseph,MI, USA), complemented 
with an auto-sampler (MultiPurpose Sampler 2 XL, Gerstel, Mülheim an der Ruhr, Germany). 
The samples were injected in split mode (split 1:5, injection volume 1 μL) in a temperature-
controlled injector (CAS4, Gerstel) with a baffled glass liner (Gerstel). The following 
temperature program was applied during sample injection: initial temperature of 80°C for 30 s 
followed by a ramp with 12°C/min to 120°C and a second ramp with 7°C/min to 300°C and final 
hold for 2 min. Gas chromatographic separation was performed on an Agilent 6890 N (Agilent, 
Santa Clara, CA, USA), equipped with a VF-5 ms column of 30-m length, 250-μm inner diameter, 
and 0.25-μm film thickness (Varian, Palo Alto, CA, USA). Helium was used as carrier gas with a 
flow rate of 1.2 mL/min. Gas chromatography was performed with the following temperature 
gradient: 2-min heating at 70°C, first temperature gradient with 5°C/min up to 120°C and hold 
for 30 s; subsequently, a second temperature increase of 7°C/min up to 350°C with a hold time 
of 2 min. The spectra were recorded in a mass range of 60 to 600 U with 20 spectra/s at a 
detector voltage of 1650 V.  
The GC-MS chromatograms were processed with the ChromaTOF software (LECO). Mass 
spectra data were extracted using the software tool MetMax (http://gmd.mpimp-
golm.mpg.de/apps/metmax/) or the in-house software Maui-VIA (Kuich et. al., 2014). Mass 
isotope distribution of unlabeled metabolites were used to determine the 13C-glucose derived 
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stable isotope incorporation of 13C in metabolites of interest. Absolute quantities were 
determined by the examination of the peak area in the GC-MS-derived chromatograms and 
their comparison to quantification standards. Acquired data were normalized to the internal 
standard cinnamic acid, the sum of area per sample and cell count.  
Cell culture, inhibitor treatment, labeling, sample extraction and preparation were done by 
Nadine Royla and me. Data analysis was done by Nadine Royla. 
 
3.1.20 Seahorse Experiments 
In order to see the effector of the GPT2 inhibitor on mitochondrial respiration of the cells the 
Seahorse Bioanalyzer and XF cell mitostress kit from Agilent was used and Oxygen consumption 
rate (OCR) was measured by the seahorse bioanalyzer. The cell mitostress kit can be used to 
measure key parameters of mitochondrial function via determination of the oxygen 
consumption rate of the cells via serial injection of different compounds. Oligomycin, ATP 
synthase (complex V) inhibitor, is first injected leading to a decrease in OCR which corresponds 
to the mictochondrial respiration associated with cellular ATP production. The next compound 
to be injected is Carbonyl cyanide-4 (trifluoromethoxy) phenylhydrazone (FCCP). FCCP is an 
uncoupling agent that collapses the proton gradient and disrupts the mitchondrial membrane 
potential. This leads to an increase in oxygen consumption by complex IV as the electron flow 
through the ETC is uninhibited. The increase in OCR can be used to calculate the spare 
respiratory capacity of the cells. Finally, a mix of rotenone (complex I inhibitor) and antimycin A 
(complex II inhibitor is injected into the cells to completely shut down the respiration, the 
remaining oxygen consumption gives a measure of the non-mitochondrial respiration of the 
cells.  
Seahorse analysis was performed according to the manufacturer’s recommendations. Briefly, 
cells were seeded as a uniform monolayer to a confluency of 80% in seahorse 96-well 
microplates. The following day, the cells were treated with inhibitor as indicated earlier. The 
same day the sensor cartridges were hydrated with a calibrant and incubated overnight in a 
non CO2 incubator. The next day after 24h incubation with inhibitor the media was changed to 
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seahorse assay media with inhibitor and incubated for 45min in a non CO2 incubator. The 
cartridge plate was then loaded with different reagents of the mitostress kit, namely, 
Oligomycin, FCCP and Antimycin/Rotenone A and calibrated in the Seahorse bioanalyzer. After 
calibration the calibrant plate was replaced by the cell plate and the mitostress test was 
performed. Obtained data from the bioanalyzer was analyzed using the Wave 2.0 software. 
After the mitrostress test sulforhodamine staining was done on the cell plate to determine 
protein concentration. These values were then used for normalizing the Seahorse data. Prof. Dr. 
Stephan Herzig kindly allowed the use of the Seahorse Bioanalyzer belonging to his group at 
Heidelberg University Hospital. 
 
3.1.21 Dataset Analysis 
Publicly available METABRIC and TCGA datasets were downloaded from the website given in 
Section 3.1.7. METABRIC data comprised of mRNA expression microarray and clinical data of 
nearly 2000 patients with a follow up of 20 years. Box plots are represented as log2 transformed 
gene expression data. Kaplan-Meier method was used to generate survival curves(Kaplan & 
Meier, 1958.). 25% of the patients with the highest and lowest expression GPT2 were used to 
generate survival curves. TCGA data comprises of RNA-sequencing and clinical data of nearly 
1200 patients. Box plots were generated using gene expression data represented as log2 (x+1) 
rsem.  
 
3.1.22 Statistical Analysis 
Unless otherwise mentioned, data are presented as mean ± SD and statistical analyses were 
performed by unpaired two-tailed Student’s t-test and p-values <0.05 were considered 
statistically significant. P values <0.05, <0.01 and <0.001 are indicated with one, two and three 
asterisks respectively. 
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3.1.23 Graphical Illustrations 
All graphs were generated using the GraphPad Prism Software and illustrated via Inkscape v 
0.91 
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4. Results 
4.1 Metabolic characterization of Breast cancer cell lines 
To study the role of metabolic pathways in breast cancer cells, 3 different model breast cancer 
cell lines were chosen. Two were triple negative breast cancer (TNBC) cell lines, MDA MB 468 
and MDA MB 231. The third was a luminal cell line, namely MCF7. All three cell lines have been 
shown to have active glutamine metabolism(Korangath et al., 2015; Lampa et al., 2017). MDA 
MB 468 cells were moderately dependent on glutamine (Figure 1a, d) while, MDA MB 231 cells 
were observed to be a glutamine addicted cell line (Figure 4b, e), MCF7 represents a less 
aggressive subtype of breast cancer was still dependent on glutamine for growth (Figure 4 c, f). 
Proliferation slowed down in all 3 cell lines under glutamine starvation conditions, however, 
glucose deprivation had a stronger effect on cell survival (Figure 4 a-f). The doubling times were 
calculated for each cell line, MDA MB 468 was the slowest while MDA MB 231 was the fastest 
growing cell line (Figure 4h). 
 
Results 
64 
 
 
Figure 4: Metabolic characterization of cancer cells. a-c, Microscopy based nuclei counting of cells grown 
without glutamine or glucose for 72h. All values are represented as relative values normalized to media 
values. (d-f) Cells were grown without glutamine or glucose and cell density was measured over time with the 
real time cell analyzer (RTCA). (g) Doubling times of the different cell lines in cell culture. Data are presented 
as mean ± SD. For nuclei count n=2(each with 6 technical replicates), for real time cell analyzer, n=1 (with 4 
technical replicates), for doubling time n=3 (each with 6 technical replicates). *** represents p < 0.001. 
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In order to understand the nutrient dependencies of cancer cells in more detail, consumption 
of key carbon sources, glucose and glutamine were measured (Figure 5 a, b).  MDA MB 468 
consumed the highest amount of glutamine and glucose, signifying that both these pathways 
are active in the cells. This was further validated by the high secretion of ammonia and lactate, 
which are major products of glutaminolysis and glycolysis, respectively (Figure 5 c, d). 
Metabolites were quantified at the Metabolomics Core Technology Platform (MCTP) by Dr. 
Gernot Poschet. 
 
 
Figure 5: Metabolic characterization of cancer cells. Cells were grown in growth media for 48h and spent 
media were used to measure metabolites. HPLC was used to measure glutamine (a) and glucose (b) 
consumption as well as ammonia secretion (c). GC-MS was used to measure lactate secretion (d). Data are 
presented as mean ± SD. n=3 
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At the protein level, expression of enzymes involved in different metabolic pathways was 
quantified by mass spectrometry (Figure 6).  Interestingly, MDA MB 231 showed higher 
expression of glycolysis/ gluconeogenesis enzymes, while glutaminolysis enzymes were highly 
expressed in both MDA MB 468 and MDA MB 231 (Figure 6 a, c). The TCA cycle enzymes were 
highest in MCF7 (Figure 6b), this was also confirmed by quantification of the TCA intermediates 
within the cells (Supplementary Table 1). The oxidative phosphorylation pathway was also most 
elevated in MCF7, followed by MDA MB 468 (Figure 6d). Blank boxes in the heatmap indicate 
that the respective protein was not detected. To understand whether this was due to the 
technique used, as in some cases the protein was detected in one or more of the replicates, 
other techniques were used. In a different experiment, a subset of the proteins was tested with 
RPPA, and it was found that ASS1, GPT2 and GLS could be detected in all three cell lines (Figure 
6 e, f  and 7c). Using a microarray all the other undetected proteins were found to be expressed 
at the mRNA level protein expression was not further tested (Supplementary Table 2). Mass 
spectrometry and raw data analysis was done by Nadine Royla (BIMSB). Differential expression 
analysis for mass spectrometry data was performed by Dr. Khalid Abnaof (DKFZ) and can be 
found in Supplementary Table 3. RPPA was performed by Stephan Bernhardt (DKFZ). 
Microarray was done by DKFZ microarray core facility and data normalization was performed by 
Dr. Khalid Abnaof. 
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Figure 6: Proteomic characterization of cancer cells. (a-d) Heatmaps show the levels of different proteins 
belonging to key metabolic pathways in the different cell lines measured by mass spectrometry. (e-f) 
Expression of a subset of enzymes not detected by mass spectrometry was confirmed by RPPA. Data in graphs 
are presented as mean ± SD, n=3 
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To validate metabolic pathways which are activated in these cells, amino acids were measured 
in the spent media from the cells. Interestingly, MDA MB 468 secreted the highest amount of 
alanine (Figure 7a), while other amino acids did not show similar levels of difference between 
cell lines (Supplementary table 4). This result was further consolidated by the fact that GPT2, 
which produces alanine from pyruvate, had the highest expression in MDA MB 468 at both 
mRNA and protein levels (Figure 7 b, c). mRNA of GPT, a liver specific isoform, was expressed 
much less in the cell lines (Figure 7b). To confirm that MDA MB 468 cells have an active GPT2 
catalyzed pathway, media supplemented containing 13C6 glucose was used to track the 
production of new alanine, and intracellular pools of alanine were also measured (Figure 7 d, e). 
Both experiments showed that MDA MB 468 produced high amounts of alanine compared to 
the other two cell lines. MCF7 also had a notably higher protein expression of GPT2 compared 
to MDA MB 231(Figure 7c). To confirm that this phenomenon is not restricted to a few cell 
lines, 13 different breast cancer cell lines were tested and it was found that the expression of 
GPT2 was diverse and did not conform to the molecular subtypes, however, that this pathway 
was active in many cell lines (Figure 7c). Alanine secretion quantification and raw data analysis 
was done by Dr. Gernot Poschet. The labeling and intracellular experiments were done together 
with Nadine Royla, who also did the analysis of the data.  RPPA and raw data processing was 
done by Stephan Bernhardt. 
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Figure 7: MDA MB 468 cells secrete high levels of alanine. (a) Alanine secretion in different cell lines, after 
48h of growth, measured via HPLC. (b) GPT2 and GPT mRNA expression levels in the different cell lines 
measured via microarray. (c) GPT2 protein levels in 13 different breast cancer cell lines measured via RPPA. 
(d) Intracellular alanine levels and % 13C labelling in alanine after 30 mins of 13C6 glucose media incubation. 
Data are presented as mean ± SD. n=3 
 
 
4.2 GPT2 is crucial to cancer cell growth  
4.2.1 Effect of GPT2 knockdown on cell growth 
The high levels of alanine secretion and GPT2 expression in breast cancer cell lines indicate that 
this pathway is active and possibly important for the cancer cells. Therefore, it was 
hypothesized that this pathway would provide a growth advantage to the cells and in order to 
verify this, an RNAi approach was used. As a first step, cell viability was measured using the cell 
titer glo assay from Promega. This assay measures the ATP content of the cells and thereby 
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gives an indication of their metabolic activity. Using a pool of 4 siRNAs targeting GPT2, cell 
viability was measured 72h after transfection. MDA MB 468 cells (Figure 8a), which had the 
highest expression of GPT2 protein showed a significant decrease in cell viability. Hs578T, 
another TNBC cell line, (Figure 8b) which also had significantly higher GPT2 levels compared to 
the other tested cell lines (Figure 7c) showed a significant decrease in cell viability. MCF7 
(Figure 8c) showed a small but significant decrease in cell viability. Interestingly, MDA MB 231 
(Figure 8d) which had both low expression of GPT2 and little production of alanine showed a 
similar decrease in cell viability upon GPT2 knockdown as MDA MB 468. In contrast, T47D 
(Figure 8e), one of the cell lines which had the lowest expression of GPT2 (Figure 7c), did not 
show any decrease in cell viability in the RNAi experiment. 
 
 
Figure 8: GPT2 knockdown affects cell viability. a-e, Cells were transfected with siGPT2 and cell viability 
was assessed after 72h with the cell titer glo assay. All values are represented as relative values normalized to 
non-targeting control siRNA (NTC).  Data are presented as mean ± SD, *** represents p < 0.001. n=2 (each 
with 6 technical replicates) 
 
As the cell viability assay did not take into account the number of cells in each well, further 
assays were required to validate these results. In order to check whether the decrease in 
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viability was a result of a decrease in cell numbers, microscopy based nuclei counting was done, 
after GPT2 knockdown, in the three cell lines of interest, namely, MDA MB 468, MDA MB 231 
and MCF7. Using Hoechst nuclei staining the cell numbers were measured 72h post 
transfection. Knockdown of GPT2 significantly decreased cell numbers in MDA MB 468 (Figure 
9a). Again, MDA MB 231, showed a similar decrease in cell numbers as compared to MDA MB 
468 (Figure 9b). MCF7, however, did not show a decrease in cell numbers post knockdown 
(Figure 9c). 
 
 
Figure 9: Knockdown of GPT2 decreases cell proliferation. Microscopy based nuclei counting of MDA MB 
468 (a), MDA MB 231 (b) and MCF7 (c) 72h after transfection with siGPT2. All values were normalized to 
NTC. Data are presented as mean ± SD, n=3 (each with 6 technical replicates).  *** represents p < 0.001.  
 
To confirm these findings with a different method, real time cell analyzer (RTCA) technology 
was used and cell growth was measured over time. Cell Index measurements showed that GPT2 
knockdown started to affect MDA MB 231 cells at an earlier time point compared to MDA MB 
468 cells (Figure 10 a, b). 
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Figure 10: Effect of GPT2 knockdown on cell proliferation determined by RTCA based assay. Cells were 
transfected with siGPT2 and cell proliferation was measured over time with the real time cell analyzer 
(RTCA). Data are represented as mean ± SD  of 4 technical replicates. Graphs are representative of  n=2. 
Deconvolution of the 4 siRNAs of the GPT2 pool revealed that all siRNAs show a strong decrease 
in GPT2 mRNA and protein levels (Figure 11, pool was also tested with RPPA, data not shown).  
 
 
Figure 11: Knockdown efficiency and deconvolution of siGPT2 pool. Cells were transfected with siGPT2 
(pool and individual). RNA and protein were harvested 72h after transfection and knockdown efficiency was 
determined by qPCR (a) and western blot (b) respectively. All values were normalized to NTC. For cell 
numbers, data are presented as mean ± SD, of 6 technical replicates). Values for mRNA expression were first 
normalized to PUM1 levels and are presented as mean ± SD of 3 technical replicates. Protein expression 
values were first normalized to actin levels, n=1. *** represents p < 0.001, ** represents p<0.01, * represents 
p<0.05. 
 
Next, phenotypic effect of the individual and pool GPT2 siRNAs was assessed. The different 
siRNAs affected cell growth variably, however, the pool behaved the same as 2 siRNAs (#1 and 
#3) which gave similar effect (Figure 12). 
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Figure 12: Deconvolution of siGPT2 pool. Cells were transfected with siGPT2 (pool and individual). 
Microscopy based nuclei counting of cells were done 72h after transfection with siGPT2. All values were 
normalized to NTC. Data are presented as mean ± SD, of 6 technical replicates. *** represents p < 0.001, ** 
represents p<0.01, * represents p<0.05.  
Knockdown efficiency was also tested in the MDA MB 231 and MCF7. All cell lines showed >80% 
decrease in mRNA expression 72h post transfection of the GPT2 siRNA pool (Figure 13 a-d). 
Protein expression levels were also determined for MDA MB 231 and MCF7 and the siRNA 
decreased the expression of GPT2 in both cell lines (Figure 13 a, b). The decrease in GPT2 
protein levels in MDA MB 231 was not as strong as in the other cell lines, this could be due to 
the fact that MDA MB 231 already has a low level of GPT2 expression under basal conditions 
and therefore the decrease is not accurately quantifiable.Hs578t and T47D also showed >80% 
decrease in GPT2 mRNA after transfection. 
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Figure 13: Knockdown efficiency of siGPT2. Cells were transfected with siGPT2 pool. RNA and protein 
were harvested 72h after transfection and knockdown efficiency was determined by qPCR and western blot 
respectively. All values were normalized to NTC. Values for mRNA expression were first normalized to PUM1 
levels and are presented as mean ± SD of 3 technical replicates. Protein expression values were first 
normalized to actin levels, n=1. . *** represents p < 0.001. 
 
In order to confirm that the siRNA did not cross target GPT, GPT mRNA levels were measured 
after transfection, MDA MB 468 showed a slight decrease in GPT (Figure 14a), while in MCF7 
the levels remained unchanged (Figure 14c). Interestingly, MDA MB 231 showed an increase in 
GPT expression (Figure 14b). 
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Figure 14: Off target effect of GPT2 siRNA on GPT1 gene expression. (a-c) Cells were transfected with 
siGPT2. RNA was harvested 72h after transfection and GPT1 levels were assessed by qPCR analysis. All values 
were normalized to NTC. Values for mRNA expression were first normalized to PUM1 levels and then to non-
targeting control and presented as mean ± SD of 3 technical replicates. ** represents p<0.01, * represents 
p<0.05. 
 
In conclusion, knockdown of GPT2 showed significant decrease in cell growth in all cell lines 
with a high to moderate expression of GPT2. Contrary to expectations, MDA MB 231 showed a 
significant decrease in cell growth indicating that, despite low GPT2 protein levels and alanine 
being produced, this pathway is still essential for the growth of these cells. 
 
 
4.2.2 GPT2 inhibition and cell growth 
While RNAi is an efficient method to determine the effect of gene knockdown in cells, there are 
drawbacks to this method due to the fact that both gene specific and non-targeting controls 
can have off-target effects. In order to circumvent this and to prove that the effects seen with 
RNAi are independent of the off target effects siRNAs might have, a commercially available 
alanine aminotransferase inhibitor, β-chloro-L-alanine (BCLA) was used. BCLA can target both 
GPT isoforms, however, any possible cross reactivity was not relevant as GPT2 is more 
abundant than GPT in breast cancer and the focus was to block the interconversion of pyruvate 
to alanine. 
Measurement of cell numbers 72h after inhibitor treatment showed a dose dependent effect of 
the inhibitor on cell growth and alanine secretion (Figure 15). While MDA MB 468 cell growth 
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and alanine secretion were considerably affected with 75µM inhibitor treatment (Figure 15 a, 
b), MDA MB 231 cells had the highest sensitivity and showed significant effects from 25µM 
(Figure 15a, d), MCF7 cell growth was least affected by the inhibitor with the highest effect at 
100uM (Figure 15 a, c). Subsequent experiments were done with the indicated effective 
concentrations.  
 
 
 
Figure 15: Alanine aminotransferase inhibitor reduces cell proliferation and alanine secretion. (a) 
Cells were treated with increasing concentration of alanine aminotransferase inhibitor and cell numbers 
were counted via microscopy after 72h. (b-d) Cells were treated with increasing concentration of BCLA, after 
24h supernatants were collected and alanine was measured by the alanine assay kit. All data were normalized 
to untreated control (0). For cell numbers data are presented as mean ± SD, n=2 (6 technical replicates each). 
Alanine levels are presented as mean ± SEM, n=3. *** represents p < 0.001, ** represents p<0.01, * represents 
p<0.05.      
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These results were also confirmed with the RTCA analyzer, both MDA MB 468 and MDA MB 231 
showed a strong decrease in cell growth after inhibitor treatment (Figure 16 a, b). 
 
 
Figure 16: Effect of alanine aminotransferase inhibitor on cell proliferation determined by RTCA 
assay. Cells were treated with GPT2 inhibitor, BCLA (MDA MB 468: 75uM, MDA MB 231 25uM) and cell 
proliferation was measured over time with the real time cell analyzer (RTCA). Data are presented as mean ± 
SD. MDA MB 68 n=3 and MDA MB 231 n=4. 
 
In order to confirm that the observed decrease in alanine levels in the media came from a 
blockage of the GPT2-catalyzed reaction, the cells were treated with the inhibitor for 24h and 
then incubated in inhibitor-containing media supplemented with 13C6 Glucose. Metabolite 
analysis after 30 minutes incubation with the labeled media showed almost complete 
abrogation in alanine production thereby proving that the inhibitor is efficacious in all three cell 
lines (Figure 17).   The labeling experiment was done together with Nadine Royla, who also did 
the initial analysis of the data.           
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Figure 17: Efficiency of alanine transferase inhibitor. Cells were treated with GPT2 inhibitor, BCLA (MDA 
MB 468: 75uM, MDA MB 231: 25uM, MCF7:100uM) for 24h (with a media change after 20h). Cells were then 
incubated with media containing 13C6 glucose for 30min and metabolites were extracted. % incorporation of 
glucose derived carbon-13 into alanine was measured by GC-MS.  Data are presented as mean ± SD. n=3. *** 
represents p < 0.001, ** represents p < 0.01. 
 
Therefore, two independent methods, namely RNAi of mRNA encoding GPT2 and targeting the 
activity of the protein, proved that GPT2 has an effect on cell proliferation and this pathway is 
essential for breast cancer cell growth. 
 
 
4.3 Effect of GPT2 on cancer cell metabolism  
4.3.1 Effect of GPT2 on extracellular metabolites 
To determine whether the inhibition of GPT2 had a role in nutrient cycling in the cancer cells, 
the composition of the media surrounding the cells was analyzed. All 3 cell lines were treated 
with inhibitor or control (water) containing media. Spent media was collected after 20h of 
inhibitor treatment. Then, cell numbers were determined and used later as normalization 
control. Spent media was then treated as described in the methods. MDA MB 468 cells treated 
with inhibitor showed a significant decrease in glutamine consumption indicating that GPT2 
plays an important role in glutaminolysis. Perturbation of GPT2 catalyzed pathway thus, seems 
to block an essential route of nitrogen cycling thereby forcing the cells to consume less 
glutamine (Figure 18a, first panel). In contrast, MDA MB 231 and MCF7 did not show any 
significant changes in glutamine consumption upon inhibitor treatment (Figure 18, c, first 
panel). Glucose, the other important carbon source of the cells indeed showed some changes 
(Figure 18 a-c, second panel). Inhibitor-treated MDA MB 468 cells showed a slight albeit 
significant increase in glucose consumption, whereas MDA MB 231 showed a significant 
decrease and MCF7 did not show any changes. To further confirm the effect of GPT2 inhibition 
on glycolysis, lactate secretion was measured. None of the cells showed a change in lactate 
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secretion confirming that the glycolytic pathway remains unchanged in these cells (Figure 18 a-
c, third panel). Glutamine was measured via HPLC by Dr. Gernot Poschet and glucose and 
lactate were measured via GC-MS together with Nadine Royla. Both performed extraction and 
initial data processing of the respective chromatograms. 
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Figure 18: Effect of GPT2 inhibition on extracellular metabolites. Cells were treated with GPT2 inhibitor, 
BCLA (MDA MB 468: 75uM, MDA MB 231: 25uM, MCF7:100uM) for 20h. Spent media was collected and 
glutamine was measure via HPLC and glucose and lactate were measured with GC-MS.   Data are presented as 
mean ± SD. n=3. *** represents p < 0.001, ** represents p < 0.01. 
 
To validate the metabolite data obtained from the inhibitor treated cells and to rule out any 
effects that might arise due to off-target effects, extracellular metabolites were measured of 
cells with GPT2 knocked down. In this experiment, MDA MB 468 cells were transfected with 
either GPT2 siRNA or a non- targeting control. After a media change 24h post transfection, the 
cells were incubated for a further 48h. Spent media was collected and processed according to 
the procedure described in the methods. Glutamine consumption was found to be significantly 
decreased in RNAi treated cells (Figure 19a). The decrease in glutaminolysis in the cells were 
further confirmed by the decrease in ammonia secretion which is one of the main byproducts 
of this pathway (Figure 19b). GPT2 knockdown did not affect glucose consumption (Figure 19c), 
while a small yet non-significant decrease in lactate secretion was observed (Figure 19d). The 
samples were derivatized, measured and initial data was processed by  Dr. Gernot Poschet. 
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Figure 19: Effect of GPT2 knockdown on extracellular metabolites. Cells were transfected with siGPT2 
and control siRNA (NTC). Transfection media was replaced by fresh media 24h after transfection. Spent 
media was collected after 48h of incubation with fresh media and used to measure (a) glutamine, (b) 
ammonia (c) glucose, and (d) lactate levels via HPLC. Data are presented as mean ± SD. n=4. * represents 
p<0.05. 
 
 
4.3.2 Effect of GPT2 on intracellular metabolites 
Glutamine is an important source of TCA cycle intermediates in cancer cells. The observed 
decrease in glutamine consumption upon inhibition or knockdown of GPT2, in MDA MB 468 
cells, indicates that the supply of carbon to the TCA cycle may suffer due to the blockage of this 
pathway. In order to prove this hypothesis, levels of TCA cycle intermediates within the cells 
were measured 24h after inhibitor treatment. As shown in Figure 20a, MDA MB 468 showed 
significant decrease in α-ketoglutarate (α-KG) levels, which is the direct product of alanine 
aminotransferase and other glutaminolytic reactions. Concomitantly, malate and fumarate 
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levels were also significantly decreased in the cells. Pyruvate and citrate levels, however, did 
not show any significant change, further validating the fact that the decrease in the TCA cycle 
intermediates was a result of change in glutamine metabolism. Interestingly, MDA MD 231 
(Figure 20b) did not show a similar decrease in the TCA cycle intermediates, instead α-KG even 
showed a slight increase under inhibitor treatment. Pyruvate and citrate levels remained 
unchanged in MDA MB 231 cells like in the MDA MB 468 cells. MCF7 cells (Figure 20c), on the 
other hand did not show any change in α-KG levels, while, succinate, fumarate and malate 
levels increased slightly which is in line with data showing that MCF7 is least affected by the 
inhibitor (Figure 15a, 20c). These results indicated that even though the cells show similar 
phenotypic effects at the cellular level, the adaptation or reaction to inhibitor treatment differs 
between different cell lines at the molecular level. 
 
a MDA MB 468                                                                   b MDA MB 231    
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c MCF7 
 
Figure 20: Effect of GPT2 inhibition on TCA cycle intermediates. Cells were treated with inhibitor ((a) 
MDA MB 468: 75µM, (b) MDA MB 231: 25µM, (c) MCF7: 100µM) for 24h (with a media change after 20h). 
Cells were harvested, polar metabolites were extracted and TCA cycle intermediates were absolutely 
quantified via GC-MS. Data are presented as mean ± SD, n=3. ** represents p<0.01, * represents p<0.05. 
 
 
4.3.3 Effect of GPT2 inhibiton on metabolic enzymes 
The changes in metabolite levels seen after GPT2 inhibition indicated that the cells undergo 
metabolic rewiring when the alanine aminotranferase reaction is blocked. While these 
modifications arise as an adaptation to the altered substrate and product levels, there may be 
additional changes to the enzymes as well. In order to test this, levels of key enzymes in glucose 
as well as glutamine metabolism and the TCA cycle were analyzed after 24h treatment with the 
inhibitor (Figure 21). In MDA MB 468 cells, while glutamine metabolism enzymes showed a 
trend to decrease with inhibitor treatment, the TCA cycle enzymes decreased significantly 
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which was in concomitance with the changes observed at the metabolic level(Figure 21a). 
Glucose transporter also displayed a small but significant decrease even though consumption of 
glucose did not show any significant change. In MDA MB 231, the results again corroborated 
with the metabolite data as most enzymes tended to increase after inhibitor treatment 
although the changes were not significant(Figure 21b). MCF7 did not show any sgnificant 
change and there was not any clear trend in the enzyme levels seen(Figure 21c). RPPA and 
initial data analysis was done together with Stephan Bernhardt.  
 
  Results 
85 
 
 
Figure 21: Effect of GPT2 inhibition on key metabolic enzymes. Cells were treated with inhibitor BCLA 
(MDA MB 468: 75µM, MDA MB 231: 25µM, MCF7: 100µM). Protein was harvested after 24h and expression 
levels of the different metabolic enzymes were determined via RPPA. Protein levels were first normalized to 
total protein levels and then to control samples. Data are presented as mean ± SD, n=3. * represents p<0.05. 
 
 
Results 
86 
 
4.3.4 Effect of GPT2 inhibiton on metabolic phenotypes 
The significant changes seen in the TCA cycle both at the metabolic and protemic levels in MDA 
MB 468 cells suggest that upon inhibitor treatment the cells suffer from the lack of crucial TCA 
cycle intermediates (Figure 20, 21). One of the main functions of the TCA cycle is to provide 
electron carriers for oxidative phosphorylation, absence of which causes an energy deficit in the 
cells. In Figure 8, the decrease in luminescence post GPT2 knockdown indicated that there was 
an energy deficit in the cells due to the fact that the cell titer glo assay measures ATP content in 
the cells.Therefore, it was intriguing to see what effect the inhibitor has on the oxygen 
consumption rate (OCR), which is often used as a proxy for oxidative phosphorylation. The 
seahorse bianalyzer was used to detect OCR (details in section 3.2.9) MDA MB 468 cells treated 
with BCLA indeed showed  decreased oxygen consumption (Figure 22a). Interestingly, despite 
not showing any significant changes at the metabolite or protein levels, OCR  also of MCF7 cells 
was found to be decreased post inhibitor treatment (Figure 22b). When the cells were pushed 
to utilize their maximum respirative capacity (via addition of mitochondrial uncoupler FCCP) the 
difference between control and inhibitor treated cells became even stronger, suggesting that 
indeed the fitness and flexibility of the cells are affected by the inhibition of GPT2. 
 
 
Figure 22:  Effect of GPT2 inhibition on oxygen consumption rate. Cells were treated with inhibitor (MDA 
MB 468: 75µM, MCF7: 100µM) for 24h. Oxygen consumption rate in the cells were analyzed by the seahorse 
bioanalyzer. Graphs are representative of n=3 (each with 7 technical replicates). 
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4.3.5 Effect of GPT2 on carbon labeling of intracellular metabolites 
The data above indicates that GPT2 inhibition results in a decrease in glutamine uptake in MDA 
MB 468 cells. This results in a reduction of carbon flow from glutamine into the TCA cycle. 
However, uptake of glucose which provides the carbon backbone of alanine remains 
unchanged. Lactate secretion is also unaltered under these conditions. This led to the question 
of what happens to the carbon from glucose that would enter the alanine aminotransferase 
pathway in non-perturbed conditions. In the absence of GPT2 activity and change in lactate 
secretion the excess carbons should lead to a buildup of pyruvate which might then enter into 
the TCA cycle. This way the decrease in carbon atoms entering the TCA cycle from glutamine 
could also be compensated for. In order to test this, cells were treated with inhibitor for 24h 
and then incubated with media supplemented with 13C-glucose instead of 12C-glucose for 30 
min. Thereafter, the cells were harvested and the incorporation of carbon-13 in TCA cycle 
metabolites was determined. In all cell lines, the glucose pools were replaced by 90% or more 
and lactate labeling remained unchanged by BCLA. The results are represented as % label 
incorporation into the intermediates which will be referred to as labeling, and total labeled 
quantities. The results corroborated the initial hypothesis as it was observed that all measured 
TCA cycle intermediates showed an increase in glucose carbon labeling in MDA MB 468 cells 
(Figure 23a). However, most interestingly, it was seen that as a result of GPT2 inhibition, MDA 
MB 468 showed a high increase in pyruvate carboxylase (PC) activity which results in the 
formation of labeled malate and fumarate m+3 fractions. Citrate m+3 fraction which can 
originate from both pyruvate dehydrogenase (PDH) and PC catalyzed reactions, also increased 
significantly. Further analysis of the total labeled products showed that indeed, the 13C labeled 
malate and fumarate m+3 fractions as well as citrate m+3 fractions were higher when GPT2 
activity was inhibited, whereas the m+2 fractions which exclusively originate from the PDH 
reaction remained unchanged.  
MDA MB 231 (Figure 23b) showed a trend of increased 13C-glucose derived incorporation in  
TCA cycle intermediates although this was not significant, which is in accordance with the fact 
that carbon flow into the alanine aminotransferase pathway is low in MDA MB 231 already in 
non-pertubed conditions. Hence, blockage of this pathway was not expected to lead to much 
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buildup of carbon atoms that could be shuttled elsewhere. Interestingly, MDA MB 231, did not 
show an increase in PC activity, however, it was observed that the PC reaction was already 
elevated in these cells compared to the other two cell lines (Figure 23, 24). Subsequently, the 
labeled quantities coming from the PC reaction did not increase further, however, labeled 
quantities of products coming from the PDH reaction showed an increasing trend.  
MCF7 (Figure 23c) showed a significant increase in fumarate and malate carbon labeling, while 
citrate, α-KG and succinate, remained unchanged, decreased or showed an increasing trend 
respectively. Although, MCF7 had a lower PC pathway activity compared to MDA MB 231 and 
was similar to MDA MB 468, it did not show an increase in PC reaction. Total labeled quantities 
of malate and fumarate m+2 fractions were higher in inhibitor treated cells, confirming that 
blockage of the GPT2 pathway shunts glucose carbon atoms into the TCA cycle pathway. 
Labelling expreiments were performed in collaboration with Nadine Royla, who also did the 
initial data processing 
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c MCF7 
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Figure 23: Effect of GPT2 inhibition on Glucose Labeling of TCA cycle intermediates.  Cells were treated 
with inhibitor ((a) MDA MB 468: 75µM, (b) MDA MB 231: 25µM, (c) MCF7:100µM) for 24h (with a media 
change after 20h). Cells were incubated with media supplemented with 13C-glucose for 30min and 
subsequently polar metabolites were extracted and incorporation of glucose derived carbon-13 in 
intracellular metabolites was measured via GC-MS. Data are presented as mean ± SD, n=3. *** represents 
p<0.001, ** represents p<0.01, * represents p<0.05. 
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4.4 Effect of Combinatorial targeting of GPT2 and PC 
The aforementioned results indicate that inhibition of the GPT2 catalyzed reaction rewires 
carbon flow in cancer cells. The reduction of TCA cycle intermediate α-KG, which is produced by 
the GPT2 catalyzed reaction, and the buildup of pyruvate leads to an increased flow of glucose 
into the TCA cycle. However, glucose can enter the TCA cycle via two routes, PDH catalyzes the 
forward TCA cycle and PC catalyzes the reverse cycle. PDH irreversibly catalyzes the reaction 
that results in oxidative decarboxylation of pyruvate to form acetyl CoA and NADH, while PC 
catalyzes the carboxylation of pyruvate to form oxaloacetate, products from both reactions can 
then be used to fuel the TCA cycle.  Different cell lines behave diversely, depending on their 
metabolic landscape. MDA MB 468 cells switched to a PC-driven TCA cycle under GPT2 
inhibition, while the other two cell lines did not and instead upregulated the PDH catalyzed 
reaction (Figure 23). While PDH activity was observed to be similar at basal conditions for these 
cell lines (Figure 24 a-c). In contrast, PC activity was diverse in the cell lines also at basal 
conditions which could be the rationale for differential usage of this pathway under metabolic 
stress (Figure 24 d-f). RPPA was done by Stephan Bernhardt, labelling was done together with 
Nadine Royla who did the initial data processing. 
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Figure 24: PDH and PC expression and activity in different breast cancer cell lines. (a,d) Basal levels of 
PDH and PC were measured by RPPA. (b-c, e-f). Protein expression was normalized to total protein levels 
Cells were labeled for 30min with glucose labeled media and subsequently harvested and labeling in 
intracellular metabolites was measured via GC-MS. Data are presented as mean ± SD, n=3. 
 
In order to see how much the cells depend on PC for their growth, first PC was knocked down 
using 4 siRNAs and knockdown efficiency was assessed 72h post transfection. All 4 siRNAs 
showed greater than 70% decrease in mRNA and protein levels in MDA MB 468 and MDA MB 
231 cells (Figure 25). siPC#3  and siPC#4 were used for further experiments.  
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Figure 25: Knockdown efficiency of siPC in MDA MB 468 and MDA MB 231 cells Cells were transfected 
with siPC (pool and individual). RNA and protein were harvested 72h after transfection and knockdown 
efficiency was determined by qPCR (a,c) and western blot (b,d) respectively. All values were normalized to 
NTC. Values for mRNA expression were first normalized to PUM1 levels and are presented as mean ± SD of 3 
technical replicates. Protein expression values were first normalized to actin levels. n=1 *** represents p < 
0.001, ** represents p < 0.01 
 
In the next experiments the effect of PC knockdown on cell proliferation was tested. While 
MDA MB 468 was affected the most, MDA MB 231 was least affected despite having a higher 
activity of PC. (Figure 26 a-c)  This was contrary to expectations as MDA MB 231 had the highest 
PC protein expression as well as activity (Figure 24).To investigate the effect of GPT2 inhibition 
on cells lacking PC, cells were treated with BCLA 8h after transfection with PC siRNA (Figure 26a 
and b). MDA MB 468 cells showed a moderate but significant decrease in cell proliferation 
following the combinatorial treatment with a PC siRNA and BCLA compared to the individual 
treatment (Figure 26a). MDA MB 231 showed no significant additional change in proliferation 
when treated with inhibitor in combination with siPC#3, while the minor difference seen with 
siPC#4 indeed reached significance (Figure 26b). MCF7 also seemed to be affected by 
combinatorial treatment since this showed a slight albeit significant change in cell proliferation 
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(Figure 26c). Knockdown of PC mRNA after 8h of transfection was confirmed in MDA MB 468 
cells (Figure 26d). 
 
 
Figure 26: Combinatorial Effect of GPT2 inhibition and PC knockdown on cell growth.  (a-c) Cells were 
transfected with PC siRNA. 8h post transfection cells were treated with inhibitor (MDA MB 468: 75µM, MDA 
MB 231: 25µM, MCF7:100µM) for 72h. Microscopy based nuclei counting was performed to determine cell 
numbers. (d) RNA was harvested from MDA MB 468 8h after transfection and knockdown efficiency was 
determined by qPCR. All values were normalized to control (NTC + water). For cell numbers data are 
presented as mean ± SD, n=2(each with 6 technical replicates). Values for mRNA expression were first 
normalized to PUM1 levels and are presented as mean ± SD of 3 technical replicates. *** represents p < 0.001, 
** represents p<0.01. 
 
Knockdown efficiency of the siRNAs in MCF7 was tested at both RNA and protein levels and was 
found to be >70% (Figure 27). 
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Figure 27: Transfection efficiency of siPC in MCF7 cells. Cells were transfected with siPC (pool and 
individual). RNA (a) and protein (b) were harvested 72h after transfection and knockdown efficiency was 
determined by qPCR and western blot respectively. All values were normalized to non-targeting control 
siRNA (NTC). Values for mRNA expression were first normalized to PUM1 levels and are presented as mean ± 
SD of 3 technical replicates. Protein expression values were first normalized to actin levels. n=1. ** represents 
p < 0.01 
 
As MDA MB 468 cells showed an increase in the flow of carbon atoms through the PC catalyzed 
pathway after inhibitor treatment, further investigation was required to answer the question of 
what effects PC and GPT2 proteins have on each other. Preliminary experiments showed that 
while GPT2 knockdown or inhibition did not have an effect on PC protein expression (Figure 
28a, inhibitor data not shown), PC knockdown did increase the levels of GPT2 protein (Figure 
28b). Further experiments need to be done to confirm these observations. 
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Figure 28 : Effect of GPT2 and PC on the expression of one another.  Cells were transfected with siGPT2 
(a) or siPC (b). Protein was harvested 72h after transfection and expression levels were determined by 
western blot. All values were first normalized to actin levels and then to NTC, n=1. 
 
 
4.5 Combinatorial Treatment of GPT2 and Oxidative 
Phosphorylation Inhibition 
4.5.1 Combinatorial Treatment of GPT2 Inhibitor and Rotenone 
Glycolysis and TCA cycle are important sources of electron carriers which are used in oxidative 
phosphorylation to generate ATP. The rewiring of the TCA cycle as a result of GPT2 inhibition, 
therefore not only affects the macromolecular biosynthetic pathways it supports but also 
energy generation which the cells strive to keep operative by pushing carbon flow into the TCA 
cycle. Therefore, it was hypothesized that a combinatorial treatment inhibiting GPT2 and 
oxidative phosphorylation be more effective in retarding cancer cell growth. Rotenone is a 
highly potent mitochondrial complex I inhibitor used in several studies to induce mitochondrial 
dysfunction(W. Hu et al., 2016). It inhibits the oxidation of NADH to NAD leading to oxidative 
stress. In breast cancer it has been shown to cause DNA damage and apoptosis(Deng, Huang, & 
Lin, 2009). 
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Using various concentrations of rotenone reported in previous studies conducted with the 
cancer cell lines, the effects of rotenone on the 3 cell lines used in this project were studied. All 
cell lines showed significant decreases in cell numbers 72h after treatment in a dose dependent 
manner (Figure 29a). However, MDA MB 231 cells were affected most severely, with an 80% 
decrease in cell numbers at the higher concentrations. Notably, in all three cell lines there was a 
sharp drop in cell numbers at 1µM concentration of rotenone. To confirm the effects of 
rotenone on the cell lines, reported markers, cleaved PARP (marker for DNA damage) and Bcl2-
L-4 (apoptosis marker), were tested (Figure 29 b-d). Cleaved PARP indeed increased in MDA MB 
468 and MCF7 even at the lowest concentration of rotenone tested, MCF7 showed a greater 
increase in cleaved PARP levels in line with the effect on cell numbers. Cleaved PARP could not 
be detected in MDA MB 231. Interestingly, even though MDA MB 231 showed a greater effect 
in cell proliferation, increase in Bcl2-L-4 was similar to that in MDA MB 468, while MCF7 had the 
highest increase in Bcl2-L-4 levels.  Bcl2-L-4, however, increased in all three cell lines confirming 
the toxic effect of rotenone on all three cell lines 
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Figure 29: Effect of rotenone on breast cancer cells.  (a) Cells were treated with different concentrations 
of rotenone for 72h. Microscopy based nuclei counting was performed to determine cell numbers. (b-d). 
Protein was harvested after treatment with different concentrations of rotenone for 24h and expression 
levels of target proteins were determined via Western blotting. All values were normalized to the untreated 
control (0). For cell numbers, data are presented as mean ± SD, n=1(with 6 technical replicates). Values for 
protein expression were first normalized to actin levels, n=1. *** represents p < 0.001, ** represents p<0.01. 
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Next, cells were treated with a combination of rotenone (rot) and the GPT2 inhibitor. For this 
experiment 3 concentrations of rotenone were chosen.  Firstly, 1µM was chosen as it was the 
least tested concentration showing the most pronounced effect in all 3 cell lines, thereafter, 0.1 
and 10µM were chosen to cover a large spectrum. BCLA concentrations were kept the same as 
before. As predicted, the combination of 0.1µM rotenone with the BCLA had an additive effect 
on the decrease in cell proliferation of MDA MB 468 cells (Figure 30a). In MDA MB 231, BCLA 
showed high toxicity and possibly therefore, the combination did not show any further effect 
(Figure 30b). In order to circumvent this, a lower concentration of the BCLA (10µM) was used in 
combination with rotenone, and similar to MDA MB 468, the combination of BCLA and 0.1 µM 
rotenone in MDA MB 231 cells showed an additive effect on growth (Figure 30c). MCF7 did not 
show a strong effect as a result of the combinatorial treatment (Figure 30d). While the effect of 
rotenone alone was high, the effect of BCLA was minor. Therefore, a higher concentration of 
BCLA (100µM)  was used in combination with rotenone, the combinatorial effect was negligibly 
more than the effect of rotenone (Figure 30e), further proving that the effect of GPT2 inhibition 
strongly affects MDA MB 468 and MDA MB 231 but is not significant in MCF7. 
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Figure 30: Combinatorial effect of rotenone and BCLA on breast cancer cells.  (a) Cells were treated with 
different concentrations (µM) of rotenone (rot) and BCLA for 72h. Microscopy based nuclei counting was 
performed to determine cell numbers. All values were normalized to untreated control. Data are presented as 
mean ± SD, n=2(each with 6 technical replicates). *** represents p < 0.001, ** represents p<0.01, * represents 
p<0.05. 
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4.5.2 Combinatorial Treatment of GPT2 Inhibitor and Metformin 
To further validate the findings made with rotenone, a different complex I inhibitor, namely, 
metformin was used. While rotenone is a specific inhibitor of complex I, metformin is not 
specific and has a milder effect on complex I(Madiraju et al., 2014). Similar to rotenone, a range 
of concentrations were used for metformin treatment as obtained from studies with breast 
cancer cell lines(Liu et al., 2009). For metformin, MDA MB 468 and MCF7 showed maximum 
and similar effects. Contrary to rotenone, metformin had the least effect on MDA MB 231 
which could be due to difference in efficiency or due to the fact that the two drugs act via 
different routes (Figure 31a). As metformin acts via phosphorylation of AMPKa, the levels of 
phosphoAMPKa were determined(Galdieri, Gatla, Vancurova, & Vancura, 2016). All cell lines 
showed an increase in phospho AMPKa levels (Figure 31 b-d). Furthermore metformin causes 
dephosphorylation of RPS6 which leads to growth arrest(Sacco et al., 2016). All the 3 cell lines 
showed significant decrease in PRPS6 (Figure 31 b-d). 
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Figure 31 : Effect of metformin on breast cancer cells.  (a) Cells were treated with different concentrations 
of metformin for 72h. Microscopy based nuclei counting was performed to determine cell numbers. (b-d). 
Protein was harvested after treatment with different concentrations of metformin for 24h and expression 
levels of target proteins were determined via western blotting. All values were normalized to untreated 
control. For cell numbers data are presented as mean ± SD, n=2(each with 6 technical replicates). Values for 
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protein expression were first normalized to actin levels, data is representative of two experiments. *** 
represents p < 0.001, ** represents p<0.01. 
 
As MDA MB 468 and MCF7 showed a sharp decrease in cell numbers at 2.5mM Metformin 
concentration and MDA MB 231 at 5mM these were chosen as the effective concentrations. In 
order to test a range of combinations, 0.25mM and 20mM were also tested.  MDA MB 468 
showed a slight additional decrease in cell numbers when a combination of metformin 2.5 mM 
and BCLA was applied (Figure 32a) compared to individual BCLA or metformin treatment. The 
combinatorial treatment did not result in any additional effects when higher or lower 
concentrations of metformin were applied. Effects seen in MDA MB 231 were similar to those 
observed with the combination of rotenone and BCLA (Figure 32b). However, in this case 
reducing the BCLA concentration did not change the effect of the combination (data not 
shown). MCF7 on the other hand showed an additional effect with combination of highest 
concentration of metformin and BCLA (Figure 32c), while increasing BCLA concentration did not 
have any additional effect in combination with lower concentrations of metformin (data not 
shown). 
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Figure 32 : Combinatorial effect of GPT2 inhibition and metformin on cell growth.  (a-c) Cells were 
treated with different concentration of metformin (Met) and BCLA (MDA MB 468: 75µM, MDA MB 231: 25µM, 
MCF7:100µM) for 72h. Microscopy based nuclei counting was performed to determine cell numbers. All 
values were normalized to untreated control. Data are presented as mean ± SD, n=2(each with 6 technical 
replicates). *** represents p < 0.001, ** represents p<0.01, * represents p<0.05. 
 
Therefore, the combination of BCLA, which has an impact on the TCA cycle and, likely, also on 
oxidative phosphorylation, and complex I inhibition further stresses the cells. However, this 
additional effect is dependent on the effect of the GPT2 inhibitor on the cells. 
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4.6 Clinical significance of GPT2 
The above experiments prove that in an in vitro setup, GPT2 plays a crucial role in maintaining 
cancer cell growth. However further investigation was required to establish a clinical role of 
GPT2 in breast cancer patients. Using two publicly available datasets METABRIC (2000 patients) 
and TCGA (1200 patients), the expression of GPT2 was analyzed. It was observed that in both 
datasets GPT2 expression is the highest in the basal subtype of breast cancer, which has the 
worst prognosis (Figure 33 a, b). A more in depth analysis of the METABRIC dataset showed that 
GPT2 expression significantly increases with increasing grade of tumor, which substantiates its 
role in aggressive cancers (Figure 33 c). As the METABRIC dataset has long follow-up data of 
patients (20 years), impact of GPT2 on overall patient survival was analyzed. The dataset 
showed that high GPT2 expression was associated with poor patient prognosis thus further 
consolidating the role of GPT2 in tumor progression (Figure 33c). 
 
 
Figure 33: GPT2 expression in breast cancer patients and correlation with overall survival.  (a) GPT2 
mRNA expression analysis [log2 (x+1) rsem] of the TCGA dataset comparing the PAM50 subtypes Lum A 
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(n=421), Lum B (n=192), Her2 (n=67) and Basal (n=141). (b) GPT2 mRNA expression analysis (log2 a.u.) of 
the METABRIC dataset comparing the PAM50 subtypes Lum A (n=721), Lum B (n=492), Her2 (n=240) and 
Basal (n=331). (c) GPT2 mRNA expression analysis of the METABRIC dataset comparing different grades, 
G1(n=170), G2(n=775) and G3(n=957). Quartile based survival analysis of the METABRIC dataset (Curtis et 
al., 2012) of GPT2 high vs. low gene expression (for each quartile n=492). *** represents p < 0.001, ** 
represents p<0.01, * represents p<0.05. 
 
The two analyzed datasets comprised of mRNA expression of genes. It was, therefore, 
important to find out whether or not these associations were correlating also at the protein 
level. Using an independent dataset from our group, containing clinical information of 800 
breast cancer patients, the expression of GPT2 was explored. In corroboration with the mRNA 
data, GPT2 protein levels were the highest in triple negative breast cancers most of which are 
basal (Figure 34a). GPT2 protein also positively correlated with increasing grade of tumors in 
this dataset (Figure 34b). RPPA and raw data processing was done by Stephan Bernhardt. 
Statistical analysis was done by collaboration partners at Freiburg Institute for Advanced 
Studies  
 
 
Figure 34: GPT2 protein expression in breast cancer patients. Box plots show GPT2 protein expression 
analysis of the 800 patient cohort comparing (a) molecular subtypes Lum (n=614), Lum HER2 (n=76), HER2 
(n=35) and triple negative (n=75) and (b) different grades, G1 (n=91), G2 (n=501) and G3 (n=207).  Kruskal-
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Wallis Rank Sum test was applied to compare the groups and p-values were adjusted using the Benjamini-
Hochberg procedure (Section 3.2.5.2). 
 
4.7 Regulation of GPT2 expression  
4.7.1 Regulation of GPT2 expression by c-Myc  
The high expression of GPT2 seen in patients having a poor prognosis indicates that cancer cells 
rewire their metabolic pathways to increase alanine production. This reveals a higher level of 
regulation that may take place. c-Myc has been shown to regulate glutamine metabolism in 
several tumor entites including breast cancer (Korangath et al., 2015). To test if GPT2 levels 
might also be regulated by c-Myc, the MDA MB 468 cell line was used as a biological test 
system. Indeed, GPT2 both mRNA and protein levels decreased upon knockdown of c-Myc 
(Figure 35 a, c). c-Myc knockdown was confirmed at both mRNA and protein levels (Figure 35 
b,d). Furthermore, GLS levels (Figure 35e) were also tested as a positive control for c-Myc 
knockdown(Gao et al., 2009) and showed a significant decrease.  
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Figure 35: Regulation of GPT2 expression by c-Myc. (a-f) Cells were transfected with siMYC (30nM). RNA 
and protein were harvested 72h after transfection and knockdown efficiency was determined by qPCR (a-b) 
and RPPA (c-f) respectively. All values were normalized to non-targeting control. For mRNA the values were 
first normalized to PUM1 levels and are presented as mean ± SD of 3 technical replicates. For protein levels 
the values were first normalized to total protein levels and are presented as mean ± SD, n=3. *** represents p 
< 0.001, ** represents p<0.01. (g)  
 
To understand whether c-Myc regulation plays a role in breast cancer patients, c-Myc levels 
were next correlated with GPT2 levels in the the METABRIC dataset as well as in the in-house 
800 patient dataset (RPPA done by Stephan Bernhardt, analysis done by Khalid Abnaof)(Figure 
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36 a,b). Myc levels correlated positively with GPT2 levels at both mRNA and protein levels. In 
fact the correlation was better at the protein levels. 
 
 
Figure 36: Correlation between MYC and GPT2 expression in patients. (a)Correlation analysis of MYC 
with GPT2 gene expression of the TCGA dataset (n= 1215). (b) Correlation analysis of c-Myc with GPT2 
protein expression of the 800 patient cohort (n=800).  Correlation coefficient was calculated using Pearson 
correlation. 
 
 
4.7.2 Regulation of GPT2 expression by ATF4  
The previous experiments revealed that while c-Myc does play a role in GPT2 regulation, it does 
not regulate the entire expression, and GPT2 could thus be regulated also by other 
transcription factors. ATF4 has been reported to regulate GPT2 expression in other cell 
types(Salgado et al., 2014a). Therefore, it was interesting to see whether it also plays a role in 
breast cancer. Indeed GPT2 mRNA levels decreased significantly upon ATF4 knockdown (Figure 
37 a,b).  Additionally, tunicamycin treatment, which is a commonly used ER stress 
inducer(Salgado et al., 2014a), led to ATF4 up regulation(Figure 37d),  and it  also increased 
GPT2 expression significantly (Figure 37c).  
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Figure 37: Regulation of GPT2 expression by ATF4. (a-d) Cells were transfected with siATF4. RNA and was 
harvested 72h after transfection and mRNA levels were determined by qPCR. All values were normalized to 
PUM1 levels and non-targeting control. Data are presented as mean ± SD of 3 technical replicates. *** 
represents p < 0.001.  
 
This observed regulation in the previous figure was further consolidated by a positive 
correlation between the expression of ATF4 and GPT2 at the patient level in the TCGA dataset 
(Figure 38). 
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Figure 38: Correlation between ATF4 and GPT2 expression in patients. Correlation of ATF4 with GPT2 
expression of the TCGA dataset (n= 1215). Correlation coefficient was calculated using Pearson correlation 
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5. Discussion 
Breast cancers, like several other cancers undergo global metabolic shifts in order to sustain 
their growth and survival. Considerable evidence suggests that unraveling these metabolic 
transformations holds the promise for discovery of new therapeutic susceptibilities(Chakrabarti 
et al., 2015; Morin, Letouzé, Gimenez-Roqueplo, & Favier, 2014; Sotgia, Martinez-Outschoorn, 
& Lisanti, 2013; Tennant, Durán, & Gottlieb, 2010; X. Zhang et al., 2016).  In this project I aimed 
to dissect the metabolic landscape of breast cancer with the aim of finding important players in 
the bioenergetics and biosynthetic pathways of tumor cells. This led to the identification of 
alanine aminotransferase (GPT2) which I found to have a strategic role in maintaining the 
glycolytic and glutaminolytic equilibrium of breast cancer cells and may thus qualify as a 
potential target for therapeutic intervention. This study also underlines metabolic 
heterogeneity within and between different subtypes of breast cancer, highlighting the fact 
that when it comes to metabolism, the conventional classifications may not apply.  
 
5.1 Metabolic characterization of cancer cells reveals 
heterogeneity within breast cancer cell lines 
While it is widely accepted that the aggressive subtypes of breast cancer, like triple negative 
breast cancers, display pronounced dependence on metabolic rewiring (Lim et al., 2016; Maiti, 
Kundranda, Spiro, & Daw, 2010; J. H. Park et al., 2016; Pelicano et al., 2014; Peterson, Walker, 
Sloan, & Creek, 2016; Shen et al., 2015; van Geldermalsen et al., 2015b), there is a large body of  
evidence which suggests that less aggressive subtypes of breast cancer such as the ER positive 
ones, can also undergo large-scale metabolic transformations (Audet-Walsh et al., 2016; A. R. 
Clark & Toker, 2014; Lloyd, Arnold, & Sreekumar, 2015; Mishra & Ambs; S. Park et al., 2016; 
Penkert et al., 2015). This could also be recapitulated in this project where all three cell lines, 
MDA MB 468, MDA MB 231 and MCF7, despite their genetic differences, showed comparable 
levels of glucose and glutamine consumption, as well as active breakdown of these carbon 
sources as marked by high levels of lactate and ammonia secretion (Figure 5). However, amino 
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acid metabolism activity was found to be higher in the triple negative breast cancer cell lines as 
seen by the protein levels of the enzymes involved in these pathways (Figure 6c). Previous 
studies have also reported aberrant amino acid metabolism in triple negative breast cancer 
cells (M. I. Gross et al., 2014; Possemato et al., 2011a; Timmerman et al., 2013; van 
Geldermalsen et al., 2015a). It is to be noted however, that MDA MB 468 showed a higher 
consumption of both carbon sources as well as higher secretion of their end products when 
compared to MDA MB 231 (Figure 5). Additionally, MDA MB 468 had a higher expression of 
oxidative phosphorylation (OXPHOS) related proteins compared to MDA MB 231 (Figure 6d), 
validating functional experiments which showed higher oxygen consumption rates of MDA MB 
468 (Lanning et al., 2017). This is not surprising as TNBC patients have high levels of genetic 
heterogeneity (Lehmann et al., 2011; Lehmann, Jovanović, et al., 2016). While both the MDA 
cell lines belong to the triple negative subtype of breast cancer, they are assigned to different 
subclasses. MDA MB 468 belongs to the basal A subclass while MDA MB 231 is basal B 
(Lehmann, Jovanovi, et al., 2016) (it was previously assigned to mesenchymal like (Lehmann et 
al., 2011)). MCF7, which is a luminal cell line, had the highest expression of enzymes involved in 
oxidative phosphorylation, in concordance with previous studies (Pelicano et al., 2014) (Figure 
6d). Expression of enzymes of the citric acid (TCA) cycle, which directly feeds OXPHOS, was also 
higher in MCF7 compared to the triple negative breast cancer cell lines (Figure 6b), further 
underlining the difference between the luminal and triple negative subtypes. 
While basal metabolic rates and enzyme levels are important to understand the metabolic 
tendencies of the cells, tumor cells can easily switch between pathways and sources to quickly 
adapt to changing metabolic environments, thereby increasing fitness of the cells resulting in 
sustained growth and proliferation. It is important to introduce perturbations to these cells and 
find out how they behave under different stress conditions and what alternative pathways can 
get activated in order to target them efficiently. All 3 cell lines were grown under different 
nutrient starvation conditions, namely, glucose and glutamine deprivation. It was clear that all 
cell lines were affected by the lack of either nutrient, however, the extent of the effect varied 
between the different cell lines (Figure 4 a-f). In line with previous studies (Dilshara et al., 2017; 
Korangath et al., 2015; Timmerman et al., 2013; van Geldermalsen et al., 2015b) MDA MB 231 
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cells were most sensitive to glutamine deprivation. In contrast, MCF7 cells were most affected 
under glucose deprived conditions. Other studies have shown that ER+ cells are more 
dependent on glucose than on glutamine (Timmerman et al., 2013). However, the subtypes are 
not clearly separated into glucose and glutamine dependent groups, for example, glucose is a 
critical source for ER- cells as well and they tend to have higher glycolytic rates, as I have shown 
in this project and has also been reported(Rizwan et al., 2013; Shen et al., 2015). MDA MB 468 
cells showed moderate dependence on both carbon sources which was also in line with other 
studies (Lampa et al., 2017; Lukey, Greene, Erickson, Wilson, & Cerione, 2016), suggesting that 
they may be metabolically more flexible and can switch on/off certain pathways rapidly to 
adapt to changes in the environment. In fact, another study has shown that even though MDA 
MB 468 cells have higher OXPHOS versus glycolytic levels compared to MDA MB 231 cells, 
under conditions of glycolytic stress they survive better as they have a higher glycolytic reserve 
(Lanning et al., 2017).  MDA MB 468 cells depend on arginine as an important source for 
nitrogen to sustain polyamine biosynthesis and blocking the breakdown of this amino acid can 
lead to cell apoptosis (Singh, Pervin, Karimi, Cederbaum, & Chaudhuri, 2000). In this project, as 
well, it was clear that this pathway was active from the high levels of arginase 2 (ARG2) 
particularly in MDA MB 468 cells (data not shown).This data suggests that MDA MB 468 cells 
can use multiple nutrient sources for their sustenance and can thus compensate for the lack of 
one source by switching to other sources they are already ready to utilize. However, further 
experiments need to be done to confirm this hypothesis. 
Metabolic intermediates derived from both glycolysis and glutaminolysis, provide the 
biosynthetic molecules required for the cancer cells. In cancer cells, glycolysis provides carbon 
atoms for different biosynthetic intermediates that lead to the production of building blocks 
required for the cell growth(Lunt & Vander Heiden, 2011). Conventionally, glutamine is the 
primary nitrogen donor of the cells which supports nucleotide and protein synthesis, however, 
in cancer cells the role of glutamine is extended to become the second major carbon source as 
it also supplies intermediates that keep the TCA cycle functional(R. J. DeBerardinis et al., 2007; 
L. Yang et al., 2017). As a result, cancer cells have highly deregulated amino acid metabolism. 
These deregulated pathways facilitate the transport of carbon from glutamine into the 
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biosynthetic pathways. An important example of this, particularly in breast cancer, is the serine 
synthesis pathway which is upregulated in cancers with poor outcome, especially the ER- 
subtype(Pacold et al., 2016; Possemato et al., 2011b). Serine synthesis pathway has a dual role 
in these cells. On the one hand, it leads to the production of glycine which contributes to the 
one carbon metabolism which has an impact on diverse pathways including nucleotide, protein 
and lipid metabolism, as well as epigenetic regulation and redox balance.  On the other hand, 
breast cancer cells have been shown to suffer under blockage of serine synthesis as a result of 
depletion of the α-Ketoglutarate (α-KG) pool. Indeed, glutamine contributes to the TCA cycle 
mainly via maintaining α-KG levels in the cells (Lampa et al., 2017; C. Yang et al., 2014b). While 
α-KG is important for TCA cycling, it can also undergo reverse carboxylation to produce citrate 
which feeds the fatty acid biosynthesis (Zaidi, Swinnen, & Smans, 2012). Additionally, it can 
provide the substrate for the oncometabolite 2-HG production, which can promote 
tumorigenesis(L. Dang et al., 2009).  α-KG is therefore, the crucial metabolite that cancer cells 
depend on glutamine for. As a consequence, high glutamine uptake in the cells results in the 
upregulation of aminotransferase reactions, in addition to the serine biosynthesis pathway. 
Indeed alanine and aspartate aminotransferases play critical roles in cancer cells(Korangath et 
al., 2015; Thornburg et al., 2008).  
 
5.2 Alanine aminotransferase (GPT2) is deregulated in breast 
cancers and is crucial for their growth 
I have shown (Figure 7b, c) that several breast cancer cell lines have high expression of GPT2 
both at the mRNA and protein levels. This is consistent with other studies which have shown 
that glutamine addicted cells upregulate their aminotransferase expressions including 
GPT2(Korangath et al., 2015; Son et al., 2013b). In liver tumors, GPT1 activity is elevated already 
in the pre-tumor state and increased secretion of alanine has been found to be among the 
earliest metabolic changes that occur (S. Hu, Balakrishnan, Bok, Anderton, Larson, Nelson, 
Kurhanewicz, Vigneron, Goga, et al., 2011). The expression of GPT2 correlated with alanine 
levels, MDA MB 468 cells (which have the highest expression of GPT2) showed the highest 
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production and secretion of alanine (Figure 7a, d). Furthermore, high GPT2 activity in these cells 
was confirmed by the high rates of glucose label incorporation into alanine (Figure 7e).  
Interestingly, GPT1 is expressed at much lower levels than GPT2 at the mRNA level and does 
not show any difference between the three tested cell lines (MDA MB 468, MDA MB 231 and 
MCF7) and (Figure 7b). It must be noted that GPT1 and GPT2 genes map to two different 
chromosomes suggesting that the genes are regulated independently(Yang, Roong-Ze; 
Blaileanu, Greorche; Hansen, Barbara C;Shuldiner, Alan R; Gong, 2002). Furthermore, the GPT1 
protein is cytosolic, whereas GPT2 is mitochondrial. GPT1 is expressed in the kidneys, liver, 
skeletal muscle, and in low amounts in the heart, whereas GPT2 is expressed in the heart, 
skeletal muscle and pancreas. While GPT1 is mostly abundant in liver and is a biomarker for 
liver toxicity, GPT2 has higher expression in other specific organs(Salgado et al., 2014a). 
Therefore, the upregulation of GPT2 in cancer and the lack thereof of GPT1 suggest that when 
the need to upregulate alanine aminotransferase activity arises in cancer cells, they tend to rely 
on GPT2. Indeed, in cancer cells it has been shown that alanine is produced mainly by the 
mitochondrial pyruvate (Vacanti et al., 2014; C. Yang et al., 2014a). 
The dependence of breast cancer cells on GPT2 was confirmed with two independent 
approaches. In one, RNAi approach was used to specifically knockdown GPT2. This led to 
decreases in viability and cell growth in all cell lines tested except T47D (luminal subtype) which 
had the lowest expression of GPT2 (Figure 8, 9 and 10). Notably, MDA MB 231 which had low 
GPT2 expression and activity, as seen by the low labeled glucose carbon incorporation into 
alanine, showed significant dependence on alanine biosynthesis pathway, in accordance with a 
previous report (Korangath et al., 2015). Although this result was surprising in the light of GPT2 
activity levels (which had not been tested in the previous report (Korangath et al., 2015)) in the 
cells, it highlighted the fact that this enzymatic reaction is crucial to the cells even when protein 
levels are low. 
The second approach was to use a commercially available alanine aminotransferase inhibitor, 
β-chloro-L-alanine (BCLA), a substrate analog of the enzyme. Previously used in a study in lung 
cancer cell lines(Beuster et al., 2011), this inhibitor is not specific to either isoform of GPT but 
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since breast cancer cell lines did not have high or changing expression of GPT1 (Figure 7b)and 
the aim was to inhibit the production of alanine, this inhibitor was chosen. In this approach, 
MDA MB 468 showed a significant decrease in cell proliferation while MCF7 was the least 
affected (Figure 15a and 16a). MDA MB 231 turned out to be the most affected cell line, in line 
with the data obtained with the siRNA approach (Figure 9d, 10b, 15a and 16b). This indicates 
that the GPT2 catalyzed reaction is still important for MDA MB 231 cell survival and the cells 
cannot quickly compensate for the perturbation in this pathway. In the study on lung cancer 
cells previously stated, inhibition of alanine transaminase impaired cell growth by reducing ATP 
production and growth inhibitory signals leading to an increase in AMPK and reactive oxygen 
species (ROS) and a decrease in cell cycle proteins (Beuster et al., 2011). Aminooxyacetate, a 
broad spectrum inhibitor of aminotransferase, has been shown in several studies to suppress 
cell growth. In breast cancer cell lines, aminooxyacetate treatment increases the sub-G1 
population and S-phase arrest (Korangath et al., 2015). Furthermore, inhibition of 
aminotransferase causes a decrease in amino acids thus activating the ER stress pathway and 
leading to cytotoxicity (Hao et al., 2016; Korangath et al., 2015). The disadvantage of this 
approach is that aminooxyactate is a broad spectrum aminotransferase inhibitor and its effects 
cannot be solely attributed to GPT2 inhibition. BCLA, on the other hand, has been shown in 
previous studies to specifically target alanine aminotransferase. This is the first time that the 
effect of specific inhibition of GPT2 has been studied in breast cancer. 
 
5.3 Perturbation  of alanine metabolism affects nutrient 
utilization capacity of cancer cells 
Alanine, produced via the transfer of α-nitrogen from glutamate to pyruvate, supports protein 
synthesis, but is also secreted from the cells in large amounts to get rid of excess carbon from 
glycolysis and nitrogen from glutaminolysis (R. Deberardinis & Cheng, 2009). One report even 
revealed that alanine may function as an important carbon fuel in pancreatic cancer cells which 
take it up from the tumor microenvironment where it is secreted by the pancreatic stellate cells 
(Sousa et al., 2016). The alanine amintransferase reaction is one of the pivots joining the 
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glycolysis and glutaminolytic pathways. Therefore, it was interesting to find out whether GPT2 
inhibition affects either pathway. In colorectal cancer cells upregulation of GPT2 leads to 
increased glutamine consumption (Hao et al., 2016). A study in mammary epithelial cells 
demonstrated that the transition from quiescence to proliferation is accompanied by an 
increase in glutamine consumption and subsequent GPT2 expression (Coloff et al., 2016). 
Indeed, it was observed that a decrease in alanine production in MDA MB 468 cells results in 
reduced uptake of glutamine (Figure 18a and 19a). This was further validated by a decrease in 
ammonia production, an important outlet for excess nitrogen (Figure 19b). In MDA MB 231 and 
MCF7 cells, glutamine uptake showed a tendency to decrease, indicating that this 
aminotransferase pathway might be one of several routes for glutamine cycling and that 
MDA MB 231 as well as MCF7 cells do not depend on it for nitrogen cycling to the same extent 
as MDA MB 468 (Figure 18b,c). This is also seen in other cancer entities, which demonstrates 
that alanine production is an important glutaminolytic route (Hao et al., 2016; Smith et al., 
2016a). Glucose uptake and lactate secretion on the other hand did not show considerable 
change in MDA MB 468 cells (Figure 18a and 19c, d) whereas MDA MB 231 cells displayed a 
slight but significant decrease in glucose uptake, underlining the fact that the two cell lines are 
metabolically quite diverse (Figure 18b). The lack of any significant change in nutrient uptake in 
MCF7 cells further supports the fact that it is least affected by GPT2 inhibition (Figure 18c). 
 
5.4 GPT2 Inhibition reduces the pool of TCA cycle 
intermediates in cancer cells  
Alanine is an important nitrogen source in cells which can provide building blocks for protein 
and nucleotides that are essential for cell growth. However, it has been shown in other cancers 
that the GPT2 catalyzed reaction is also an important source of α-KG for the cells. In colorectal 
cancer, PI3KCA mutations have been shown to render the cells addicted to glutamine and 
thereby dependent on aminotransferases, in order to replenish the α-KG pools driving the TCA 
cycle (Hao et al., 2016).  In another study, young adult murine colon (YAMC) cells which were 
transformed to malignant cells via activation of RAS and p53 mutation showed upregulation of 
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GPT2 expression(Smith et al., 2016). These cells became GPT2 dependent. GPT2 is, therefore, a 
critical factor that utilizes products of glycolysis (i.e., pyruvate) to shunt glutamine-derived 
carbon atoms into the TCA cycle. Similarly, studies in mammary epithelial cells have shown that 
as the cells transition from quiescent to proliferative states, similar to cancer cells, they become 
more dependent on transaminase reactions to support glutamine catabolism which, in turn, 
promotes cell proliferation (Coloff et al., 2016). In corroboration with other reports, I have 
shown that inhibitor treatment in breast cancer cells led to a decrease in α-KG pools (Figure 
20a). It is however, interesting to note that even though MDA MB 231 cells were severely 
affected by GPT2 inhibition, they showed an increase in α-KG levels (Figure 20b). This indicates 
that even though both MDA MB 468 and MDA MB 231 have similar phenotypic reactions in 
response to GPT2 inhibition they respond differently at the molecular level. It has been shown 
in other studies that increases in α-KG can stabilize hypoxia inducible factor 1 α (HIF1α) 
resulting in a stressful environment in the cells. Hence, this could be the mechanism activated 
in MDA MB 231 cells which leads to slowing cell growth (Hou et al., 2014). However, the exact 
source of this α-KG needs further investigation.  
The decrease in α-KG is concurrent with a decrease in the pool of TCA cycle intermediates 
downstream of α-KG, further supporting the data that cells are affected by a decrease in 
glutamine uptake and alanine production both of which contribute to the TCA cycle via α-KG 
production (Figure 20a). An earlier study in colorectal cancer (Hao et al., 2016) showed that 
upregulation of GPT2 expression and glutamine increased the flux of glutamine derived TCA 
cycle intermediates, the entry point for which is α-KG. Decrease in TCA cycle activity extended 
to reduced oxygen consumption rates, which indicated reduced cellular respiration (Figure 22). 
 
5.5 GPT2 activity influences expression of enzymes involved 
in anaplerosis 
Here, I have also demonstrated that the effect of GPT2 inhibition on nutrient cycling extends to 
the enzymatic level (Figure 21). MDA MB 468 cells showed a decrease in glutamine transporters 
as well as glutaminolytic proteins, while glycolytic proteins remained unchanged in line with the 
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metabolite data (Figure 18, 19 and 21a). In concurrence with metabolite data TCA cycle 
enzymes showed significantly decreased levels upon GPT2 inhibition. Interestingly, most tested 
enzymes tended to increase in MDA MB 231, indicating that the cells might be responding to 
the perturbation by upregulating these enzymes in order to maintain/regain the rapid 
proliferation rates seen in MDA MB 231, though most changes were not significant (Figure 
21b).  MCF7 did not show any clear tendencies (Figure 21c). However, understanding the 
mechanism by which enzyme levels are adjusted entails further study.  
 
5.6 GPT2 inhibition redistributes glucose carbon utilization in 
cancer cells 
The data discussed above demonstrate that GPT2 is indeed used by breast cancer cells to 
propel glutamine derived α-KG into the TCA cycle. However, this reaction is also fed by glucose. 
The fate of glucose carbon atoms under GPT2 inhibition has not been explored so far. In this 
study two of the cell lines did not show any significant decrease in glucose consumption levels, 
MDA MB 468 rather increased slightly, MDA MB 231 showed a small decrease in uptake in 
glucose (Figure 18, 19 c). Pyruvate which is the final glycolytic product has three main fates, it 
can feed into the TCA cycle to produce ATP via OXPHOS and other biosynthetic intermediates or 
produce lactate which builds up the NADH reserves in the cells or produce alanine. In the 
absence of alanine production the pyruvate buildup can lead to an increase in lactate 
production or TCA cycle intermediates.  
As the total levels of lactate did not change (Figure 18 and 19d) it is clear that the excess carbon 
atoms from glucose do not feed into this pathway and could thus flow into the TCA cycle to 
compensate for the reduced input from glutamine. Indeed glucose labeling showed significant 
increase in carbon atoms flowing from glucose into the TCA cycle (Figure 23). In the PDH-
catalyzed forward TCA cycle the percentage of glucose carbon increased, likely due to decrease 
in carbon flow from glutamine, but this could not be observed in the total labeled 
quantities(citrate showed a small but insignificant increase in total labeled levels) (Figure 23a). 
Intermediates of the reverse reaction catalyzed by pyruvate carboxylase showed an increased 
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input of carbon atoms from glucose both in percentage and quantity. The oxaloacetate derived 
from pyruvate by PC can feed the reverse TCA cycle via malate or can be converted to citrate. In 
MDA MB 468 cells there was a significant increase in carbon labeling of malate and fumarate 
coming from this reverse reaction. Citrate, whose sources are a little more difficult to detect, 
also showed an increase of 13C-incorporation if the fragment indicating the forward and reverse 
reaction but not the fragment reflecting the forward reaction.. This indicates that the 
oxaloacetate coming from pyruvate cycles into the TCA cycle via malate but some of it might 
also be used to produce citrate. The absence of a change in the labeled quantities of α-KG may 
indicate that either the labeling time was too short for the reverse reaction to reach it and/or 
produced citrate was utilized to be transported outside mitochondria in order to feed other 
biosynthetic pathways. Further experiments are required to confirm this. 
While the labeling data clearly showed that in MDA MB 468 cells the inhibition of GPT2 shunts 
more carbon atoms from glucose into the TCA cycle via the PC catalyzed pathway, the results 
from the other two cell lines were more complicated to interpret. MDA MB 231 cells did not 
show any change in the proportion of glucose labeling, but the total labeled quantities of the 
intermediates in the PDH catalyzed forward reaction showed a tendency to increase (Figure 
23b). This could be due to the fact that MDA MB 231 cells already have a high PC activity and 
probably this pathway is functioning to its maximum capacity and therefore, under conditions 
of stress, they cannot switch to this pathway and have to rather push the forward reaction.  
MCF7 cells, similar to MDA MB 468 cells, showed significant increase in malate and fumarate 
labeled proportions and quantities of the forward reaction (Figure 23c). However, despite their 
basal PC activity being similar to MDA MB 468 cells, MCF7 cells did not increase PC activity 
under stress.  
Thus, even though the increase in PC activity under inhibition is unique to MDA MB 468 cells, it 
is clear from the labeling data that when the GPT2 pathway is not available to the cells, the 
carbon from the glucose flows into the TCA cycle. As MDA MB 231 cells already have a higher 
PC activity, they tend to push more carbon through the PDH catalyzed pathway, and it is clear 
that both routes are active under stress. MCF7 does not increase PC activity despite having a 
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low basal activity, this could be due to the metabolic landscape of the cell line in general or that 
the GPT2 inhibitor has the least effect on the cells and the cells probably have other 
compensatory pathways to overcome the blockage. Higher concentrations of the inhibitor and 
the identification of possible compensatory pathways need to be tested. 
 
5.7 Combinatorial perturbation of GPT2 and PC retards cell 
growth 
Pyruvate carboxylase (PC) is a mitochondrial enzyme which is highly active in liver and kidneys 
where it promotes gluconeogenesis. It is also expressed in other organs where it has a role in 
replenishing the TCA cycle by converting pyruvate to oxaloacetate. The alternative to PC 
catalyzed replenishment of TCA-cycle intermediates is glutamine dependent anaplerosis. 
Cancers use different anaplerotic sources. Lung cancers chose PC-dependent anaplerosis over 
GLS1 activity (Sellers et al., 2015), however, major changes in the tumor microenvironment 
have been shown to shift lung cancer cells to being more dependent on glutamine (Davidson et 
al., 2016). Breast cancers mostly use the glutamine anaplerotic route and thus, have low PC  
activity (Christen et al., 2016), as is also evident in some of the cell lines tested in this project 
(Figure 24 a-c). MDA MB 231, despite having the highest basal activity of PC, was not affected 
by PC knockdown, while MDA MB 468, which has very low basal activity of PC, is significantly 
more affected (Figure 26 a, b). This could be traced back to differential glutamine metabolism 
between the cell lines (Figure 4 a-f). While MDA MB 231 is more dependent on glutamine for 
survival, MDA MB 468 is just moderately affected by changing levels of glutamine indicating 
that this cell line might use other anaplerotic sources to maintain a functional TCA cycle. PC has 
been associated with glutamine independent growth (Biancur et al., 2017; T. Cheng et al., 
2011). Thus, it makes sense that when cells reduce their uptake of glutamine under GPT2 
inhibition, PC driven anaplerosis is induced to feed the TCA cycle. PC activity therefore, may be 
a compensatory route that is activated by cells to offset the effect of decreased or abolished 
GPT2 activity (Figure 23a). The combination of PC knockdown and GPT2 inhibition 
consequently, had a stronger effect compared to the individual treatments, in both MDA MB 
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468 and MCF7 (even though MCF7 cells did not show an activation of PC pathway) (Figure 26 
a,c).  However, the lack of a synergistic effect signals that there are other compensatory 
pathways that can get activated in the cells. In MDA MB 231 cells, the combined knockdown of 
PC did not have any additional effect probably because the effect of the inhibitor was severe 
(Figure 26b). 
 
5.8 Dual targeting of alanine and energy metabolism has a 
combinatorial effect on cell growth 
The TCA cycle provides energy precursors to be fed into the electron transport chain via 
oxidative phosphorylation. Depletion in TCA cycle intermediates will therefore, directly impact 
OXPHOS. Following GPT2 inhibition the cells displayed a decrease in oxygen consumption rate, 
a measure of OXPHOS (Figure 22). As discussed earlier, under conditions of stress the cells 
compensate for the lack of glutamine anaplerosis with PC driven anaplerosis which could be 
used to feed the ETC as well. Additionally, targeting the respiratory chain directly upregulates 
reductive glutamine metabolism (Fendt, Bell, Keibler, Olenchock, et al., 2013), which in turn 
could render the cells more susceptible to inhibition of glutamine metabolism. As GPT2 
inhibition showed a change in glutamine metabolism, combinatorial targeting of GPT2 and 
OXPHOS could provide a more effective treatment strategy for cancer cells. In order to test this 
hypothesis, the cell lines were treated with the two drugs, rotenone and metformin. 
Rotenone, an irreversible complex I inhibitor, blocks the NADH oxidation in the respiratory 
chain and has been show to induce apoptosis in breast and lung cancer cells (Deng et al., 2009; 
W. Hu et al., 2016) mainly via ROS generation. Figure 29 shows that all three cell lines were 
sensitive to rotenone treatment. MDA MB 231 was found to be the most susceptible even 
though it is the least OXPHOS dependent cell line (Lanning et al., 2017; Pelicano et al., 2014). As 
mentioned earlier, respiratory chain targeting has been shown to make cancer cells more 
dependent on glutamine metabolism. Combinatorial treatment of rotenone and BCLA (Figure 
30a-c) in MDA MB 468 and MDA MB 231 cells showed some additional effect than the 
individual inhibitors, while MCF7 showed effects similar to rotenone treatment alone. This is in 
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line with data that shows that ER+ cell lines are more OXPHOS dependent (Pelicano et al., 2014) 
and less dependent of glutamine.  
Metformin is another complex I inhibitor which is widely used to control blood sugar levels in 
type 2 diabetes patients. Epidemiological data suggests that diabetic patients treated with 
metformin have a lower risk of developing cancer (Evans, Donnelly, Emslie-Smith, Alessi, & 
Morris, 2005). Preclinical studies have also provided evidence for metformin being a potential 
candidate for anticancer treatment (Birsoy et al., 2014). One report showed that in triple 
negative breast cancers, which occur frequently in women with obesity or type II diabetes, 
metformin treatment can be used as effective therapy(Liu et al., 2009). The same report 
showed that treatment results in growth arrest and apoptosis and has been shown to also 
reduce tumor formation in xenograft models. Another report, however, suggests that 
metformin can have diverse effects, such as cell cycle arrest and reduction in colony formation 
and cell growth, in all molecular subtypes of breast cancer(Alimova et al., 2009). 
Metformin can act through several routes. In diabetes, it is used for its ability to reduce blood 
glucose levels by increasing glucose uptake by skeletal muscles, inhibiting gluconeogenesis in 
the liver, and controlling the blood insulin levels (Teicher, Linehan, & Helman, 2012). Metformin 
targets gluconeogenesis via glycerophosphate dehydrogenase (Madiraju et al., 2014). This is 
important also for cancer cells as glycerophosphate dehydrogenase is an important enzyme 
which supports the glycolytic phenotype of the cells and provides electrons for the respiratory 
chain (Chowdhury, Gemin, & Singh, 2005). Moreover, the role of metformin in targeting the 
mitochondrial complex I and inhibiting the energy metabolism of cells makes it an attractive 
drug. Unlike rotenone, metformin is a reversible inhibitor and less toxic and is also thought to 
be targeting complex I at a different site(Wheaton et al., 2014). In this study metformin is 
shown to induce significant retardation of cell growth in all three cancer cell lines, though it 
should be noted that MDA MB 231 is comparatively least affected (Figure 31). These results 
corroborate previously reported data (Liu et al., 2009). The difference in the behavior of the cell 
lines to the two complex I inhibitor treatments could be due to different efficiencies of the 
drugs or due to the notion that they act on different sites. Additionally, metformin can act on 
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targets other than complex I for example the targeting of glycerophosphate dehydrogenase, 
which may contribute to the difference as the cell lines are also metabolically distinct. However, 
further experiments need to be done to confirm this. 
Similar to rotenone, metformin-induced reduction in glucose oxidation induces a switch to 
glutamine anaplerosis (Fendt, Bell, Keibler, Davidson, et al., 2013; Fendt, Bell, Keibler, 
Olenchock, et al., 2013). In triple negative breast cancer xenografts, metformin has been shown 
to reduce cancer cell growth by reducing c-Myc and HIF1α levels(Li, Xue, Xi, & Xie, 2017; J. 
Zhang et al., 2017). These reports in combination show that metformin can directly target 
tumor cells and render the cells sensitive to glutamine targeting therapy. In this study as well, I 
have shown that treatment of metformin and BCLA had a combinatorial effect on MDA MB 468 
(Figure 32). These changes could not be recapitulated in the other cells, and can potentially be 
attributed to the fact that the change in glutamine metabolism after GPT2 inhibition is not as 
prominent in these other cell lines as in MDA MB 468 cells. Additionally, as MDA MB 231 is least 
affected by metformin, it clearly can bypass any inhibitory effect coming from this drug, while 
MCF7 are more dependent on OXPHOS than glutamine anaplerosis, hence they are more 
affected by the drug than by GPT2 inhibition. 
 
5.9 GPT2 expression correlates with poor prognosis in breast 
cancer patients 
There is substantial evidence that alanine metabolism is important for cancer cell growth in 
culture(Hao et al., 2016; Korangath et al., 2015; Smith et al., 2016a). However, the potential 
relevance of these findings depends on the clinical implications they have.   
Earlier findings focused on the role of GPT1 rather than GPT2, owing to its association with liver 
toxicity(Conde et al., 2015; S. Hu, Balakrishnan, Bok, Anderton, Larson, Nelson, Kurhanewicz, 
Vigneron, & Goga, 2011; Maximos et al., 2015). A review of different population studies 
showed that GPT1 expression is associated with the risk of cancers in digestive 
organs(Kunutsor, Apekey, Hemelrijck, Calori, & Perseghin, 2014). Similarly, in liver tumors, GPT1 
activity is elevated in the pre tumor state and increased secretion of alanine is one of the 
  Discussion 
131 
 
earliest metabolic changes that occur (S. Hu, Balakrishnan, Bok, Anderton, Larson, Nelson, 
Kurhanewicz, Vigneron, Goga, et al., 2011).  
Studies have shown that tissues and blood samples from cancer patients, including breast 
cancers, have elevated levels of Alanine (Budczies et al., 2012; Poschke et al., 2013), suggesting 
that it is indeed secreted at a higher rate by neoplastic cells. A study in a small group of patients 
also showed that compared to healthy samples, serum from breast cancer patients have a 
higher activity of alanine and aspartate transaminase(Al-Mashhadani, Muk, & Al-Faraji, 2012).  
While upregulation of GPT2 expression in cancer cells is evident from in vitro studies(Hao et al., 
2016; Korangath et al., 2015; Smith et al., 2016a), there is a need for population studies into the 
association between GPT2 expression and tumorigenesis. Analysis of the TCGA and METABRIC 
datasets (Cancer Genome Atlas Network, 2012; Curtis et al., 2012) revealed that GPT2 
expression is upregulated in the more aggressive subtypes of breast cancer, including basal and 
HER2+ (Figure 33a, b). It is also associated with a more malignant phenotype owing to a positive 
correlation with increasing grades of cancer (Figure 33c). GPT2 expression also correlated 
significantly with poor overall survival (Figure 33 d). 
However, most available information is comprised of mRNA data which requires researchers to 
assume that the same is reflected at the protein level which may be inaccurate in certain cases. 
There is, therefore, the need for more functional studies in patient tissues to confirm the 
conclusions drawn from genetic data. Using an in house generated dataset of 800 breast cancer 
patients, GPT2 was analyzed at the proteomic level for the first time in a large scale breast 
cancer cohort (Figure 34a) (Bernhardt et al., 2017). This analysis confirmed that the 
upregulation of GPT2 in the more aggressive subtypes also translates to the protein level. This 
association also extended to other clinical parameters, including grading of tumors (Figure 34b). 
This study, thus consolidates the fact that GPT2 is indeed deregulated in tumors, and better 
detection methods for this enzyme might prove to be an important analytical tool. Despite 
some smaller cohorts showing higher alanine levels in patients versus normal patients, as 
discussed earlier, there is a lack of large scale analysis of alanine levels in patients of different 
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subtypes of breast cancer. Furthermore, it would be worth investigating the correlation 
between the levels of GPT2 expression with alanine secretion levels in the patients.  
 
5.10 GPT2 expression is controlled by metabolism regulators c-
Myc and ATF4 
Progress in the field of cancer metabolism has established this as a hallmark of cancer (Hanahan 
& Weinberg, 2011). To better comprehend tumorigenesis it becomes vital to understand how 
the cancer cells efficiently rewire their metabolic pathways to ensure a ‘favourable’ outcome 
for their growth. While some metabolic genes, like IDH, are mutated in certain cancer entities 
like brain cancer(Yan et al., 2009), most metabolic genes especially those belonging to 
glutamine metabolism do not have any reported mutations or amplifications in cancers. 
Therefore, understanding the rewiring of metabolic pathways in cancers necessitates a deeper 
look into the genetic background of the tumor and its microenvironment. Indeed, several 
oncogenic signaling pathways have been implicated in orchestrating metabolic rewiring to fuel 
the tumorigenic properties that they propagate(Cairns et al., 2011; Iurlaro et al., 2014). In a 
recent study it was also shown that several cancer associated metabolic genes, due to their 
proximity to oncogenic genes get co-altered (Sharma, Eils, & König, 2016). Therefore, large 
scale metabolic changes in cancers may be driven by the virtue of proximity of metabolic genes 
to other mutated genes or as a result of regulation by oncogenic proteins. Prominent among 
them, is c-Myc which is frequently deregulated in cancers. In breast cancer, it is overexpressed 
in 30-50% high grade tumors and which are mostly basal (Blancato, Singh, Liu, Liao, & Dickson, 
2004; Deming et al., 2000). c-Myc has been linked to several of the metabolic changes that 
cancer cells undergo (Anso et al., 2013; Chi V Dang, n.d.; Chi V Dang et al., 2009; Hsieh, Walton, 
Altman, Stine, & Dang, 2015; Shen et al., 2015). While its role in glycolysis has been well 
established(Le et al., 2012; Shim et al., 1997), recent studies have focused on the role of c-Myc 
in glutamine metabolism. c-Myc is considered to be the master regulator of glutamine 
metabolism in cancer cells(C. V. Dang, 2013; Chi V Dang, n.d.; R. Deberardinis & Cheng, 2009; Le 
et al., 2012; McCarthy, 2015). By upregulating glutamine transporters, c-Myc triggers glutamine 
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addiction in tumors(David R Wise et al., 2008). Subsequently, efficient utilization of glutamine is 
ensured by c-Myc which also regulates the expression of glutaminolytic genes(Gao et al., 2009). 
In a study in breast cancer cell lines, glutamine dependence and expression of glutaminolytic 
genes increased in a c-Myc dependent manner (Korangath et al., 2015). c-Myc either directly 
targets metabolic genes, or indirectly for example via microRNAs(Gao et al., 2009).  
In this study, c-Myc knockdown resulted in significant knockdown of GPT2 levels (Figure 35 a, 
c). In addition to the positive correlation between the MYC and GPT2 at the mRNA level (Figure 
36a), there was a positive correlation observed even at the protein levels in patients (Figure 
36b). The correlation was positive for each individual subtype of breast cancer. In fact the 
correlation was higher at the protein level compared to the mRNA level emphasizing the need 
for proteomic and functional analyses to complement genetic studies.  
c-Myc, however, does not account for the all the metabolic changes that occur in cancer cells. 
In this study it was observed that knockdown of c-Myc did not completely obliterate GPT2 
levels. This finding led me to explore other transcription factors that might be relevant for 
regulating GPT2 expression. ATF4 has a well-recognized role in amino acid management: under 
conditions of ER stress, redox imbalance, hypoxia and nutrient deprivation, it regulates the 
amino acid synthesis genes to ensure cell survival (Harding et al., 2003; Quirós et al., 2017; Ye 
et al., 2010; E. Zhao et al., 2016). ATF4 is found to be upregulated in solid tumors where it 
controls amino acid metabolism and consequently cell proliferation (Ye et al., 2010) as well as 
contributes to drug resistance (Tanabe et al., 2003). In esophageal squamous cell carcinoma 
ATF4 is upregulated which in turn controls the expression of serine synthesis genes (E. Zhao et 
al., 2016).  In fibrosarcoma and colorectal adenocarcinoma cells, induction of ER stress and 
NEAA deprivation results in ATF4 upregulation, and addition of NEAA rescues cells deficient in 
ATF4 (Ye et al., 2010). ATF4 is also reported to be overexpressed in cancer associated stromal 
cells leading to the induction of asparagine synthesis which, in turn, is used as a nitrogen source 
by the surrounding cancer cells to combat glutamine deprivation (Linares et al., 2017). ATF4 is a 
known transcription factor of GPT2. Under conditions of stress, liver cells have been reported to 
upregulate GPT2 via stress response factor ATF4 (Salgado, Metón, Anemaet, & Baanante, 
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2014b). In colorectal cancer, PIK3CA mutations have been shown to make cells glutamine 
dependent by upregulating GPT2 via PDK1-RSK2-ATF4 signaling (Hao et al., 2016). 
In this study, ATF4 knockdown significantly reduced GPT2 expression (Figure 37a). Conversely, 
ER stress induced ATF4 upregulation via tunicamycin treatment and increased GPT2 expression 
(Figure 37c), confirming previous reports(Salgado et al., 2014b). To test this association at 
clinical level the METABRIC dataset was analyzed which revealed a strong positive correlation 
exists between ATF4 and GPT2 in breast cancer patients (Figure 38). ATF4 has been previously 
linked to glutamine metabolism in breast cancer patients (van Geldermalsen et al., 2015a). In 
the cohort of 96 triple negative breast cancer cases ATF4 gene expression significantly 
correlated with glutamine transporter ASCT2 and glutamine metabolism related genes GLS and 
GLUL. Therefore, similar to c-Myc, ATF4 might play an important role in regulation of glutamine 
metabolism in cancer. 
While c-Myc and ATF4 play important roles in cancer cell metabolism rewiring, in case of GPT2 
and other genes as well, knockdown of the transcription factors does not induce complete 
elimination of gene expression. In the same way as cancer cells can compensate for blockage of 
one metabolic pathway by using another pathway, signaling pathways can also be switched 
according to the need of the cells(McCormick, 1999). Furthermore, gene expression can be 
controlled by multiple regulatory factors. Even though the afore-mentioned two transcription 
factors play a role in GPT2 expression, there could be other factors as well. The factors may also 
vary according to the subtype and genetic background of the cancer. It is interesting to note 
that MDA MB 468 cells, which have the highest expression of GPT2, are deficient of the tumor 
suppressor RB1 (Retinoblastoma transcriptional corepressor 1), which is commonly mutated in 
cancers(Johnson et al., 2016). Loss of RB1 in mouse embryonic fibroblasts, has been shown to 
increase glutamine consumption via upregulation of ASCT2 and consequent increase in 
glutamine breakdown via GLS1 activity (M. R. Reynolds et al., 2014). Therefore, it is reasonable 
to assume that lack of RB1 in MDA MB 468 may have a function in regulating metabolism and it 
would be worth investigating if it plays a role in GPT2 expression as well. The expression of 
GPT2 could, however, be dependent on a many more factors, including, the genetic landscape 
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like mutations, amplifications, epigenetic regulation as well as the tumor microenvironment 
and all these factors have to be taken into consideration while investigating the regulation of 
GPT2. 
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6. Conclusions and Outlook 
In conclusion, GPT2 plays a crucial role in connecting the glycolytic and glutaminolytic pathways 
as the GPT2 catalyzed reaction requires both to be functional. Warburg effect and 
glutaminolysis, the two pillars of cancer metabolism are, therefore, not independent of each 
other, rather they work in a concerted manner, via aminotransferases, to meet the energetic 
and biosynthetic demands of the cells. Finally, alanine secretion and alanine aminotransferase 
activity have the potential to be biomarkers as well as therapeutic targets. 
While it is clear from this study that GPT2 is important for breast cancer cell growth and is also 
deregulated in patients, there is a need to prove that the effect it has on cell growth translates 
to tumorigenesis in vivo. In this regard, future experiments have been planned to study this 
aspect. While the RNAi approach and chemical inhibition are suitable for cell lines studies, in 
vivo experiments necessitate a different approach. Therefore, in the planned experiments, 
GPT2 in MDA MB 468 cells will be knocked out using the CRISPR/Cas9 system and used to 
monitor tumor growth in xenograft mouse models. These experiments are currently on-going. 
There is evidence that in the case of metabolism, the boundaries between the well-established 
molecular subtypes of breast cancer become indistinguishable. This gives rise to the need for 
different markers, possibly metabolic to identify the metabolic propensity of cell lines (and 
subsequently of patients). In this regard this study should be extended to more cell lines in 
order to represent a larger genetic and metabolic spectrum seen in patients. Furthermore, 
there is a need for larger cohorts of patient tissues and blood to be analyzed for both GPT2 
expression and alanine levels. As an extension to this project, future studies have been planned 
to correlate GPT2 and alanine levels in breast cancer patient cohorts. Associations seen in these 
analyses could help develop alanine as a biomarker. 
While combinatorial effects of targeting GPT2 together with other factors involved in energy 
metabolism were observed, none of these effects substantial. This indicates that cells have yet 
other pathways that can compensate for these blockages and there is a need to discover what 
these are. It is clear that the cells reorganize their glucose carbon expenditure under GPT2 
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inhibition, therefore, dual targeting of GPT2 and glycolysis might lead to substantial decrease in 
cell growth. Furthermore, effects of GPT2 on other biosynthetic pathways that are fed by 
transaminase pathways need to be investigated to get a broader understanding of the role of 
GPT2 in cell growth. 
This study, therefore, emphasizes the heterogeneity in the metabolic landscape of breast 
cancer, and the importance of glutamine driven anaplerosis in the cells. Effects of GPT2 on cell 
growth indicate that this is an important factor for cancer cells, however, combinatorial 
treatment with other compensatory pathways will hopefully ensure maximum success in 
combating tumor progression. 
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Appendix 
Supplementary Table 1                                                                                                
MDA MB 468, MDA MB 231, MCF7 were grown under normal growth conditions in 10cm dishes 
in triplicates. Following day, media was changed and after 4h polar metabolites were extracted 
and quantified via GC-MS. 
Please refer to the supplementary CD due to the length of the table. 
Supplementary Table 2 
MDA MB 468, MDA MB 231, MCF7 were grown under normal growth conditions in 6 well 
dishes in triplicates. After 48h RNA was harvested and mRNA expression was measured via 
microarray. Data was then normalized and differential gene analysis was performed by Khalid 
Abnaof. 
Please refer to the supplementary CD due to the length of the table. 
Supplementary Table 3 
MDA MB 468, MDA MB 231, MCF7 were grown under normal growth conditions in 6 well plates 
in triplicates. Cell pellets were collected and lysates were harvested for mass spectrometry 
analysis after 48h. Harvesting of lysates, mass spectrometry, raw data extraction and initial 
analysis was done by Nadine Royla. Differential expression analysis and heatmaps were 
prepared by Khalid Abnaof. 
Please refer to the supplementary CD due to the length of the table. 
Supplementary Table 4 
MDA MB 468, MDA MB 231, MCF7 were grown under normal growth conditions in 10cm dishes  
in triplicates. Spent media was collected after 48h and cell numbers were counted with CASY 
and used for normalization. Amino acids were derivatized, measured and initial analysis was 
done by Gernot Poschet. 
Please refer to the supplementary CD due to the length of the table. 
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Abbreviations 
α-KG  α-ketoglutarate 
AKT  Serine/Threonine Kinase 1 
AMPK  Adenosine monophosphate-activated kinase 
ARG2  Arginase 2 
ASCT2  Solute-linked carrier family A1 member 5 (SLC1A5) 
ASS1  Argininosuccinate Synthase 1 
ATF4  Activating transcription factor 4 
ATP  Adenosine triphosphate  
BAX  BCL2 Associated X, Apoptosis Regulator  
BCA  Bicinchoninic acid protein assay 
BCLA  β-chloro-L-alanine 
BL  Basal-like 
BRCA  Breast Cancer 
CDK  Cycling dependent kinase 
CEST   Chemical exchange saturation transfer 
CO2  Carbon dioxide 
CRISPR  Clustered Regularly Interspaced Short Palindromic Repeat   
cDNA  Complementary deoxyribonucleic acid 
DNA  Deoxyribonucleic acid 
DMSO  Dimethyl sulfoxide 
ECM  Extracellular matrix 
EDTA  Ethylenediaminetetraacetic acid 
EGFR  Epidermal growth factor receptor  
ER  Endoplasmic reticulum 
ER+  Estrogen positive 
ER-  Estrogen negative 
ERBB2  Erb-B2 Receptor Tyrosine Kinase 2 
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ESR1  Estrogen Receptor 1 
ETC  Electron transport chain 
FBS  Fetal Bovine Serum 
FCCP  Carbonyl cyanide-4 (trifluoromethoxy) phenylhydrazone 
FDG  Fluorodeoxyglucose 
FISH  Fluorescence in situ hybridisation 
FGFR  Fibroblast growth factor receptor 
FH  Fumarate hydratase 
FOX  Forkhead Box 
FSPG  (S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid  
GC-MS  Gas chromatography-mass spectrometry 
GLS  Glutaminase  
GLUL  Glutamate-ammonia ligase 
GLUD  Glutamate dehydrogenase 
GLUT  Glucose transporter 
GOT  Glutamic-oxaloacetic transaminase 
GPT   Glutamate pyruvate transaminase  
GSH  Glutathione 
HER2  Human Epidermal Growth Factor Receptor 2 
HIF1α  Hypoxia inducible factor 1α 
HK2  Hexokinase 2 
HPLC  High pressure liquid chromatography 
IDH  Isocitrate dehydrogenase 
IM  Immunomodulatory 
LAR  Luminal androgen receptor 
LAT1  Solute Carrier Family 7 Member 5 (SL7A5) 
LDH  Lactate dehydrogenase 
LKB1  Serine/Threonine Kinase 11 
KRAS  Kirsten Rat Sarcoma Viral Oncogene Homolog  
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M  Mesenchymal 
MAPK  Mitogen-Activated Protein Kinase 
MCT  Monocarboxylate transporters 
MPER  Mammalian Protein Extraction Reagent 
mRNA  Messenger ribonucleic acid 
MRSI  Magnetic resonance spectroscopic imaging 
MSL  Mesenchymal-like 
mTOR  Mechanistic Target Of Rapamycin Kinase  
NAD  Nicotinamide adenine dinucleotide 
NADH  Nicotinamide adenine dinucleotide + hydrogen 
NaF  Sodium Fluoride 
NEAA   Non-essential amino acids 
NTC  Non targeting control 
OAA  Oxaloacetic acid 
OCR  Oxygen consumption rate 
OXPHOS Oxidative phosphorylation 
TP53  Tumor protein 53 
PARP  Poly(ADP-Ribose) Polymerase 
PBS  Phosphate buffered saline 
PC   Pyruvate carboxylase 
PD-1  Programmed cell death protein 
PD-L  Programmed cell death protein ligand 
PDH  Pyruvate dehydrogenase 
PDK1  Pyruvate dehydrogenase kinase 1 
PET  Positron emission tomography 
PHGDH  Phosphoglycerate dehydrogenase 
PI3K  Phosphatidylinositol-4,5-Bisphosphate 3-Kinase 
PI3KCA  Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha  
PKM  Pyruvate Kinase, muscle 
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pRb  Retinoblastoma-associated protein 
pRPS6  Phospho ribosomal protein S6 
PTEN  Phosphatase and Tensin Homolog 
PVDF  Polyvinylidene fluoride 
PUM1  Pumilio RNA Binding Family Member 1 
qRT-PCR Quantitative reverse transcriptase polymerase chain reaction 
RB1  Retinoblastoma Transcriptional Corepressor 1 
RNA  Ribonucleic acid 
RNAi  Ribonucleic acid interference 
ROS  Reactive oxygen species 
RPPA  Reverse phase protein array 
RT  Room temperature 
RTCA  Real time cell analyzer 
SD  Standard deviation 
SDHA  Succinate dehydrogenase A 
SDS PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
siRNA   Small interfering ribonucleic acid  
TBST  Tris buffered saline with Tween 20 
TCA cycle  Tricarboxylic acid (citric acid) cycle 
TCGA  The cancer genome atlas 
TEMED  Tetramethylethylenediamine 
TNBC  Triple negative breast cancer 
WST-1  Water-soluble tetrazolium salt 1 
XBP1  X-Box Binding Protein 1 
2-HG  2-hydroxyglutarate 
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